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Abstract 
Advancements in burn care have improved immediate outcome, however, the 
prevalence of sepsis and multiple organ failure (MOF) remain significant. Although 
well characterised the mechanisms responsible for the pathogenesis of MOF and 
increased propensity to infection are poorly understood. Neutrophil extracellular 
traps (NETs) provide protection against invading pathogens but also contribute to 
thrombosis.  
Sepsis is required for NET generation following severe thermal injury. 
Quantification of circulating NET biomarkers shows good discriminatory power for 
diagnosis of sepsis. Interestingly, neutrophils isolated from 24 patients with severe 
thermal injuries, ≥ 15% total body surface area, had a significantly reduced ability 
to form NETs ex vivo, potentially mediated by phenotypical changes of neutrophils 
and inhibitory effects of formyl peptides. 
This thesis identified a major biological mechanism driving MOF after severe 
thermal injury, namely the compromise to the actin scavenging system which 
leads to reduced DNAse activity and a build-up of circulating DNA. Preliminary 
analysis suggests that DNAse activity can be restored by prehospital use of fresh 
frozen plasma following major trauma. Thus, administration of blood products or 
manipulation of the actin scavenging system is a potential therapeutic target. 
This thesis has identified a number of novel mechanisms responsible for the 
regulation of NETs following severe thermal injuries and their implications for 
sepsis and MOF. 
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Introduction 
1.1 Trauma and thermal injury  
There are approximately 5-8 million fatalities each year as a result of injuries and 
trauma (1, 2). As a group alone, fatalities account for more deaths than malaria, 
tuberculosis and HIV/AIDS. Trauma affects all age groups in developed and 
developing countries globally and associated mortalities account for around 10% 
of the deaths worldwide (1). Traumatic injury is an umbrella term which 
encompasses many forms of injury, including road traffic accidents, wars, falls and 
thermal injuries (1). For many years thermal injury and trauma were used 
interchangeably. However, investigation of thermal injury alone is now required. 
Thermal injuries are a common and debilitating form of traumatic injury which is 
associated with considerable morbidity and mortality. They are among the most 
expensive forms of traumatic injury due to the consequent length of 
hospitalisation, rehabilitation and wound management (3). In 2015 it was reported 
that approximately 13,000 injuries which required hospital attention occur every 
year in England and Wales. Approximately 58% of these patients were admitted to 
hospital for further medical care. Throughout this thesis the term ‘thermal injury’ 
will refer to injuries caused by flame, contact and scald injuries, the most 
predominant causes in England and Wales (4). 
Morbidity and mortality post thermal injury is heavily influenced by a plethora of 
elements. Firstly, severe thermal injuries which are larger in size and depth have 
an increased risk of nosocomial infection and thus an increased mortality rate (5). 
More recently, studies have shown that age has a considerable effect on the 
immune system (6-9) and thus ageing is a crucial confounding factor in the clinical 
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outcome. Elderly patients have a higher mortality rate, longer length of hospital 
stays and more complicated outcomes (10). This may be driven by the immune 
dysfunction and immunosenescence associated with ageing (7-9), or may also be 
affected by pre-existing medical and premorbid conditions which are common in 
elderly patients. Finally, patients with inhalation injuries have increased mortality 
rates despite increased understanding and advancements within respiratory care 
(11). A combination of these confounding factors in patients presenting with 
severe thermal injuries increases the associated mortality and morbidity rate.  
1.2 Pathophysiology of thermal injury 
The pathophysiology of burn is dependent upon the degree of initial injury and 
complications the patients incur. Severe thermal injury results in immediate local 
and systemic responses which are extremely complex and critical to outcomes 
post injury. 
Jackson described 3 zones which make up the local response to burn injury (12). 
These include the zones of coagulation, stasis and hyperaemia (Figure 1.1). The 
zone of coagulation occurs at the point of maximal tissue damage and is 
comprised of necrotic tissue where there is irreversible tissue loss. This is 
surrounded by the zone of stasis which is characterised by decreased tissue 
perfusion. The tissue in this area can be rescued however secondary 
complications such as infection or ischemia may lead to further tissue necrosis. 
The zone of hyperaemia has increased tissue perfusion and without secondary 
complications, this will recover. The three zones of burn injury are subject to 
changes and loss of the zone of stasis will result in wound deepening and 
widening (12, 13).  
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Figure 1.1. Described model of burn zones according to adequate and 
inadequate resuscitation as described by Jackson. The burn wound consists 
of 3 zones which make up the local response to burn injury. These zones include 
a zone of coagulation, stasis and hyperaemia. Loss of the zone of stasis will result 
in wound deepening and widening of the wound. The figure is taken directly from 
‘ABC of burns: pathophysiology and types of burns’ by Hettiaratchy and 
Dziewulski (12, 13). 
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1.3 Burn shock 
Following thermal injury correct diagnosis, treatment and clinical practice are 
essential for positive outcomes. Smaller thermal injuries are commonly managed 
by outpatient care. However, clinical treatment of severe injuries is much more 
complicated and require hospitalisation, timely and accurate resuscitation, 
nutritional support, and early surgical management of burn wounds. All of which is 
directed at reducing morbidity and mortality (14).  
Shock is a life-threatening condition characterised by reduced oxygen delivery and 
circulatory failure. Shock is commonly diagnosed by a combination of 
hypoperfusion and low or declining blood pressure (15). Burn shock is an umbrella 
term consisting of hypovolemic and septic shock which occurs following a severe 
thermal injury. Hypovolemic shock occurs immediately following severe thermal 
injury and without adequate fluid resuscitation it will lead to mortality. Septic shock 
is the major driver of delayed mortality associated with infection and is 
characterised by shock mediated by an infectious stimuli coupled with evident 
organ failure (15). The pathogenesis of burn shock is driven by the alteration in 
almost all components that control both fluid and protein loss from vascular space 
(16). Immediately following injury the microvasculature loses its vessel wall 
integrity which results in the loss of proteins to the interstitium (17) coupled with a 
decrease in the intra-vasculature colloid osmotic pressure resulting in loss of fluid, 
electrolytes and further proteins from the vasculature system into the interstitium 
(17). Clinically this manifests itself as hypovolemia, haemoconcentration, oedema, 
reduced urine output and significant cardiovascular dysfunction (16). Timely and 
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appropriate treatment, namely fluid resuscitation, is required to prevent and 
manage immediate burn shock and prevent poor outcomes post injury. 
1.4 Improvements in critical care management of patients with thermal 
injuries 
Improvements in the immediate care of burn wounds have been made over the 
past four decades which have dramatically improved survival rates of patients. It is 
proposed that improvements in survival are a direct result of increased scientific 
understanding of burn injury and the immediate pathophysiology (18).  
In 2014, Jackson and colleagues reported data of revised estimates of mortality 
from the Birmingham Burn Centre spanning from 2001 to 2010 and included 4577 
patients. Although there was an increase in admissions, the overall mortality of the 
cohort decreased by approximately 3-fold compared to the previous decade. The 
authors concluded that improvements in outcome were multifactorial and included; 
improved prehospital care, rapid referral to burns institution, early burn wound 
excision and closure, and improved understanding and management of inhalation. 
Furthermore, the group proposes that further research into inhalation injury, fluid 
resuscitation, burn care in vulnerable populations (i.e. elderly patients), and skin 
substitutes are warranted if further improvements in outcome are to be met (19). 
1.4.1 Fluid resuscitation  
Fundamental to the care of patients with burn injuries is accurate and timely fluid 
resuscitation. Without intervention and fluid replacement in burns greater than 15-
20% total body surface area (TBSA) burn shock will occur (20). A delay of just 2 
hours of accurate fluid resuscitation results in a significant increase in adverse 
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outcomes (21). Therefore the primary aim of fluid resuscitation is to prevent the 
development of burn shock and to restore homeostasis during the immediate 
dysregulated cellular and hormonal response (22).  
1.4.2 Inhalation injury 
Advancements in the management of respiratory failure caused by inhalation 
injury and smoke inhalation have been fundamental in improving immediate 
outcome post thermal injury (23-25). The pathogenesis of respiratory failure is 
multifactorial and immediate airway management is essential (13, 26, 27). 
Inhalation injuries are further sub categorised in primary and secondary which 
differ by causes, progression and management. Primary inhalation injury is 
caused by direct damage to the respiratory system caused by the thermal stimulus 
which causes cellular damage, activation of inflammatory cells and oedema. This 
can cause blockage of the airways and consequently respiratory failure, a major 
clinical problem (28). Secondary injury to the respiratory system is initiated by the 
inflammatory response and is amplified by complications, including sepsis and 
multiple organ dysfunction (MODS) or multiple organ failure (MOF) (27, 29). Both 
of which require management and treatment to ensure a positive outcome (11, 
13). 
1.4.3 Burn wound care 
Burn wounds provide a major source of inflammatory mediators which orchestrate 
the propagation and initiation of inflammation following thermal injury (30). Timely 
and correct management of burn wounds is essential to prevent an uncontrolled 
systemic inflammatory response, reduce infection risk, improve healing and 
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reduce the incidence of secondary complications (31, 32). Advancements in 
immediate cleaning, debridement and excision of wounds have been critical in 
preventing rapid colonisation of wounds, secondary complications and reducing 
mortality rates (20, 32).  
Early excision and skin grafting generally occur between 24 hours and 7 days 
following injury to attenuate the inflammatory response, reduce rejection rate and 
reduce colonisation rate of wounds (20, 32). If wounds become colonised they are 
commonly treated by early debridement, wound excision and application of topical 
dressings. Novel topical dressings aim to promote wound healing, reduce scarring 
and identify/treat colonised wounds more efficiently (33, 34). Topical antimicrobial 
agents, which are commonly used, prevent graft loss and burn wound infection 
(32). Advancements in the understanding of the inflammatory response post 
thermal injury, reduced infection rates of wounds and novel topical agents have 
been pivotal to the improvements of burn wound care. 
1.5 Systemic inflammatory response syndrome following thermal injury 
Severe thermal injury results in loss of the natural defensive barrier and rapid 
onset of systemic inflammatory response syndrome (SIRS) (35). SIRS is an 
inflammatory response which can be initiated by a plethora of mechanisms 
including injury, surgery and ischemia. It clinically manifests as elevations of body 
temperature, heart rate, respiratory rate and abnormal white blood cell count or 
phenotypical changes (presence of band cells) (36). Whilst similar, sepsis is a 
SIRS response with a documented infection. Therefore, the difference between 
SIRS and sepsis is the stimuli responsible for its initiation. SIRS is initiated by a 
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sterile stimulus, e.g. trauma, and sepsis is mediated by an infectious stimulus, e.g. 
bacteria. 
Many of the resultant consequences following thermal injury are mediated by the 
rapid release of pro-inflammatory mediators and immune suppression (37). This 
hyper-inflammatory state coupled with an increased propensity to infection often 
results in sepsis which is the major cause of mortality following burn injury (38). 
Systemic responses to burn injury include profound changes in the cardiovascular, 
respiratory, metabolic, immunological and haematological systems (37). 
Classically, the SIRS and compensatory anti-inflammatory response syndrome 
(CARS) paradigm implies that CARS follows the SIRS response to restore 
homeostasis (37). However, Xiao and colleagues report a simultaneous SIRS and 
CARS following major trauma (37, 39). The SIRS response is characterised by 
increased circulating levels of pro-inflammatory cytokines and activation of innate 
immune cells (37) and the CARS response is characterised by an increase in 
circulating levels of anti-inflammatory cytokines and immunoparesis (37). Delayed 
recoveries in the SIRS and CARS response are associated with complicated 
outcome following major trauma due to the prolonged and dysregulated immune-
inflammatory state (Figure 1.2) (37). Therefore, monitoring the amplitude and 
duration of the SIRS and CARS has the potential to aid in clinical decision making 
and may improve patient outcome following severe thermal injury. 
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Figure 1.2. Novel model of simultaneous SIRS and CARs following major 
trauma. (A) The traditional paradigm of immediate SIRS response followed by 
CARS following major injury. A second hit can lead to secondary complications 
and delayed amplification of the inflammatory response. (B) Model proposed by 
Xiao and colleagues showing an immediate and simultaneous SIRS and CARS 
response. The amplitude of response is associated with adverse clinical 
outcomes. Figure is taken directly from ‘A genomic storm in critically injured 
humans’ by Xiao et al (37). 
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1.6 Damage associated molecular patterns  
Damage associated molecular patterns (DAMPs) are a collection of endogenous 
cytosolic, mitochondrial and nuclear derived proteins and DNA which are detected 
in high circulating concentrations following major trauma (40, 41). Elevation in 
circulating levels of DAMPs is associated with secondary complications, tissue 
damage and mortality (41-44). Namely, administration of mitochondrial DNA 
(mtDNA) to mice resulted in organ damage which was attributed to direct 
activation of neutrophils, subsequent neutrophil degranulation and local cytokine 
production (42, 43). Furthermore, in prospective observational cohort studies 
elevated levels of DAMPs are associated with MOF and mortality (41, 44). This 
highlights the potential interaction(s) between circulating levels of DAMPs and 
secondary complications following major trauma. 
Exposure of monocytes to mitochondrial derived DAMPs (mtDAMPs) results in a 
tolerance state in which these cells are resistant to further endotoxin stimulation 
(45). It is proposed that this induced tolerance may underpin an increased 
propensity to infection. Although described in monocytes, it has yet to be 
examined if DAMPs induce this tolerance phenotype in neutrophils. Furthermore, it 
is yet to be established if this occurs following severe thermal injury and potential 
mechanistic role in the increased incidence of infection.  
1.7 Nosocomial infections, sepsis and organ dysfunction following thermal 
injury 
Mortality rates associated with severe thermal injuries continue to steadily 
decrease. This is in part caused by a multidisciplinary approach, improved burn 
wound management, advancements in fluid resuscitation and identification of 
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comorbid conditions e.g. inhalation injury (31). Although immediate mortality rates 
have improved, the incidence and associated mortality of secondary complications 
has increased (31). Upon detection of secondary complications rapid, accurate 
and timely diagnosis is required.  
Sepsis is a life threatening condition characterised by an imbalance in both the 
immune and haemostatic systems. Sepsis is associated with cardiac dysfunction 
and acute respiratory distress syndrome which are synonymous with MOF (46). 
Although the accurate and timely diagnosis is crucial for determining patient 
outcomes, diagnosis remains difficult as criteria are insensitive and non-specific as 
they are masked by the ongoing SIRS (47). Therefore, further research into the 
pathophysiology, immune pathways and novel diagnosis criteria are required. 
Whilst this is not a new concept, the prevalence of sepsis and its associated 
mortality remain high. A systematic review, which included 9 studies reporting 
survival data for thermal injuries, reported the prevalence of sepsis was between 
8-42.5% in patients with burns. This was associated with a mortality rate (28-65%) 
that exceeded that of sepsis-related deaths for traumatic injury (2.4-19.6%) or 
critical care (21-53%) (38). In addition, the diagnosis of sepsis in burns patients 
represents a major challenge, as many of the classical diagnostic biomarkers of 
sepsis are masked by the ongoing SIRS that occurs following major burn injury 
(47). Understanding the mechanisms underlying the progression and increased 
propensity to sepsis is therefore critical if novel biomarkers for the accurate 
prediction and/or diagnosis of sepsis in patients with thermal injuries are to be 
found and novel therapeutic targets for its prevention and/or treatment identified. 
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Without intervention, sepsis can induce MOF which can be characterised by mild 
through to complete and irreversible damage to vital organs (48). Whilst MOF 
remains well defined the mechanisms responsible for its initiation and progression 
remain poorly understood. Of such, infection and immediate traumatic injury are 
attributed as initiators of MOF. 
Disseminated intravascular coagulation (DIC) is characterised by abnormal and 
uncontrolled coagulation and is a common and contributing factor to MODS and 
MOF through thrombus formation and occlusion of blood vessels (49-52). DIC can 
be classified into acute and chronic depending upon stimulating factors, length 
and pathology (53-55). Trauma and thermal injury induce acute DIC which is a 
consumptive coagulopathy state characterised by excessive thrombin generation 
(56). DIC also causes the formation of schistocytes, due to high shear forces on 
red blood cells in occluded vessels (57), which appear to have biological functions 
in addition to beings potential diagnostic markers of DIC (58). However, D-dimer, a 
soluble biomarker, is commonly used to diagnose DIC through evaluation of 
recent thrombus formation.  
MOF remains the leading cause of delayed mortality following major trauma and is 
characterised by tissue hypoxia, tissue damage and organ dysfunction (59). In 
2009, Nhu Nguyen reported that in 117 severely burn patients (≥40% TBSA) that 
the incidence of MODS was 45% and associated with severity of injury, sepsis, 
increased length of stay and importantly increased mortality rate (59). Although it 
is well recognised that damage to vital organs occurs during MODS/MOF and is 
associated with adverse outcome the mechanisms mediating this are unknown or 
poorly understood. Therefore, understanding the mechanisms driving the 
pathogenesis of MOF and organ damage has the potential to improve patient 
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outcome following thermal injury through early identification of patients at risk and 
novel clinical intervention. 
1.8 Novel biomarkers of sepsis in thermally injured patients 
Sepsis remains a significant healthcare problem in patients following thermal injury 
(38). Without timely diagnosis and treatment patients are at high risk of MOF and 
consequently mortality. The Surviving Sepsis Campaign is a joint collaboration of 
the Society of Critical Care Medicine and the European Society of Intensive Care 
Medicine committed to reducing mortality from severe sepsis and septic shock 
worldwide (60). It is advised that antibiotics should be administered to a patient 
within 1 hour of clinical diagnosis of sepsis and with each hour delay in the 
administration there is an associated significant increase in mortality (61-63). 
A major limitation of post-burn sepsis research is the absence of an accurate 
definition of sepsis as many of the classically used diagnosis criteria are 
nonspecific and masked by the ongoing SIRS response (64). In 2007, a collective 
group of burns experts defined a clinical scoring criterion for the accurate 
diagnosis of sepsis in patients with thermal injuries (65). According to the 
American Burn Association (ABA), sepsis is diagnosed when three or more of the 
following criteria listed in Table 1.1 are satisfied in addition to the clinical response 
to antibiotics, positive blood or wound culture.  
More recently a new sepsis diagnosis criterion was described in The Journal of the 
American Medical Association (66). This study aimed to replace previous 
diagnostic criteria with a new system termed the quick sequential organ failure 
assessment (qSOFA) score. Whilst this tool is an excellent bedside screening tool 
for identifying patients at risk of adverse outcomes it is non-specific in patients with 
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severe thermal injuries. This is due in part to the high incidence of intubation in 
patients with thermal injuries and the incorporation of the Glasgow coma scale 
(GCS) into the qSOFA score which is not part of the ABA scoring criteria. Thus, 
diagnosis of sepsis was made using the ABA scoring criteria for all analysis within 
this thesis.  
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Finding Value 
Temperature Fever > 39°C, hypothermia (< 36.5°C) 
Heart Rate 
Adults: Progressive tachycardia (> 110 beats 
per min). Children: > 2 standard deviations 
above age-specific norms (85% age-adjusted 
max heart rate) 
Respiratory Rate 
Adults: Progressive tachypnoea ( > 25 breaths 
per minute not ventilated or minute ventilation > 
12 L/min ventilated). Children: > 2 standard 
deviations above age-specific norms (85% age-
adjusted max heart rate) 
Thrombocytopenia (only applicable > 3 days 
post thermal injury) 
Adults: Thrombocytopenia (< 100,000/μl) 
Children: > 2 standard deviations below age-
specific norms 
Hyperglycaemia (in the absence of pre-existing 
diabetes mellitus) 
Untreated plasma glucose > 200 mg/dl  
(11.1 mmol/l). Insulin resistance i) > 7 units of 
insulin/h intravenous drip ii) significant 
resistance to insulin (> 25% increase in insulin 
requirement over 24 h) 
Feeding 
Inability to continue enteral feedings > 24 h i) 
Abdominal distension ii) Enteral feeding 
tolerance (residual > 150ml/hour in children or 
two times feeding rate in adults iii) Diarrhoea 
(Adults: > 2500 ml/day, Children > 400 ml/day) 
Table 1.1. The ABA Consensus conference 2007 criteria for sepsis diagnosis 
(65). 
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There is also the increasing problem of antibiotic resistance, a phenomenon in 
which bacteria can mutate making them more invulnerable to antibiotics. This 
resistance makes it harder to treat patients, increases medical costs, increases 
hospital length of stay and increases mortality (67). Van Langeveld et al 
investigated how multi-drug resistant organisms (MDROs) affect survival, hospital 
length of stay and secondary complications in patients with thermal injuries. 
Although the group found that MDROs had no effect on mortality they conclude 
that their findings suggest infections caused by MDROs are associated with a 
greater number of surgical procedures, longer duration of mechanical ventilation, 
more antibiotic days, and longer hospitalisation (68). 
Therefore, novel and accurate biomarkers are required for earlier and accurate 
identification of patients at risk or who have developed sepsis following thermal 
injury. This may initiate a change in clinical practice and antibiotic stewardship 
which is required to overcome the growing burden of MDROs. There are a number 
of novel biomarkers which may be of clinical utility in patients with thermal injuries. 
However, many markers still lack sensitivity and specificity and therefore further 
research is required. 
1.8.1 Procalcitonin 
Procalcitonin (PCT) is a naturally occurring 116-amino acid prohormone of 
calcitonin produced in the thyroid, lungs and intestine (69). PCT is found in 
extremely low quantities in healthy individuals but challenges such as endotoxin 
insult cause a rapid upregulation of PCT production (70). Hence, the kinetics of 
PCT is favourable for the development of a biomarker of sepsis. A number of 
studies have reported the potential use of PCT in differentiating between 
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infectious and non-infectious systemic inflammation (71, 72). As such, PCT 
remains one of the most promising biomarkers in identifying infection/sepsis (73, 
74).  
Current studies aim to elucidate the potential role of PCT in antibiotic stewardship, 
patient stratification, diagnosis and prognostic utility following burn injury. In 2016, 
Cabral and colleagues published a meta-analysis of the current understanding of 
PCT as a biomarker in patients with thermal injuries. The meta-analysis included 
14 studies published in both adults and children with thermal injuries (75). Pooled 
area under the receiver operator curve (AUROC) for PCT in diagnosis of sepsis 
was 0.83 (95% confidence intervals = 0.76, 0.90). However, substantial 
differences in AUROC values are reported for individual studies with values 
ranging from 0.55 – 0.98 (76, 77). Additionally, differences in the ‘cut off or 
threshold value’ for distinguishing sepsis exists. Many of these differences are 
attributed to the variances in methodology, heterogeneity between patient 
populations and timing of samples. Nevertheless, Cabral and colleagues conclude 
that PCT should be regarded as a strong diagnostic marker of sepsis in burns 
patients and further work is required to standardise PCT measurements (75).  
One limitation of PCT is the reported elevation that occurs postoperatively in the 
absence of infectious stimuli (78). As patients with severe thermal injuries require 
surgical intervention, caution must be taken when interpreting PCT data in these 
patients. Furthermore, a number of studies have reported negative results for PCT 
in the diagnosis of sepsis following thermal injury (47, 76). Therefore controversy 
exists regarding PCT as a biomarker of sepsis in this patient population. Thus it is 
suggested that further studies are required to explore PCT diagnostic utility 
longitudinally compared to existing biomarkers of sepsis.  
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1.8.2 C-reactive protein  
C-reactive protein (CRP) is a liver derived protein which can activate the classical 
complement pathway (79). CRP has been studied as a biomarker of infection, 
sepsis and mortality in a number of disease pathologies (80, 81). Of note, in a 
study of 43 patients admitted to intensive care unit (ICU) with burn injury, CRP did 
not correlate with severity of sepsis when PCT did (77). This further confirmed 
earlier work reporting the increased diagnostic utility of PCT compared to CRP in 
diagnosing sepsis (82). Furthermore, studies have questioned the ability of CRP to 
distinguish between inflammation caused by infectious and non-infectious stimuli 
(83, 84). As CRP is released in response to IL-6 (82), which is present in high 
quantities in patients with thermal injuries (85), it is thought this may cause the 
non-specific elevation in CRP and false positives reported in the context of 
infection. Hence, CRP should be regarded as a marker of inflammation in patients 
with thermal injuries rather than a potential biomarker of infection due to its non-
specific nature.  
1.8.3 Pro- and anti-inflammatory cytokines 
Thermal injury results in the simultaneous release of pro and anti-inflammatory 
cytokines which are associated with severity of injury and secondary complications 
(86-88). As the exaggerated immune response is proposed to underlie the 
increased incidence of secondary complications post burn injury, groups have 
quantified levels of pro- and anti-inflammatory cytokines and correlated levels to 
clinical outcomes (89, 90).  
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In a study which included 28 children with severe burn injuries, elevated levels of a 
panel of cytokines showed positive discriminatory power to identify patients who 
were likely to succumb to their injuries. In this study, interleukin (IL)-4, IL-6, IL-7, 
IL-10, and IL-13 were abnormal within the first 7 days post injury in patients who 
did not survive their injuries when compared to patients who did survive. With 
abnormalities in IL-6, IL-7 and IL-10 displaying the highest predictive power for 
mortality (89). Furthermore, in a study of 468 paediatric burn patients, IL-8 serum 
levels were increased in patients who developed with MOF, succumbed to their 
injuries and, interestingly, sepsis (91). Hence, IL-8 may be a potential novel 
biomarker to monitor infection and septic episodes. 
Recent studies have investigated if a combination of biomarkers offers greater 
diagnostic potential (92). For example, in a recent study of severely injured trauma 
patients, a combination of patient immune status coupled with measurement of IL-
6 concentrations improved both the specificity and positive predictive value 
compared to the cytokine data alone (92). However, as cytokines are released in 
response to inflammation it has been questioned the specificity of cytokines in 
diagnosing sepsis following burn injury. Therefore, further validation of cytokines 
post burn injury is required.  
1.8.4 Novel haematological parameters 
Following thermal injury there is often an imbalance in the haemostatic parameters 
which potentially mediates life threatening thrombotic complications, higher 
incidence of MOF and increased susceptibility to sepsis. Although a thorough 
analysis of cellular kinetics has not been performed longitudinally, evaluation of 
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the influence thermal injury has on individual cellular kinetics has been studied 
(93-95).  
Excessive stress on the bone marrow can result in emergency granulopoiesis that 
is characterised by the appearance of immature precursors of neutrophils, blood 
leucocytosis or neutrophilia. Of such, immature granulocytes (IGs) are a precursor 
of mature neutrophils and are elevated in septic patients (96). Automated systems 
now allow for the rapid quantification of IGs in human blood samples. Indeed, 
quantification of IGs in neonatal sepsis has shown positive diagnostic potential of 
this biomarker (97). More recently, Nierhaus et al investigated the diagnostic 
potential of IGs levels in 70 consecutive patients in ICU. Quantification of IGs 
could differentiate between sepsis and SIRS, within the first 48 hours after onset 
of SIRS, with a sensitivity of 89.2% and a specificity of 76.4%. Although IG count 
didn’t predict ICU mortality it exhibited a better discriminatory power than other 
inflammatory markers studied (i.e. IL-6, CRP and lipopolysaccharide binding 
protein) thus highlighting the potential predictive power of quantifying immature 
precursors of neutrophils in patients with suspected infections (96). 
Of note is the interplay between the haemostatic system and inflammation in burn 
injuries. Interestingly, platelets are implicated in acute and chronic inflammation 
due to their ability to release inflammatory mediators and their interactions with 
inflammatory cells (98). Platelets are activated by a broad range of inflammatory 
stimuli and are now recognised as a bridge between innate immunity and 
haemostasis due to their direct interactions with pathogens and inflammatory cells 
and immune-modulatory effects (99). 
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Platelet levels following severe thermal injury have been evaluated as a potential 
prognostic marker for patients most at risk of complications (93). Indeed, platelet 
levels fall and remain lower in patients with poorer outcomes. Recently, it has 
been demonstrated that platelets can bind to and activate neutrophils, in turn, 
influencing their functions (100). Therefore, abnormalities in platelet number or 
function will affect host defence and response to the initial trauma and potential 
infection. However, it is not known how reliable this is as a prognostic marker 
given the inaccuracy of the most commonly used methodology (i.e. impedance 
analysis) in determining platelet counts (101, 102). 
There are a number of sources which can induce error into traditional methods of 
platelet counting; via impedance or optical counting (101, 102). However, using a 
novel parameter to accurately measure platelet levels, platelet fluorescence (PLT-
F) can eliminate this interference. This parameter utilises traditional fluorescence 
flow cytometry in which platelets are stained with the RNA binding dye oxazine 
which eliminates interference mediated by cellular debris approximately the same 
size as platelets. This is especially relevant in burn injury as red cell destruction 
occurs which in turn generates cellular fragments that can interfere with platelet 
counting (103, 104). As their name suggests fragmented red cells (FRCs) are 
products of red cell lysis or shearing present in a number of pathological 
conditions (105). However, in a healthy individual FRCs are completely absent or 
in extremely low quantities (106). Due to the heterogeneous nature of FRCs direct 
quantification has proven difficult. 
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1.8.5 Cell-free deoxyribonucleic acid  
In recent years there have been a number of studies investigating the potential of 
quantifying circulating levels of cell-free deoxyribonucleic acid (cfDNA) in blood 
products from patients with various disease pathologies (107-109). Although 
quantification of cfDNA is non-specific, as it can be released from a number of 
sources, it has shown potential to predict poor outcome following trauma (110), 
thermal injury (111), cancer (112, 113) and critical illness (108). 
Rhodes et al studied the significance of raised plasma cfDNA upon admission to 
the ICU and its relation with clinical outcome and severity of disease (108). After 
extraction, levels of plasma DNA was measured by polymerase chain reaction 
(PCR) and levels were compared between septic patients, non-septic patients and 
healthy volunteers. Plasma levels of cfDNA were significantly higher in septic 
patients and patients who died compared to healthy volunteers, non-septic or 
survivors. Thus, cfDNA may be a useful prognostic marker of sepsis and mortality 
in patients admitted to ICU (108). This was further confirmed in a larger study 
when Dwivedi et al demonstrated the potential prognostic utility of cfDNA levels in 
a cohort of 80 patients with severe sepsis in which levels of cfDNA, IL-6, thrombin, 
and protein C were measured and correlated with clinical outcome. AUROC 
analysis for cfDNA to predict ICU mortality was 0.97 (95% confidence intervals, 
0.93, 1.00) and to predict hospital mortality 0.84 (95% confidence intervals, 0.75, 
0.94). Importantly, cfDNA exhibited improved predictive power compared to IL-6, 
thrombin and protein C (109). 
The recent development of fluorometric assays to measure cfDNA without a 
purification step has allowed for rapid and low cost quantification. Of note, 
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Shoham et al quantified levels of serum cfDNA using a rapid fluorometric assay in 
14 serum samples taken within 6 hours of thermal injury. Levels of cfDNA were 
significantly raised post injury (1797 ng/mL ± 1523 ng/mL) compared to healthy 
controls (374 ng/mL ± 245 ng/mL). Importantly, levels were significantly higher in 
patients who died (3264 ng/ml ± 2215) compared to those who survived (1211 
ng/ml ± 614). The group concluded that an admission cfDNA level equal to 
1200 ng/ml represents a lethal level of admission cfDNA over which 50% of the 
patients died (111). 
Quantification of plasma and serum cfDNA has therefore shown potential as a 
prognostic marker of outcome following trauma and thermal injury. Advancements 
in technologies available to quantify levels rapidly and accurately have furthered 
its application as a diagnostic and prognostic marker. However, cfDNA is non-
specific and can originate from a number of sources (114, 115). Using more 
precise methods, such a PCR, the source of cfDNA can be categorized into 
source of origin e.g. nuclear DNA (ncDNA) or mtDNA. Furthermore, additional 
sources of elevated levels of cfDNA are from activated, apoptotic or necrotic 
tissues, cells or neutrophils. 
1.9 Neutrophils  
1.9.1 General background 
Neutrophils are the most abundant circulating leukocyte comprising approximately 
50-70% of the circulating leukocyte population in healthy individuals. They are 
short lived cells with an approximate half-life of 6-8 hours. Because of this they are 
produced rapidly and in large quantities each day (0.5 – 1 x 1011 cells per day) 
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(116). Neutrophils are an essential component of innate immunity and are 
recruited rapidly to sites of infection in an attempt to tackle and clear invading 
pathogens.  
Unsurprisingly, neutrophils are equipped with an arsenal of antimicrobial 
properties which function to control infection. Neutrophils can tackle invading 
pathogens via phagocytic uptake and elimination through exposure to intracellular 
free radicals, proteolytic enzymes and toxic molecules termed reactive oxygen 
species (ROS) (117). Also, neutrophils can release their nuclear material to form 
neutrophil extracellular traps (NETs) which can ensnare and immobilise 
pathogens. This was first described in 2004 and is now regarded as an emerging 
area of neutrophil biology and innate immunity (118). Although NETs are a 
defensive action of neutrophils, the direct killing ability of these structures is still 
highly debated (118, 119). In addition to pathogen uptake and immobilisation, 
neutrophils are involved in the fine regulation of inflammatory and immune 
response through the secretion of a large number of cytokines and chemokines 
(120-123). The essential defensive nature of neutrophils is highlighted in patients 
with congenital neutrophil disorders who have increased susceptibility to bacterial 
and fungal infections (124). An overview of traditional and novel neutrophil 
functions is depicted in Figure 1.3 (125).  
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Figure 1.3. Traditional and novel functions of neutrophils. Upon arrival to the 
site of infection and inflammation neutrophils can clear invading pathogens by a 
number of mechanisms, including phagocytosis, NET formation and the secretion 
of cytokines and chemokines. Once engulfed, neutrophils will generate toxic 
compounds called ROS to kill bacteria. Upon resolution, neutrophils undergo 
apoptosis and are cleared. Figure taken from ‘Diverse novel functions of 
neutrophils in immunity, inflammation, and beyond’ published by Attila Mócsai 
(125). 
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1.9.2 Chemotaxis and transmigration 
It is essential for host defence that neutrophils can cross the endothelial barrier 
and migrate towards the local site of infection. Extravasation, or transmigration, is 
the process by which circulating neutrophils move into the infected tissue and 
surrounding area. This process is governed by a number of complex interactions 
between neutrophils and endothelium to ensure that transmigration remains 
controlled and effective. For transmigration to occur the neutrophils must first 
adhere to the vessel wall. Adherence occurs through transient selectin interactions 
on both the neutrophil and endothelium which are upregulated in inflammatory 
conditions (126). Neutrophils then move along the endothelium in processes 
termed ‘rolling and crawling’ before subsequently traversing the endothelial 
membrane (127, 128). Patients who have defective transmigration of neutrophils 
suffer from recurring infections (129).  
For the elimination of invading microbes and pathogens, neutrophils must first 
migrate to the site of infection in a process termed chemotaxis. This process is the 
movement of neutrophils in the direction of a chemoattractant gradient and is a 
fundamental function of neutrophil biology and host defence. This directed 
movement is dependent upon the regulation of intracellular signalling pathways 
prompting rapid and accurate migration (130). In a healthy individual, neutrophils 
will rapidly migrate towards chemokines (e.g. IL-8), bacterial components (e.g. N-
Formylmethionine-leucyl-phenylalanine (fMLP)) and complement proteins. In 
support of the tight regulation of chemotaxis, there appears to be a hierarchy of 
chemoattractant signals (131). The ability of neutrophils to sense 
chemoattractants is acquired during terminal differentiation in the bone marrow 
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and is highly affected by both in vitro and in vivo stimuli (132). Thus, dysregulation 
of this process will result in abnormal neutrophil chemotaxis. 
1.9.3 Phagocytosis 
Upon trafficking to a pathogen, phagocytosis and elimination can occur. 
Phagocytosis is the engulfment of invading pathogens and is central to host 
defence. Neutrophils express a number of complement receptors (e.g. CD35) in 
addition to the Fc receptor CD16 which result in enhanced phagocytosis upon 
activation (133). 
Once engulfed pathogens are localised within a phagosome and subjected to 
volatile components produced intracellularly by neutrophils (134). There are 2 
independent mechanisms for killing engulfed pathogens. Firstly, neutrophils 
generate high levels of ROS through nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH) oxidase complex (135). ROS species generated 
include hydroxyl radical and hydrogen peroxide which are unstable and toxic 
(136). Neutrophils from patients following traumatic injury have elevated baseline 
ROS production and enhanced production following secondary stimulation (137, 
138). This is indicative of systemic priming of neutrophils most likely caused by the 
inflammatory environment induced immediately post injury. Secondly, neutrophils 
can kill pathogens via the delivery of granule products to the phagosome (139). 
One such enzyme derived from azurophilic granules is neutrophil elastase which 
is a serine proteinase and is known to directly digest bacteria (140). As these 
compounds, ROS and granular proteins are extremely toxic, dysregulation or 
abundant production is also implicated in host tissue damage which is a common 
feature post traumatic and thermal injury (134).  
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1.9.4 Apoptosis 
Neutrophil apoptosis is a tightly regulated pathway which prevents tissue damage 
by inhibiting the release of toxic intracellular compounds of neutrophils. 
Recognition and clearance of dead neutrophils, via macrophages, is an essential 
step in the resolution of inflammation (141, 142). Apoptosis is controlled 
predominantly by a number of bcl-2 homologues within neutrophils. Of such, MCL-
1 is a pro-survival protein which is produced and cleared rapidly and functions to 
prevent apoptosis and is regarded as a major orchestrator in neutrophil circulating 
life span (143, 144). In addition, neutrophils express pro-apoptotic bcl-2 
homologues including, Bax (145), Bid (146) and Bim (147). Which all function to 
induce apoptosis and, unlike MCL-1, take a long time to be cleared upon 
generation. Severe traumatic injury results in a dysregulation of neutrophil 
apoptosis which is proposed to underlie the pro-inflammatory phenotype, 
increased incidence of infection and host tissue damage (148-151). 
One mechanism behind dysregulated apoptosis is the elevated levels of pro-
inflammatory cytokines and/or elevated levels of ROS, which can induce apoptosis 
via indirect activation of caspase 8 (152). Whilst it has been reported that 
neutrophil apoptosis is dysregulated following major trauma, the mechanism 
responsible and clinical implications remain unknown.  
1.9.5 Anti-microbial actions 
The importance of neutrophils in host defence is emphasised in disease 
pathologies in which fundamental neutrophil processes are dysfunctional. One 
such disease is chronic granulomatous disease (CGD) in which the individual is 
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incapable of producing ROS due to the absence of the NADPH oxidase complex 
and thus suffer from recurring infections throughout their life (153). Additionally, 
patients with Chediak-Higashi syndrome have a mutation in the LYST gene, which 
is responsible for a lysosomal trafficking regulator (154). Patients with this 
syndrome are susceptible to infections due to the inability to form functioning 
phagolysosomes. Furthermore, in a murine model of Staphylococcus aureus 
infection, there is a significant increase in mortality when mice are depleted of 
neutrophils (155). Hence neutrophils and their components are key orchestrators 
of host defence and essential for survival following bacterial challenge. 
Although there is evidence showing that severe thermal injury results in altered 
neutrophil function. It is currently unclear if thermal injury results in a longitudinal 
disruption in neutrophil functions which may underlie the increased incidence of 
infection, tissue damage and secondary complications. Hence, longitudinal and 
extensive investigation of neutrophil function post thermal injury is required.  
1.10 Neutrophil dysfunction post traumatic injury 
Traumatic and thermal injury results in a profound immune dysregulation which is 
characterised by an immediate activation closely followed by a subsequent period 
of immune suppression (37). It has been proposed that this second period of 
dysregulation may underlie the increased incidence of nosocomial infections.  
1.10.1 Maturity and phenotype of neutrophils post traumatic injury 
Of note, trauma results in profound changes in maturity, survival, phenotype and 
function of neutrophils (156-161). As neutrophils are an essential component of 
innate immunity, functional dysregulation has been linked to host tissue damage 
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and increased propensity to infections. However, mechanisms responsible are 
poorly understood. 
Maturation and production of neutrophils are controlled within the bone marrow by 
a complex panel of mediators and signals. The principal regulator of 
granulopoiesis is granulocyte-colony stimulating factor (G-CSF) which functions to 
commit progenitor cells to myeloid lineage (162), reduce maturation time (163), 
proliferation of granulocyte precursors and release of mature cells from the bone 
marrow. There are secondary signals of neutrophil production and release 
including; IL-6, IL-3 and granulocyte macrophage colony-stimulating factor (GM-
CSF) (164-166). In states such as severe bacterial infection, the body can adjust 
to a state of ‘emergency granulopoiesis’ in which large quantities of neutrophils 
are released in part mediated by G-CSF (167). Gardner and colleagues reported 
in a mouse model of trauma that increased levels of G-CSF caused the release of 
high levels of mature neutrophils which protected mice against a lethal Klebsiella 
pneumoniae pulmonary challenge. Neutralisation of G-CSF reduced neutrophil 
release and reduced survival (168). Thus one might expect that G-CSF plays a 
predominantly positive role in host protection following major trauma. 
However, excessive stress and stimulation of the bone marrow can result in 
emergency granulopoiesis that is characterised by the appearance of immature 
precursors of neutrophils, blood leucocytosis or neutrophilia (167). IGs are a 
precursor of mature neutrophils and are elevated in septic patients (96). Even 
though they are capable of mediating innate immune functions this is reduced 
compared to mature neutrophils and may underlie the increased susceptibility to 
infection following thermal injury (169). In a cohort of 83 severely injured patients, 
Cook et al reported that immediate and sustained elevation in G-CSF was 
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associated with the release of immature cells from the bone marrow and an 
increased risk of infection (157). Hence, the role of G-CSF in mediating survival 
following thermal injury remains unclear and is most probably multi-factorial and 
time dependent.  
In 2011, Pillay and colleagues described a distinct change in the circulating 
neutrophil phenotype following endotoxin challenge or following severe injury 
(158). This group characterised neutrophil subsets by flow cytometry staining for 
CD16, a low affinity Fc receptor expressed on neutrophils, and CD62L, an 
adhesion molecule involved in leukocyte trafficking that is shed upon activation. 
Three hours after lipopolysaccharide (LPS) administration there is a dynamic 
change in neutrophil phenotype with the appearance of three subsets of 
neutrophils (Figure 1.4). Two of which were detectable in challenged participants 
and were absent from healthy individuals. These subsets were; 
CD16dim/CD62Lbright and CD16bright/CD62Ldim neutrophils.  
Firstly, CD16dim/CD62Lbright neutrophils were banded in their nuclear morphology 
and most likely released from the bone marrow prematurely in response to the 
LPS challenge. The second population of hyper-segmented CD16bright/CD62Ldim 
neutrophils had increased maturation compared to normal blood neutrophils.  
Furthermore, each of the novel subsets had differing functions with 
CD16dim/CD62Lbright neutrophils having reduced apoptosis compared to the 
CD16bright/CD62Ldim population. Whereas the CD16bright/CD62Ldim population 
exhibited increased ROS production compared to the CD16dim/CD62Lbright 
population (158).  
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More recently the authors have shown that CD16bright/CD62Ldim neutrophils are a 
distinct population of circulating neutrophils released in response to inflammation 
and not LPS challenge (170). Banded cells, CD16dim/CD62Lbright phenotype, were 
released much quicker into the circulation following LPS challenge compared to 
CD16bright/CD62Ldim cells. Furthermore, CD16bright/CD62Ldim cells were different at 
the proteome level compared to band and/or hypersegmented cells. Whilst the 
source of these CD16bright/CD62Ldim cells remains unknown, the group proposed 
that they are a unique population of cells released during inflammation and 
participate in the regulation of the immune system (170). Data like these highlight 
the importance of characterising neutrophil phenotype and its correlation with 
clinical outcome post thermal injury.  
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Figure 1.4. Administration of LPS results in distinct phenotypical changes in 
circulating neutrophils. (A) Flow cytometry of neutrophils, based on CD16 and 
CD62L staining, before administration of LPS. (B) Neutrophil populations 180 
minutes following LPS administration. Three populations of neutrophils are 
observed based on CD16 and CD62L staining. Two populations are unique to 
LPS challenge and absent from healthy individuals. Figure taken directly from ‘A 
subset of neutrophils in human systemic inflammation inhibits T cell responses 
through Mac-1’ by Pillay et al. (158). 
  
 
35 
 
1.10.2 Functional dysregulation of neutrophils post traumatic injury 
Chemotaxis describes the movement of a cell to a stimulus in a concentration 
dependent manner. Neutrophils utilise chemotaxis to migrate to sites of infection 
and tackle and clear invading pathogens and bacteria. Studies dating back to 
1974 have identified an inherent defect in neutrophil migration following thermal 
injury (159-161). Until recently, technologies used to measure neutrophil migration 
have been limited, time-consuming and require a large volume of blood.  
In 2010, Butler and colleagues described a novel microfluidic device that is simple 
to use, allows for precise and robust measurements of chemotaxis speed and 
persistence characteristics at single-cell resolution. Importantly, this device uses 
only a single drop of blood which is important to prevent anaemia in critically ill 
patients (171). This group has shown that thermal injury results in a significant 
reduction of directional migration speed within 24 hours of injury which reaches 
maximal reduction at 72-120 hours post injury when compared to healthy 
individuals. In this study one patient, with a 60% TBSA thermal injury, did not have 
reduced neutrophil migration. This patient was admitted with a documented 
infection unlike the rest of the cohort. The authors propose that the immediate 
inflammatory cascade post thermal injury results in suppression of chemotaxis 
which increases the propensity to infections and that the infection itself does not 
reduce chemotaxis (171). Hence, modulation of chemotaxis remains an early 
therapeutic target. 
More recently the authors have described a novel phenotype of spontaneous 
neutrophil migration in septic patients following severe thermal injury. This 
phenotype was observed 1 – 2 days before the diagnosis of sepsis and was not 
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detectable in patients who did not develop an infection or healthy individuals 
(172). Therefore quantification of chemotaxis phenotypes may aid in early 
diagnosis of patients at risk of developing sepsis during their hospital stay. This 
could aid in the timing of antibiotic and clinical treatment in the aim of improving 
patient outcome post thermal injury (171). 
Once a neutrophil has trafficked to the site of infection it functions to either 
phagocytose or generate NETs to ensnare the invading pathogen. Phagocytosis is 
a complex process that forms an essential component of innate immunity through 
the ingestion and elimination of pathogens. As such, a dysregulation in phagocytic 
function may precede the development of infections which are extremely common 
in patients with thermal injuries (38). Although this has been proposed, only a 
small number of studies have examined this relationship and none have studied 
the dynamic longitudinal changes in relation to clinical complications post thermal 
injury. 
Sheng and colleagues studied neutrophil bactericidal activity in 36 patients with 
thermal injuries using a chemiluminescence assay. The group demonstrated that 
septic patients had lower neutrophil bactericidal function compared with healthy 
controls. Bactericidal activity was significantly lower in thermal injuries above 35% 
TBSA suggesting that severity of injury orchestrates the amplitude of 
dysregulation consistent with previous literature examining chemotaxis (171, 173). 
Alexander et al performed a prospective analysis of neutrophil function in 20 
patients with severe thermal injuries (≥45% TBSA). The group reported a 
significant reduction in neutrophil bactericidal activity, in response to 
Staphylococcus aureus 502A, and chemotaxis in infected patients compared to 
non-infected patients. Thus suggesting a broader dysregulation of neutrophil 
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functions mediated by initial injury and subsequent sepsis not previously reported 
(171, 174). 
ROS are essential anti-microbial compounds which function to directly kill and 
eliminate engulfed pathogens within a neutrophil. Production of ROS is controlled 
by NADPH oxidase complex which produces O2- and H2O2 upon activation which 
are toxic compounds. It has been reported that trauma results in an increase in 
ROS production (137). Conversely, multiple groups have shown that thermal injury 
results in significant reduction in the ability of neutrophils to generate ROS and a 
reduced phagolysosomal acidification (175-177).  
Parment and colleagues in a prospective exploratory cohort study investigated 
neutrophil oxidative burst in response to Escherichia coli (E.Coli), phorbol 12-
phorbol myristate 13-acetate (PMA), and fMLP. This study included 28 patients 
with thermal injuries with an average TBSA of 36%. Thermal injury resulted in a 
significant reduction in neutrophil oxidative burst, in response to all stimuli, from 
admission up to 3.5 months post injury compared to levels seen in healthy 
volunteers. Thus, thermal injury results in an immediate and sustained 
immunosuppression which appears to be different from general trauma (177). 
Trauma and thermal injuries result in a significant dysregulation of a number of 
neutrophil functions. Although multiple groups have described the dynamic 
changes in neutrophil function no group has conclusively studied the longitudinal 
changes in neutrophil functions in relation to acute injury and subsequent 
infections following thermal injury.  
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1.11 Neutrophil extracellular traps 
1.11.1 Structure and function 
NETs, although first described in 2004, are still emerging as a potentially important 
area of neutrophil biology (118). NETosis (178) is a tightly regulated active cell 
death pathway facilitated by neutrophil activation resulting in the extrusion of DNA 
to the exterior of the cell decorated in granular proteins which can ensnare, trap or 
sometimes kill bacteria (118, 119, 179). Discovery of NETs sparked an entirely 
new area of neutrophil research and their association with innate immunity and 
haemostasis. Systemic markers of NETosis have been reported following major 
trauma, burn injury and during sepsis (180, 181).  
1.11.2 Vital and suicidal NETosis 
Traditionally NETs are generated by incubating neutrophils with chemical 
agonists, e.g. PMA, a known potent activator of protein kinase C (PKC). In 2013, 
this pathway of NET generation was termed ‘suicidal NETosis’ (178). This process 
results in complete loss of the nucleus and terminal cell death hence the name. 
Although NETosis was first described in 2004 there are earlier reports indicating 
that PMA could cause chromatin decondensation, nuclear swelling, release of 
nucleoplasm into the cytoplasm and membrane perforation (182). It wasn’t until 
2004 that the process of NET release was discovered by Zychlinsky and 
colleagues (118). This initial description was advanced by further studies revealing 
that NETs are an important arm of innate immunity as they can bind to both gram-
positive and gram-negative bacteria (183).  
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The mechanisms causing terminal NET production are still not fully understood. 
Many groups have reported that the generation of oxidants is an essential 
requirement for NETosis. However, signalling components downstream of 
oxidants responsible remain unknown. For instance, Fuchs et al reported that 
formation of NETs is dependent upon activation of NADPH oxidase. Additionally, 
the authors state that patients with CGD carry a mutation for NADPH oxidase and 
therefore cannot make NETs which may be responsible for recurring infections 
(184). Following activation of NADPH oxidase, ROS initiates the translocation of 
neutrophil elastase to the nucleus which results in chromatin decondensation and 
NETosis. Importantly, neutrophil elastase deficient mice do not form NETs in a 
pulmonary model of Klebsiella pneumoniae infection thus supporting the proposed 
mechanism of NADPH oxidase dependent NETosis. Hence, mobilisation of 
granular proteins following ROS production are fundamental in the regulation of 
chromatin density and structure (185). However, it has also been reported that 
biological stimuli, e.g. Staphylococcus aureus, can result in NADPH oxidase 
independent NET formation (186). Thus it is proposed that NETosis can occur 
through multiple signalling pathways which may be unique to individual stimuli. 
A fundamental step in suicidal NET generation is the rupture of the cellular 
membrane and death of the neutrophil. Therefore one would propose that suicidal 
NETosis inhibits the ability of neutrophils to perform other traditional defensive 
actions, e.g. phagocytosis or chemotaxis, and may leave the host 
immunocompromised which would be fatal to patients following traumatic or 
thermal injury. Therefore, it is important to consider how neutrophils can generate 
NETs and still perform vital defensive actions. A number of possibilities exist 
including; 1) neutrophils generate NETs and survive the process; 2) neutrophils 
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are split into pools which perform different specialised functions depending upon 
orchestrating signals; 3) NET formation is the the last line of defence of the 
neutrophils when the host is overwhelmed.  
A second pathway of NET generation has also been described and coined ‘vital 
NETosis’. The first major difference between the vital and suicidal pathway is the 
stimulus. Vital NETosis is mediated by naturally occurring stimuli, e.g. bacterial 
components and/or activated immune cells, and is therefore seen as the NETosis 
pathway occurring in vivo (178, 187). Moreover, vital NETosis occurs rapidly, 
within 30 - 45 minutes, whereas suicidal NETosis is much slower, within 3 - 4 
hours post stimulation. Theoretically, this allows for rapid entrapment of invading 
pathogens and doesn’t compromise the host. The final difference between the two 
pathways is the mechanism of release. Vital NETosis is still in part mediated by 
activation of NADPH oxidase, mobilisation of granular proteins/enzymes and 
histone citrullination (178). However, vital NETosis also employs vesicular 
trafficking of DNA to the exterior of the cell. Vesicles co-localised with the cell 
membrane and delivered the nuclear material to the outside of the cell without 
membrane perforation (Figure 1.5 G, H and I) (186). This could represent a 
conserved mechanism to tightly control NET release and allow additional 
neutrophil functions to occur. In support of this hypothesis, Clark et al 
demonstrated that neutrophils which had released NETs were impermeable to 
SYTOX Green stain, suggesting that neutrophils can remain intact following 
NETosis (100). The differences between ‘vital and suicidal’ NETosis are depicted 
in Figure 1.5 (178).   
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Figure 1.5. Proposed novel mechanisms of NET release: suicidal and vital 
NETosis. (A-C) ‘Suicidal NETosis’ is initiated by chemical agonists, e.g. PMA, 
resulting in activation of PKC and translocation of granular proteins and eventual 
chromatin decondensation which ultimately leads to NETosis. This process 
requires approximately 180 minutes. (D-F) Bacteria and immune cells can cause 
rapid ‘vital NETosis’. Again this process requires the mobilisation of granular 
proteins for eventual NET release. (G-I) However vital NETosis can utilise vesical 
transport to expel DNA to the exterior of the cell without membrane rupture. The 
total figure was taken from (178) which took figures G-I from ‘A novel mechanism 
of rapid nuclear neutrophil extracellular trap formation in response to 
Staphylococcus aureus’ by Pilsczek et al (186). 
  
 
42 
 
Neutrophils may be split into specialised pools which perform actions depending 
upon complex orchestrating signals. In 2014, Branzk et al identified a novel 
microbe sensing mechanism that tailored neutrophil anti-microbial actions 
depending upon pathogen size. Neutrophils selectively released NETs in 
response to large microbes, namely Candida albicans hyphae and extracellular 
aggregates of Mycobacterium bovis, but did not respond to single bacteria or 
yeast which were phagocytosed instead. The ‘decision’ made by neutrophils to 
release a NET or undergo phagocytosis was controlled by competition for 
neutrophil elastase between the two processes. Dectin-1, a pattern recognition 
receptor involved in innate immunity, was the key signalling molecule in this 
decision process. If phagocytosis occurred via dectin-1, neutrophil elastase 
translocation was inhibited, thus preventing NET production. Conversely, knockout 
of dectin-1 led to excessive NETosis and tissue damage. Thus phagocytosis 
appears to act as a checkpoint to induce or prevent NET formation via dectin-1 
and competition of neutrophil elastase (188). Therefore, NET formation may 
represents the last resort of neutrophil defence against invading pathogens to 
prevent complete loss of the circulating neutrophil pool and in turn 
immunocompromising and potentially damaging the host. This is of particular 
interest when studying patients with traumatic injuries as they are prone to 
nosocomial infections and sepsis (38). Hence, this pathogen sensing ability may 
aid patients by switching to a pro-phagocytosis phenotype, reducing the risk of the 
patient becoming immunocompromised. 
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1.11.3 Citrullinated histone H3 and reactive oxygen species generation  
ROS are a heterogeneous collection of molecules which are highly reactive and 
formed in multiple cellular organelles as bi-products of redox reactions. NADPH 
oxidases are a group of membrane bound multiprotein enzymes that generate 
ROS and are expressed in large quantities in neutrophils (136). ROS play an 
important link between cellular activation and NET formation as discussed above 
(184). Although the full mechanisms behind ROS induced NET formation aren’t 
fully understood it is known that ROS can induce histone citrullination by activation 
of the enzyme peptidylarginine deiminase 4 (PAD4) which results in 
decondensation of nuclear chromatin (189). PAD4 is a nuclear enzyme which is 
highly abundant in human neutrophils and mediates the replacement of amino 
acid arginine with citrulline (190, 191). Citrullinated histone H3 (Cit H3) is 
expressed within NETs and is regarded as a specific marker of NET generation 
and has recently been detected in the bloodstream of critically ill patients (181). In 
addition to their role in the pathogenesis of inflammatory conditions, modified 
histones are potential biomarkers of sepsis (181, 192). 
1.11.4 Histones, DNA and nucleosomes 
Histones are a group of small positively charged proteins including; H1, H2A, H2B, 
H3 and H4. They are highly conserved and responsible for gene transcription 
(193, 194). Free histones are extremely cytotoxic due to their charged nature and 
administration results in rapid mortality in animal models (195-198). 
DNA is the fundamental orchestrator of cellular growth, repair, function and 
reproduction. DNA is released abundantly following severe tissue damage and 
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can activate a number of inflammatory cascades (199), because of this DNA is 
regarded as a DAMP. A DNA molecule consists of two polynucleotide chains with 
each nucleotide containing a 5-carbon sugar molecule attached to a phosphate 
group (194). These phosphate groups make DNA negatively charged which 
means that they can bind to histones and form nucleosome complexes (Figure 
1.6).  
Comprised of a nucleosome core, an octameric complex of histones and DNA, 
and linker DNA, nucleosomes are the principal component of chromatin (194, 200, 
201). Nucleosomes have multiple functions including signalling as a centre for 
chromatin orchestrated processes and assembling higher-order structures which 
aid in compaction of genomic components (200). The presence of circulating 
nucleosomes is associated with NET release and cell death in patients with 
chronic myeloproliferative neoplasms and deep vein thrombosis (DVT) (202, 203). 
Nucleosomes have different cytotoxic and procoagulant properties compared to 
free histones and DNA (198, 204-206). Despite this, many studies investigating 
these components interchangeably use nucleosomes, histones and DNA to 
describe in vivo associations. Therefore, characterisation of the structure and 
properties of circulating nucleosomes, histones and DNA is required to 
conclusively understand their roles in inflammation, coagulation and tissue 
damage. 
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Figure 1.6. Nucleosome structure. Nucleosomes are comprised of a 
nucleosome core, an octameric complex of histones (H3-H4) and DNA, and linker 
DNA (H2A-H2B). Nucleosomes form through charge interactions with the overall 
charge being neutral. Figure adapted from ‘Histone exchange, chromatin structure 
and the regulation of transcription’ by Venkatesh and Workman (194) 
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1.11.5 Autophagy and neutrophil extracellular traps 
Autophagy is a normal physiological response of the cell that maintains 
homeostasis by protein degradation and turnover of destroyed cell organelles to 
induce new cell formation (207). Recent evidence has demonstrated that NET 
formation is dependent upon both ROS generation and activation of autophagy 
(208). Additionally, multiple bacterial strains can activate autophagy, implicating its 
activation in neutrophil biology and host defence (209-212). To date, it is currently 
unknown if thermal injury and/or soluble factors released affect neutrophil function 
via alteration in autophagy signalling.  
1.12 NETs and traumatic injury 
Traumatic and thermal injury are characterised by an initial sterile injury and 
subsequent infectious stimuli. The generation of NETs is regarded as defensive 
action of neutrophils to invading stimuli in an attempt to ensnare and potentially 
trap bacteria. It has been demonstrated that NETs are present in septic individuals 
via the measurement of non-specific circulating markers of NET formation (213, 
214). Furthermore, studies have concluded that NETs are produced during 
subsequent septic episodes following traumatic injury (181, 215, 216). Thus, NETs 
may form an orchestrating role in the defence against invading pathogens in 
patients with thermal injuries. However, it has yet to be conclusively established if 
NETs are generated following thermal injury.   
Interestingly there is an emerging body of evidence to implicate NET formation 
and non-infectious stimuli (217-219). With elevations in circulating NET 
biomarkers reported post traumatic and thermal injury (215, 220). It is proposed 
that the severe tissue damage is enough to induce rapid NET formation within 
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minutes of injury through the release of inflammatory mediators. In a cohort of 
patients with burn injury, plasma cfDNA are increased compared to healthy 
individuals and thus suggests immediate NET formation (220). Although this study 
reports elevation in NET components it does not measure any specific markers of 
the process. Quantification of cfDNA alone is non-specific to NETosis, with plasma 
cfDNA originating from a number of sources including apoptotic, necrotic or 
NETosing cells and bacteria themselves (115). Therefore, to our knowledge, it has 
yet to be conclusively established whether NETosis is occurring in patients with 
burn injury. 
1.13 In Vivo host defensive functions of neutrophil extracellular traps 
Despite extensive studies of NETs, their direct in vivo interactions and effects are 
still being investigated with multiple groups reporting contradicting results (119, 
221). Therefore, how NETs contribute to host defence post thermal injury is poorly 
understood and warrants further investigation.  
Meng and colleagues provided evidence that NETs were responsible for in vivo 
killing of bacteria. Administration of deoxyribonuclease (DNAse) to mice in a cecal 
ligation puncture (CLP) model of sepsis resulted in reduced in vivo NET markers 
coupled with increased colony forming units of bacteria and an increased pro-
inflammatory response (221). Hence, in this study NETs are directly responsible 
for killing bacteria and host protection. However, in 2012 Menegazzi challenged 
the current paradigm of NETs directly killing bacteria. The group reports that NETs 
ensnared bacteria but did not kill them as incubation of NETs with DNAse freed 
bacteria which were still alive (119). Therefore, NETs may have more of a physical 
bacteriostatic role in ensnaring bacteria and preventing dissemination rather than 
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a direct bactericidal activity. Though the potential implications this has in severe 
infections, e.g. sepsis following severe thermal injury, are currently unknown and 
seem rather redundant if neutrophil function is already reduced.  
Furthermore, in a murine model of sepsis, NETs accumulate within various organs 
and interact with the vascular endothelium. Within the microvasculature NETs 
colocalised with inflammatory cells, including platelets, and may be contributing to 
thrombosis which is commonly observed post infection (222).  
1.14 Excessive NETosis, thrombosis and host tissue damage 
Advancements in the treatment of thermal injuries have improved initial survival 
following severe thermal injury. However, delayed mortality remains a significant 
health care issue with sepsis and MOF being the leading causes of mortality (4, 
5). Even though MOF is well characterised the mechanisms mediating the 
pathogenesis are poorly understood. Therefore advancements in understanding 
the pathogenesis of MOF may improve patient outcome. 
Although neutrophils are an essential component of innate immunity, recent 
evidence has shown that NETs can initiate a procoagulant phenotype, tissue and 
organ damage (195, 221, 223-225). Prolonged or uncontrolled NET generation 
results in damage to host tissues and significantly contributes to the pathogenesis 
of inflammatory conditions (195, 198, 226, 227). DNA and histones are key 
components of NETs, but elevation in circulating levels may also mediate organ 
damage through their cytotoxic nature (228). As such, NETs can provide a bridge 
between the innate immunity and haemostatic systems. For example, they can 
directly bind to and activate platelets along with various coagulation system 
components (100, 229). These interactions during excessive NETosis may then 
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promote thrombosis, DIC (52) and potentially mediate the pathogenesis of MOF 
following sepsis (230, 231). 
Elevated levels of NET components have been implicated in thrombosis formation 
in a murine model of DVT induced stenosis in the inferior vena cava. 6 hours after 
stenosis, levels of plasma cfDNA were significantly elevated compared to sham-
treated animals and neutrophils were visible in both the red (red blood cell rich) 
and white (platelet rich) thrombi. Moreover, Cit H3, a specific marker of NETs, 
colocalised with neutrophils in red thrombi. This data is consistent with a previous 
publication which identified nucleosomes in thrombi of baboons following induction 
of DVT (232). Infusion of DNAse protected animals against ﬂow restriction induced 
by DVT regardless of the length of stenosis. Furthermore, DNAse treated mice 
had no visible thrombi suggesting DNAse disrupts the mechanisms leading to 
thrombosis. The group hypothesised that ‘the anti-thrombotic effect of DNAse is 
likely to be mediated by removal of NETs generated locally at the site of stenosis’ 
(233).  
The procoagulant effect of NET components and cfDNA, is well documented (230, 
234). However, the role of cfDNA on fibrinolysis is poorly understood. Fibrinolysis 
is the enzymatic breakdown of fibrin in blood clots predominantly by the enzyme 
plasmin. In 2015, Gould and colleagues investigated the effect cfDNA has on 
fibrinolysis in sepsis. The group quantified levels of cfDNA in plasma obtained 
from 400 patients with severe sepsis and clot lysis was measured in an isolated 
system and breakdown of formed clots was visualised using electron microscopy. 
Clots formed in plasma from septic patients had decreased permeability, 
decreased susceptibility to fibrinolysis and increased clot stability which could be 
reversed by the addition of DNAse. It is proposed that this impairment of 
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fibrinolysis was caused by cfDNA forming a ternary complex between plasmin, 
cfDNA and fibrin that inhibits the activity of plasmin (235). Hence, this study 
highlights the multifaceted actions of NET components in the production and 
maintenance of thrombosis and potentially the pathogenesis of MOF following 
sepsis.  
MOF is characterised by the formation of thrombi in the microvasculature resulting 
in tissue hypoxia, damage and ischemia. Boneschansker et al have demonstrated, 
using a microfluidic device replicating capillary plexuses, that NETs are capable of 
perturbing blood flow in capillary networks (Figure 1.7 A-B) (236). NETs generated 
from a very small number of neutrophils resulted in more than half of the 
microfluidic device being obstructed from red blood cell flow and this inhibition 
lasted for hours post NET formation despite the presence of naturally occurring 
DNAse in the blood. Administration of Turbo™ DNAse, a more potent analogue of 
naturally occurring DNAse 1, degraded NETs and restored blood flow within 30 
minutes of infusion (Figure 1.7 B). Importantly, digestion products of NETs did not 
impair blood flow within the microfluidic device (236). Complete breakdown of the 
NET structures and removal of DNA from the channels was therefore sufficient to 
prevent this obstruction. This study highlighted a potential mechanism in which the 
physical properties of NETs may result in the pathogenesis of MOF by obstructing 
blood flow through capillary networks. 
NETs and their components have the potential to not only induce thrombosis but 
can also propagate further detrimental effects by impairing fibrinolysis and 
obstructing blood flow. The formation of excessive or uncontrolled NETosis may 
result in tissue hypoxia, the onset of DIC, cause host tissue damage and 
potentially mediate the pathogenesis of MOF in patients with thermal injuries. 
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Importantly, digestion or breakdown of NETs via DNAse may be a therapeutic 
target to prevent NET mediated pathogenesis of MOF.  
 
52 
 
 
Figure 1.7. NETs form a physical barrier and impair blood flow through a 
microfluidic device. (A-B) Extracellular chromatin from NETs (yellow stain) 
extends deep into microfluidic devices and impairs blood flow (red stain). 
Incubation for 30 minutes with DNAse results in degradation of NETs and restores 
blood flow through the device. The figure was taken directly from ‘Capillary 
Plexuses are Vulnerable to Neutrophil Extracellular Traps’ by Boneschansker et al 
(236). 
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1.15 Degradation of neutrophil extracellular traps 
DNAse is the major extracellular endonuclease found in a number of bodily fluids 
and functions to breakdown chromatin and DNA which are released following 
cellular damage, cell death and NETosis. Levels of circulating cfDNA are elevated 
in a number of disease pathologies but the mechanisms behind uncontrolled 
elevation in this marker are poorly understood. Of note, elevated levels of plasma 
cfDNA are associated with and contribute to the progression of autoimmune 
diseases (237, 238). In a subpopulation of patients with systemic lupus 
erythematosus (SLE), DNAse activity was impaired by DNAse inhibitors or 
inhibitory antibodies (237). Although a reduction in DNAse activity and build-up of 
cfDNA has been shown to be associated with the development of autoimmune 
diseases, to date no group has investigated DNAse activity following thermal injury 
(237). 
To date, only one study has investigated DNAse levels post traumatic injury. This 
study recruited 39 patients with traumatic injury and quantified levels of DNAse 1. 
Whilst there was a significant elevation in circulating DNA levels post-injury, only 
on the day of injury was a difference observed in DNAse 1 levels, with patients 
having significantly higher circulating DNAse 1 levels. At all other study time-
points, DNAse 1 levels in patients were comparable to that for healthy controls 
(239). Thus, the accumulation of circulating NET markers may be due to a 
reduction in DNAse activity rather than quantity and may be one mechanism for 
the pathogenesis of MOF following thermal injury. 
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1.16 Actin  
Actin is the most abundant protein in mammalian cells and is a fundamental 
protein for cell motility (240). Actin exists in a balance between monomeric and 
filamentous actin. Processes such as cell motility are dependent upon the rapid 
polymerisation of monomeric actin into filamentous actin (241, 242). However, this 
predisposition to polymerise is of detrimental consequences if actin is released 
into the circulation, as extracellular actin can cause direct damage to the 
microvasculature capillaries, impair clot lysis and activate platelets (240, 243, 
244). Elevation in circulating actin is attributed to a saturation of the actin 
scavenging system. 
Interestingly, DNAse activity is indirectly controlled by actin scavenging system 
(240, 245) as actin can bind to DNAse and inhibit its enzymatic activity (237, 245). 
Due to the extensive amount of tissue damage post severe thermal injury one 
might hypothesise that actin is released following severe thermal injury and results 
in the inhibition of DNAse activity and build-up of circulating cfDNA. Data reported 
by Lee et al support this hypothesis as elevated levels of actin have been detected 
in a cohort of septic patients (246). Therefore, DNAse activity may be inhibited in 
septic patients predisposing them to risk of actin toxicity, accumulation of 
circulating DNA, host tissue damage, a pro-thrombotic phenotype and MOF.  
1.17 Actin Scavenging System 
Control of the actin scavenging system is mediated by two key proteins; gelsolin 
(GSN) and vitamin D binding protein (VDBP) (240). Both proteins functions to 
clear monomeric and filamentous actin from the circulation through the liver. The 
actin scavenging system is summarised in Figure 1.8. 
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1.17.1 Gelsolin 
Plasma GSN is found in high quantities in healthy individuals and can bind to both 
monomeric and filamentous actin (246). Levels of circulating GSN in healthy 
individuals range from 150 – 300 µg/ml and plasma GSN has a half-life of 
approximately 2 days (247). GSN is a 90 kDa cytoplasmic actin binding protein 
which also exists as a plasma variant. The plasma variant of GSN is larger, 93 
kDa, and more positively charged compared to cytoplasmic GSN. Although both 
variants are similar in structure, their processing and eventual actions are 
independent (248). 
GSN functions in collaboration with VDBP to rapidly depolymerise and reduce 
circulating levels of actin. GSN has three actin binding sites and functions to clear 
actin in two distinct processes (249-251). Firstly, GSN functions to prevent any 
further addition of monomeric actin to existing chains by binding to the barbed end 
of actin (250). Secondly, GSN binds to two distinct sites on the side of polymerised 
actin and severs the filaments resulting in depolymerisation (240, 251). As GSN 
binds to circulating actin it is not surprising that studies have reported a decrease 
in circulating levels of GSN in a number of disease pathologies connected with 
actin release (252-259). Furthermore, it has recently been reported that 
administration of GSN can reverse actin inhibition of lung macrophage binding and 
uptake of bacteria (260). In addition to being part of the actin scavenging system, 
GSN has direct interactions in modulating the immune response. Thus, reduced 
levels of GSN will have a multifaceted role in host response. 
Huang et al reported in 95 patients with thermal injuries that plasma GSN levels 
were reduced and associated with mortality, development of sepsis and MODS 
 
56 
 
(254). Furthermore, in a rat burn model (40% TBSA) plasma GSN levels decrease 
12 hours post injury and remain lower for up to 6 days post injury. This was 
accompanied by increased pulmonary microvasculature permeability in burn 
treated animals. Importantly, administration of recombinant plasma GSN prior to 
burn injury protected against this pulmonary microvasculature dysfunction (261). 
Therefore plasma GSN may not only serve as a biomarker of poor outcome but 
could also be a potential therapeutic target to prevent secondary complications. 
However, the potential translation of GSN and its action in human burn injury have 
not been fully invesitgated.  
1.17.2 Vitamin D binding protein 
VDBP, also referred to as Gc-globulin, is a 58-kd alpha-2-globulin which is a key 
component of vitamin D transport (262). VDBP is found in abundant quantities in 
healthy individuals with levels comparable to GSN (263). Unlike GSN, VDBP binds 
to monomeric actin only allowing GSN to bind to polymeric actin (264). This 
relationship suggests an orchestrated response to enhance actin clearance in vivo 
by VDBP and GSN (265). 
Binding of VDBP to actin prevents further polymerisation by clearing residual 
monomeric actin from the circulation. The clearance of actin-vitamin D binding 
protein complexes is rapid and is mediated through the liver primarily but this can 
also occur through the spleen and lung (266, 267). It is important to note that 
clearance of actin via GSN and VDBP results in consumption with a transient 
decrease in their circulating levels. 
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Levels of VDBP have also been suggested as a prognostic marker of outcome 
and organ damage following severe traumatic injury (268-271). Interestingly, it has 
been reported that trauma results in an eventual over production of VDBP (271). 
This implies a reactive response of the body to saturation or dysregulation of the 
actin scavenging system. However, this has not been studied longer than 1 week 
post trauma.  
To date, no group has studied the relationship between VDBP, GSN and DNAse 
post thermal injury. As VDBP and GSN are responsible for actin clearance one 
might hypothesise that in thermal injury low plasma VDBP and GSN levels will be 
associated with dysregulated DNAse activity. Therefore dysregulation in the actin 
scavenging system may precede actin inhibition of DNAse activity and is 
potentially contributing to the complicated outcomes associated with MOF post 
thermal injury.  
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Figure 1.8. Actin scavenging system in a healthy individual. Following acute 
tissue injury there is the release of monomeric and polymerised actin into the 
circulation. VDBP rapidly binds to monomeric actin and clears it from the 
circulation, preventing further polymerisaiton. GSN clears polymerised actin by two 
mechanisms (249-251) in collaboration with VDBP. This rapid clearance of actin 
maintains circulating DNAse activity.  
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1.18 Targeting neutrophil extracellular traps 
It is proposed that targeting the formation or breakdown of NETs in various 
diseases pathologies may have positive effects on disease progression (236, 237, 
272, 273). One proposed mechanism for targeting NETs is the breakdown of pre-
formed and excessive NETosis via the administration of DNAse to reduce 
thrombotic complications, host tissue damage and pro-inflammatory response 
during infection (230, 232, 235, 236, 274). However, administration of DNAse in a 
murine model of sepsis, induced by CLP, resulted in increases in the pro-
inflammatory response, the colonisation of bacteria and mortality (221). This was 
attributed to increased bacterial dissemination caused by early and inappropriate 
degradation of NETs. This study highlights the potential importance of time 
dependent treatment as NETs should only be targeted when in excess and 
contributing to the pro-inflammatory and thrombotic phenotype.  
NET production may also be inhibited via the inhibition of PAD4. In a murine 
model of sepsis, PAD4 deficient mice had comparable mortality to wild-type mice. 
Similarly, PAD4 knockout mice were partially protected against LPS induced 
shock, suggesting that knock-out of PAD4 and elimination of NETs may protect 
against the pro-inflammatory and toxic effects of NETs during sepsis. The authors 
conclude ‘preventing NET formation by PAD4 inhibition in inflammatory or 
thrombotic diseases is not likely to increase host vulnerability to bacterial 
infections’ (275). However, this model does not take into account pre-existing 
immunosuppression which is observed post burn injury (159-161, 173, 175-177). 
Moreover, in a murine model of infection, using necrotizing fasciitis, PAD4 
knockout mice were more susceptible to infection than wild-type mice. The authors 
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attributed this susceptibility to the inability to form NETs in response to the 
infection (276). Therefore full characterisation of NET formation kinetics, functions 
and the relationship with other neutrophil functions is required to understand if 
targeting NETs post thermal injury would provide any host protection.   
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1.19 Aims and hypothesis 
Advancements in the initial care of burn wounds and immediate survival have 
increased dramatically over the past four decades (3, 18). However, sepsis and, 
consequently, MOF remain leading causes of delayed mortality following severe 
thermal injury (47). Although sepsis and MOF are well characterised, the 
mechanisms driving the increased incidence of infection and pathogenesis of MOF 
are poorly understood.  
Evidence has implicated abnormal neutrophil function in the increased propensity 
to infection. However, this has not been studied longitudinally (159-161, 173, 175-
177). The recent discovery of NETs has identified a novel paradigm in which 
neutrophil functions may be dysregulated post thermal injury and contributing to 
the pathogenesis of MOF (230, 232, 235, 236, 274). To date, no group has 
conclusively shown that NETs are produced following thermal injury and no group 
has examined the relationship between NETs, MOF and sepsis following severe 
thermal injury.  
Accordingly, the aims of this thesis were to: 
1. Determine the effect severe thermal injury has on neutrophil function and 
understand potential mechanisms mediating the dysfunction. 
2. Investigate if thermal injury initiates NETosis and to investigate if NETosis 
is induced by sterile injury and/or infectious stimuli. 
3. Determine if NET generation is associated with secondary complications, 
MOF and sepsis, and to investigate potential mechanisms and therapeutic 
targets. 
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4. Investigate if clearance of DNA was dysfunctional and associated with 
MOF.  
5. Determine if reduced DNAse activity is a potential therapeutic target to 
reduce secondary complications.  
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Chapter 2 
Materials and Methods 
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Materials and Methods 
2.1 Scientific Investigation of Biological Pathways Following Thermal Injury 
Study 
2.1.1 Ethical approval 
Ethical approval for the study was granted by a UK NHS research ethics 
committee (Reference 12/EM/0432). Where possible, written informed consent 
was received from participants prior to their inclusion in the study. Due to the 
severe nature of the injuries being studied, the ethics committee approved the use 
of a legal consultee, either personal or nominated, if the patient was not initially 
able to consent for inclusion in the study themselves. When the patient was able, 
they were approached to give written consent to continue to participate in the 
study. 
2.1.2 Study cohort 
Scientific Investigation of the Biological Pathways Following Thermal Injury in 
Adults and Children (SIFTI) study is a multi-centre prospective observational 
cohort study. 150 patients were recruited in total to the study from January 2013 to 
October 2015. In addition, blood samples were collected from 10 healthy 
volunteers after obtaining written informed consent from the donors, who at the 
time of participation were in good health, free of immunological illness and 
significant co-morbidity, and were not taking any medication known to interfere 
with immunity. To be included in the SIFTI Trial the patient must meet the 
inclusion criteria summarised in Table 2.1. Further inclusion and exclusion criteria 
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are listed below Table 2.1. The study aimed to evaluate changes in the 
inflammatory, immune, endocrine, metabolic and coagulation responses to severe 
thermal injury in children, adults and the elderly. This study is the first multi-centre 
observational study of patients with thermal injuries to be conducted in the United 
Kingdom (UK) and Europe.  
2.1.3 Blood sampling 
Blood samples from patients and healthy individuals were collected at fixed 
intervals following injury (day 1 [< 24 hours post-injury], day 3 [+/- 1 day], day 7 
[+/- 1 day], day 14 [+/- 3 days], day 21 [+/- 3 days], day 28 [+/- 3 days], month 2 
[+/- 3 days], month 3 [+/- 7 days], month 6 [+/- 7 days] and month 12 [+/- 7 days]) 
as shown in Figure 2.1. Blood samples were collected into BD Vacutainers® 
(Becton Dickinson, UK) containing either ethylenediaminetetraacetic acid (EDTA), 
z-serum clotting activator or 1/10 volume of 3.2% trisodium citrate.  
2.1.4 Preparation of platelet free plasma  
Citrate anticoagulated blood was centrifuged at 2000 x g for 20 minutes at 4oC 
and the top 2/3rds of plasma carefully removed and placed into a new sterile     
600 µl Eppendorf tube. Plasma was then centrifuged at 13,000 x g for 20 minutes 
at 4oC and the top 2/3rds of the platelet free plasma (PFP) removed and stored at     
-80°C ahead of further analysis. 
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2.1.5 Preparation of plasma 
Heparin or citrate anticoagulated blood was centrifuged at 1500 x g for 8 minutes 
at 4oC and the top 2/3rds of plasma carefully removed and stored at -80°C ahead 
of analysis.  
2.1.6 Preparation of serum  
For serum, blood samples were collected into BD Vacutainers® containing z-
serum clotting activator and allowed to clot for 30 minutes at room temperature 
(RT). Samples were centrifuged at 1500 x g for 10 minutes at RT. The top 2/3rds 
of serum was carefully removed and stored at -80°C before analysis. 
2.1.7 Clinical diagnosis of sepsis and multiple organ failure 
A diagnosis of sepsis was made when at least 3 of the sepsis trigger criteria 
agreed in 2007 by the ABA (65) were met along with either a positive bacterial 
culture or when a clinical response to antibiotics was observed. Sepsis criteria 
were assessed on a daily basis. The source of sepsis for each episode was made 
through the prospective recording of adverse events during the study. Pneumonia 
and ventilator associated pneumonia, urinary tract infection and central line 
associated blood stream infection were diagnosed according to the US Centres for 
Disease Control criteria. This method has been published (180). 
The presence of MOF was assessed daily using the Denver post-injury MOF 
score and was defined as a score of >3 on two consecutive days with contribution 
from two organ systems (277).The APACHE II score (278) and SOFA score (279) 
were also evaluated for the first 24 hours of admission. The abbreviated burn 
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severity index (ABSI) (280) and the revised Baux score (rBaux) (281) were also 
calculated for each patient. Clinical methodology has been published (180, 282). 
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Cohort Age (years) Burn size (TBSA %) Burn depth 
Child < 16 < 10% Full thickness 
(>1%) 
Child < 16 ≥ 10% Any 
Adult 16 - 45 < 15% Full thickness 
(>1%) 
Adult 16 - 99 ≥ 15% Any 
Elderly 65 + < 15% Full thickness 
(>1%) 
Inclusion criteria: Patient of any age (0-99 years), arrival to the burn centre 
within 24 hours of injury (children and adults) and arrival to the burn centre within 
7 days (elderly)  
Exclusion criteria: Burn injury caused by chemical or deep electrical injury, 
associated multiple injuries ISS > 25, decision not to treat due to the severity of 
the injury or premorbid conditions (congestive heart failure, malignancy, patients 
receiving glucocorticoid treatments and/or multiple limb amputations). 
Table 2.1. Inclusion and exclusion criteria for patients recruited to the SIFTI 
trial.  
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Figure 2.1. SIFTI Study blood sampling timeline. Blood samples were collected 
at fixed intervals following injury (day 1 [< 24 hours post-injury], day 3 [+/- 1 day], 
day 7 [+/- 1 day], day 14 [+/- 3 days], day 21 [+/- 3 days], day 28 [+/- 3 days], 
month 2 [+/- 3 days], month 3 [+/- 7 days], month 6 [+/- 7 days] and month 12 [+/- 
7 days]). D = day and M = month. 
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2.2 Polytrauma patient group and study design 
Data regarding recruitment, bleeding and ethics were provided by Professor 
Woolley as he was the senior investigator responsible for management of the 
polytrauma cohort. This information is also presented within his doctorate thesis.  
This was a prospective observational study which recruited trauma casualties (≥18 
years of age) requiring full trauma team activation that presented to the Joint 
Force Role 3 Field Hospital in Camp Bastion, Afghanistan, between November 
2011 and August 2013 with injuries caused by explosions. A full Trauma team 
activation occurs for any patients triaged pre-hospital as T1 (the most severe 
triage category) or meeting the activation criteria, Table 2.2. Due to the logistical 
constraints of performing research in a deployed military environment, and due to 
a lack of full time dedicated researchers, it was not possible to include all trauma 
patients. All patients met the inclusion and exclusion criteria described in Table 
2.3. 
By the end of the conflict in Afghanistan, casualties were evacuated from the 
battle field either by the UK Medical Emergency Response Team (MERT) or via 
the USA forces PEDRO or Dustoff. Each of these evacuation platforms had 
different medical and military capabilities. Of note, the MERT and PEDRO could 
administer prehospital blood products to multiple casualties by the end of the 
conflict.  
Clinical details, including injury severity score (ISS) and new injury severity score 
(NISS), were collected by the on-site investigator where possible or retrospectively 
analysed. Due to the nature of military trauma and sensitivity of data, some 
information was not available for analysis.  
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2.2.1 Study approval and consenting for patients injured in explosions 
Due to the nature of major and massive haemorrhage after military trauma a 
formal ethics submission was not required by the Ministry of Defence Research 
Ethics Committee as the analysis was performed using leftover plasma (waste) 
which is a negligible amount in relation to the amount of clinical blood loss. The 
US ethical chain however granted ethical approval (log number M-10242). 
Informed consent was not required as this represented a minimal risk study. 
2.2.2 Plasma preparation from patients injured in explosions 
4.5 mls of blood was collected into tri-sodium citrate collection tubes (3.2%), with a 
final ratio of blood: anticoagulant 9:1. Blood was centrifuged at 3000 RPM for 20 
minutes (Heraeus ® Megafuge 16 series®, Thermoscientific). The plasma was 
removed and frozen at -30°C. Samples were transported to the UK using boxes 
on cardice and stored until analysis at -80°C. 
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Penetrating 
trauma 
Gunshot or shrapnel wound 
Blast injury (mine/IED/grenade)  
Stab wound 
Blunt Trauma Motor vehicle crash with ejection  
Motorcyclist or pedestrian hit by vehicle >30km/h  
Fall >5 metres  
Fatality in the same vehicle  
Entrapment and/or crush injury  
Inter-hospital trauma transfer meeting activation criteria 
AND  
Anatomy Injury to two or more body regions Fracture to two or more long 
bones Spinal cord injury 
Amputation of a limb  
Penetrating injury to head, neck, torso, or proximal limb 
Burns >15% BSA in adults or >10% in children or airway burns  
Airway obstruction  
 
Or  
Physiology Systolic blood pressure <90mmHg or pulse >120bpm (adults) • 
Respiratory rate <10 or >30 per minute (adults); SpO2 <90%  
Depressed level of consciousness or fitting 
Deterioration in the Emergency Department  
Age >70 years 
Pregnancy >24 weeks with torso injury  
 
Table 2.2. Trauma team activation criteria according to Clinical Guidelines 
for Operations. Data within this table was provided by Professor Woolley as he 
was the senior investigator responsible for management of the polytrauma cohort. 
This information is also presented within his doctorate thesis. 
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Inclusion Criteria Exclusion Criteria 
Full Trauma Team activation  Civilian casualties 
Coalition Forces Age <18 yrs 
Explosive Injury  
Evidence of shock:  
Clinical suspicion associated with 
any of the following criteria:  
 ABD >6 
 SBP<90mm Hg 
 Pulse>120bpm 
 Depressed GCS 
 
Died before start of surgery 
Clinical suspicion of requirement for 
blood transfusion 
Evidence of brain injury 
 Enemy Forces 
 Pregnancy 
 
Table 2.3. Inclusion and Exclusion Criteria for with severe injuries caused by 
explosions. Data within this table was provided by Professor Woolley as he was 
the senior investigator responsible for management of the polytrauma cohort. This 
information is also presented within his doctorate thesis. 
  
 
74 
 
2.3 Whole blood analysis using the Sysmex XN-1000 analyser 
The Sysmex XN-1000 (Sysmex UK, UK) is a state of the art whole blood analyser 
that is capable of producing a full blood cell differential count from 88 µl of human 
blood. The analyser has a set of unique parameters including, IGs, red cell 
reticulocytes, accurate platelet counts and the immature platelet fraction. The 
instrument also produces three platelet counts: platelet impedance (PLT-I), 
platelet optical (PLT-O) and PLT-F count. The instrument was utilised to study the 
immaturity index and kinetics of various cell counts affected by thermal injury. 
Cellular kinetics was determined in EDTA anticoagulated blood immediately 
following collection of sample. To ensure reproducibility the analyser was quality 
checked every day before analysis of clinical samples using an internal quality 
control (QC) (XN Check Reagent™, (Sysmex UK, UK)). The instrument was also 
enrolled into a national external QC scheme (UKNEQAS, UK). To determine 
normal ranges for each cellular parameter, EDTA anticoagulated blood from 40 
healthy volunteers was analysed. Analysis of healthy volunteers was performed in 
collaboration with the Department of Pathology at the Queen Elizabeth Hospital in 
Birmingham (UK), by Chris Watson and Miss Sumiya Ahmed (Aston University, 
Birmingham, UK). 
2.4 Measurement of neutrophil reactive oxygen species generation in whole 
blood  
Analysis of ROS production was primarily performed by Dr Peter Hampson as part 
of the SIFTI study. The methodology has subsequently been published (180). 
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Neutrophil ROS production in response to 1.62 µM PMA stimulation was assessed 
using the commercially available PhagoBURST® kit according to manufacturer’s 
instructions (BD Biosciences, UK). 100 µl of heparinised blood was aliquoted in a 
fresh flow cytometry analysis tube, ensuring no blood was on the side of the tubes. 
To the ‘negative control’ tube, 20 µl of wash buffer was added. To the ‘test’ tube 
20 µl PMA (1.62 µM) was added after gentle mixing. Samples were mixed gently 
and incubated at 37oC for 10 minutes. After incubation, 20 µl of substrate solution 
was added to each well and samples were incubated at 37oC for a further 10 
minutes. The whole blood samples were lysed and fixed with 2 ml of RT 1 x lysing 
solution. Samples were vortexed and incubated for 20 mins at RT. Cells were 
pelleted by centrifugation (5 min, 250 x g, 2 - 8 °C) and the supernatant was 
discarded. 3 ml of wash solution was added to the tubes and samples were 
washed by centrifugation (5 min, 250 x g, 2 - 8 °C) and the supernatant was 
discarded. 200 µl of DNA staining solution was added to the tubes, mixed and 
incubated for 10 minutes on ice (protected from light). ROS production was 
measured within 30 minutes. 10,000 neutrophils, gated according to their forward 
scatter/sideward scatter properties, were analysed on an Accuri C6 flow cytometer 
and data evaluated using CFlow software. Data are presented as median 
fluorescence intensity (MFI) values, which reflect the enzymatic activity per cell 
(BD Biosciences, UK).   
2.5 Isolation of neutrophils from whole blood  
EDTA Anticoagulated blood was transferred to a sterile 50 ml Falcon tube 
(Thermo Fisher, USA) and 1 ml of 2% Dextran (Sigma-Aldrich, UK) was added for 
every 6 ml of blood. This was performed to cause sedimentation of the 
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erythrocytes so that the top layer, containing white blood cells (WBC), could be 
removed following 30 minutes of incubation at RT. After 30 minutes, the leukocyte-
rich plasma was removed from the separated whole blood and was carefully 
layered onto a Percoll (Scientific Lab Supplies, UK) density gradient, which 
consisted of 2.5 ml of 80% Percoll and 5 ml 56% Percoll and centrifuged for 20 
minutes at 218 x g with no brake at RT. Following centrifugation, the neutrophils 
that are located at the 56-80% Percoll interface were removed and placed into a 
sterile 50 ml Falcon tube and resuspended in RPMI-1640 media supplemented 
with 2 mM L-glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin (Thermo 
Fisher, USA). Neutrophils were then centrifuged at 461 x g for 10 minutes at RT. 
Following centrifugation, the supernatant was discarded and the cells were 
resuspended in RPMI-1640 media and diluted to an appropriate final 
concentration. Cell count was determined using a Sysmex XN-1000 whole blood 
analyser (Section 2.3) with the aspiration sensor turned off. Following 
quantification, cellular concentration was adjusted for individual experiments.  
Viability of neutrophil preparations was analysed by cytospin and differential 
staining using a commercially available Giemsa stain (Diff-Qik; Gentaur Europe, 
Belgium). Neutrophils preparations contained ≥ 98% of neutrophil in the total cell 
population. 
2.6 Generation of neutrophil extracellular traps 
To induce NET formation, 2 x 105 of isolated neutrophils (200 µl total volume) 
were seeded into wells of a clear flat bottomed 96 well plate (Sigma-Aldrich, UK). 
Neutrophils were then stimulated with 25 nM PMA or 100 ng/ml LPS (Both: Sigma-
Aldrich, UK). Both PMA and LPS were diluted from stock solutions with RPMI-
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1640 media supplemented with 2 mM L-glutamine which alone served as a buffer 
control: 
 PMA stock solution (1.6 mM) was diluted 1:640 (dilution 1). Next, dilution 1 
was further diluted 1:100 directly into the well containing 200 µl of isolated 
neutrophils. Final dilution was equal to 1:64000 
 LPS stock solution (1 mg/ml) was diluted 1:100 (dilution 1). Next, dilution 1 
was further diluted 1:100 directly into the well containing 200 µl of isolated 
neutrophils. Final dilution was equal to 1:10000 
Neutrophils were incubated for 3 hours at 37oC and 5% CO2 atmosphere with 
either PMA or LPS to induce NET formation. Following 3 hours, NETs were 
quantified by a fluorometric assay (Section 2.7). 
2.7 Quantification of neutrophil extracellular traps 
Following stimulation, the supernatant was removed from wells and placed into 
sterile 600 µl eppendorf tubes and centrifuged at 2200 x g for 10 minutes at 4oC to 
pellet cells and ‘non-NET’ material. Whilst it is not possible to guarantee that all 
NETs were removed, the level of DNA was comparable between individuals 
suggesting low variation between experiments. Furthermore, NET release was 
confirmed by fluorescence microscopy.  Following centrifugation 100 µl of cell free 
supernatant was removed and placed into a black 96 well plate (Corning, USA). 
The supernatant was incubated with 1 µM SYTOX® Green Dye (Thermo Fisher, 
Life Technologies, UK) for 10 minutes at RT and in the dark. Fluorescence was 
measured using a BioTek® Synergy 2 fluorometric plate reader (NorthStar 
Scientific Ltd, UK) with excitation and emission set at 485 nm and 528 nm 
respectively. All samples were analysed in duplicate. As a control/calibration step, 
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cell free supernatant from unstimulated neutrophils and buffer controls were 
analysed in duplicate. For calibration of samples, a λ-DNA (ThermoFischer 
Scientific, UK) standard curve was utilised ranging from 1000 ng/ml down to 0 
ng/ml. λ-DNA (stock concentration = 0.3 µg/µl) was diluted 1:20 in sterile 
phosphate buffered saline (PBS) (Sigma-Aldrich, UK). The top standard was then 
serially diluted 7 times and finally diluted 1:15 in the plate with 1 µM SYTOX® 
Green Dye. 
2.8 Visualisation of neutrophil extracellular traps by fluorescent microscopy  
This methodology was adapted from a previous publication (283) and has been 
previously described by Dr Jon Hazeldine within his doctorate thesis.  
To visualise NET generation by fluorescence microscopy, 2 x 105 isolated 
neutrophils, resuspended in 2 ml of RPMI media supplemented with 2 mM L-
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, were seeded onto     
13 mm circular glass coverslips (VWR International, UK) and incubated for 30 
minutes at 37oC in a 5% CO2 atmosphere to allow cell adherence.  
Post incubation, neutrophils were stimulated with 25 nM PMA or 100 ng/ml LPS 
for 3 hours (37oC and 5% CO2 atmosphere). All agonists were prepared from 
stock solutions in RPMI media, which alone served as a buffer control. Following 
stimulation, cells were fixed with an additional 30 minute incubation with 4% 
paraformaldehyde (PFA) (Section 2.9) at 37oC in a 5% CO2 atmosphere. Once 
fixed, slides were processed for fluorescence microscopy as detailed below: 
 5 minute wash in sterile PBS at RT (3 times) 
 1 minute wash with 0.1% Triton X-100 at RT  
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 5 minute wash in sterile PBS at RT 
 5 minute incubation with 1 µM SYTOX® Green Dye at RT 
 5 minute wash in sterile PBS at RT 
Slides were then mounted in fluoromount medium (Sigma-Aldrich, UK) and 
imaged using a LEICA DMI 6000 B microscope at X20 or X40 objective.  
2.9 Paraformaldehyde preparation  
To make 1 L of 4% PFA, 800 ml of 1 x PBS was heated to 60oC and stirred 
continuously. Next, 40 g of PFA powder (Sigma-Aldrich, UK) was added to the 
heated 1 x PBS and stirred. The pH of the mixture was adjusted with 1 N NaOH 
dropwise until the solution cleared. Once dissolved, the volume was adjusted to 1 
L and pH was adjusted to pH 6.9. Finally, solution was filtered sterilised and stored 
at 4oC ahead of use in visualisation of NETs and degradation assays. 
2.10 Human promyelocytic leukaemia cell culture 
Human promyelocytic leukaemia cells (HL-60) (American Type Culture Collection 
(ATCC), USA) were cultured to produce a positive control, of Cit H3, for use on the 
sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
analysis. HL-60 cells were cultured in RPMI-1642 media (Thermo Fisher, USA) 
supplemented with 10% (volume/volume (v/v)) heat-inactivated fetal calf serum 
(FCS; Sera Laboratories International, UK), 2 mM L-glutamine, 100 U/ml penicillin 
and 100 μg/ml streptomycin. HL-60 cells were cultured until there was a suitable 
number to differentiate into granulocyte cells. 
To differentiate, cells were cultured for 3 days in RPMI-1642 media containing 
1.25% dimethyl sulfoxide (DMSO). After 3 days, cells were re-suspended in 
 
80 
 
Locke's Solution and stimulated with 4 µM calcium ionophore (A23187, Sigma-
Aldrich, UK) for 15 minutes at 37oC and 5% CO2. Following stimulation, 1 x 10
6 
cells, determined by cell counts using a standard haemocytometer, were pelleted 
by centrifugation at 461 x g for 8 minutes at RT. Cells were then re-suspended in 1 
mL of loading buffer ahead of SDS-PAGE analysis. HL-60 positive controls were 
further diluted 1:50 before use in western blot analysis. 
2.11 K562 cell culture 
K562 cells (ATCC number CCL-243) were cultured to create mtDAMPs (Section 
2.21). Cells were purchased from the American Type Culture Collection (ATCC, 
USA) and were maintained in RPMI-1642 media supplemented with 10% 
(volume/volume (v/v)) heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 
U/ml penicillin and 100 μg/ml streptomycin in 75 cm2 cell culture flasks at 37oC in 
a humidified 5% CO2 atmosphere. Cells were split 1 in 3 on the day preceding 
experimentation and washed once (220 x g, 8 minutes, RT) in PBS prior to use. 
Cultures of K562 cells were replaced on a monthly basis. 
2.12 Western Blot Analysis  
3 µl of patient plasma, 20 µl of in vitro preparations or 8 µl of molecular weight 
marker (New England Biolabs, UK) were diluted in hot sodium dodecyl sulphate 
(SDS) sample buffer (4% SDS (v/v), 0.1 M dithiothreitol, 20% glycerol (v/v), 0.0625 
M Tris-HCL and 0.004% bromophenol blue (w/v)). Samples were then heated at 
100oC for 10 minutes before being loaded onto a 5% acrylamide stacking gel/15% 
acrylamide running SDS-PAGE gel. Gels were run for 90 minutes at 33 mAmps. 
The gel was transferred to a polyvinylidene fluoride (PVDF) membrane (GE 
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Healthcare Life Sciences, UK) by wet transfer for 90 minutes (BioRad, UK). 
Following transfer  the membrane was blocked, at RT for 60 minutes, with 25 ml   
1 x Tris Buffered Saline (TBS) containing 4% Tween-20 (TBST), 5% milk (Marvel, 
UK), 2% bovine serum albumin (BSA) (Fisher Scientific, UK) and 276 µl of 35% 
hydrogen peroxide (to block the endogenous peroxide activity in the plasma 
samples). Blocking buffer was removed after 60 minutes and the membrane was 
washed 3 times (15 minute washes) with 1 x TBST.  
2.12.1 Western blot protocol for Cit H3  
Cit H3 in PFP was measured using SDS-PAGE and Western blotting, as 
described in Section 2.12. Following the final wash, primary antibody to Cit H3, 
diluted in 1 x TBST containing 2.5% BSA to a working concentration of 1 µg/ml, 
(ab5103, Abcam UK) was applied to the membrane overnight at 4oC with gentle 
shaking. Primary antibody was then removed and the membrane was washed 
three times (15 minutes each) with 1 x TBST. The secondary antibody (ECL™ 
Donkey Anti-Rabbit, Horseradish Peroxidase (HRP)-Linked Whole Antibody (GE 
Healthcare Life Sciences)) diluted 1 in 4000 in 1 x TBST containing 2% BSA, was 
then applied for 1 hour at RT. Following three washes of 15 minutes each with 1 x 
TBST, Amersham™ ECL Plus Western Blotting Detection System (GE Healthcare 
Life Sciences) was applied directly to the membrane for 3 minutes before it was 
developed using ChemiDoc™ Technology (BioRad, UK). Cit H3 is represented as 
a positive band at 17 kDa, calibrated using a loaded molecular weight marker. 
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2.12.2 Western blot protocol for detection of actin 
Actin in PFP was measured using SDS-PAGE and Western blotting, as described 
in Section 2.12. Membranes were incubated with 1 µg/ml primary antibody anti-
actin, N-terminal antibody produced in rabbit (A2103, Sigma-Aldrich, UK) 
overnight at 4oC. Primary antibody was then removed and the membrane was 
washed three times (15 minutes each) with 1 x TBST. Membranes were incubated 
with secondary antibody HRP-linked anti-rabbit IgG for 1 hour (GE Healthcare Life 
Sciences, USA) at RT. Following three washes of 15 minutes each with 1 x TBST, 
Amersham™ ECL Plus Western Blotting Detection System (GE Healthcare Life 
Sciences, USA) was applied directly to the membrane for 3 minutes before it was 
developed using ChemiDoc™ Technology. Actin is represented as a positive band 
at 42 kDa, calibrated using a loaded molecular weight marker. 
2.13 Detection of cell-free DNA in plasma and serum samples using an in 
house fluorometric assay 
PFP or serum samples were thawed at 37oC for 10 minutes before being gently 
mixed. Next, 10 µl of PFP or serum sample was added directly to a 96-well plate 
(Corning, USA) and incubated with 140 µl of cell-impermeable dye (1 µM) 
SYTOX® Green Dye for 10 minutes in the dark at RT, in order to stain cfDNA.  
Fluorescence was measured using a BioTek® Synergy 2 fluorometric plate reader 
with excitation and emission set at 485 nm and 528 nm respectively. All samples 
were analysed in duplicate. As a control/calibration step, plasma from healthy 
volunteers was included on every plate and a buffer control was included. For 
calibration of samples, a λ-DNA standard curve was utilised ranging from 1000 
ng/ml down to 0 ng/ml. 
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2.14 Detection of cell-free DNA in plasma and serum samples using a 
commercial CE marked assay  
Levels of cfDNA were measured in plasma using a commercially available 
fluorometric assay (Trillium Diagnostics, USA) to compare to our in-house assay 
of cfDNA quantification. Plasma samples were thawed at 37oC for 10 minutes 
before being gently mixed ahead of analysis. Next, 10 µl of thawed PFP samples 
were incubated with 90 µl reagent A, which binds to cfDNA, at RT for 15 minutes. 
Fluorescence was measured using a BioTek® Synergy 2 fluorometric plate reader 
with excitation and emission set at 485 nm and 528 nm respectively. All samples 
were analysed in duplicate. As a control/calibration step, plasma from healthy 
volunteers was included on every plate and a buffer control was included. For 
calibration of samples, a λ-DNA standard curve was utilised ranging from 800 
ng/ml down to 0 ng/ml 
2.15 Isolation of nuclear and mitochondrial DNA 
This work was performed in collaboration with Dr Peter Hampson and Dr Jon 
Hazledine. The method has subsequently been published (180). 
To isolate ncDNA or mtDNA from plasma or cellular preparations a Qiagen DNA 
isolation kit was used (Qiagen, Germany). Briefly, 200 µl of plasma or 200 µl 
cellular preparations were transferred into a sterile 1.5 ml Eppendorf tube which 
was centrifuged at 3000 x g for 10 minutes at 4oC. Following centrifugation, 150 µl 
was transferred to a new sterile Eppendorf containing 20 µl of Protease reagent. 
Next, 150 µl of Buffer AL was added to all samples and mixed by pulse vortexing 
for 15 seconds before being incubated for 10 minutes at 56oC. 150 µl of 100% 
ethanol was added to all samples and mixed by pulse vortexing for 15 seconds. 
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Following which, the mixture was carefully transferred to the QIAamp Mini spin 
column and centrifuged at 5500 x g for 1 minute at RT. The tube containing the 
filtrate was discarded and the QIAamp Mini spin column was transferred to a new 
2 ml collection tube. Next, 500 µl of Buffer AW1 was added and the column was 
centrifuged at 5500 x g for 1 minute at RT. Again the QIAamp spin column was 
placed into a clean 2 ml collection tube and the tube containing the filtrate was 
removed.  Next, 500 µl of Buffer AW2 was added to the QIAamp spin column and 
was centrifuged at 8000 x g for 3 minutes at RT. Following centrifugation, the 
QIAamp spin column was removed and centrifuged at 14500 x g for 1 minute to 
dry the column. Finally, 50 µl of Buffer AE was added to the QIAamp spin column 
and incubated for 5 minutes at RT before being centrifuged at 5500 x g for 1 
minute. The liquid in the bottom of the tube contained the DNA which was 
quantified using the Nanodrop (Thermo Fisher, USA). DNA had a 260/280 ratio of 
1.8 – 2 and was stored at -80oC ahead of use in PCR or DAMPs experiments.  
2.16 Polymerase chain reaction for the quantification of plasma nuclear DNA 
and mitochondrial DNA levels 
This work was performed in collaboration with Dr Peter Hampson and Dr Jon 
Hazledine. The method has subsequently been published (180). 
To determine the source of the circulating cfDNA, PCR analysis was performed. 
DNA was isolated from 150 µl of PFP using a QIAamp DNA Blood Mini Kit 
(Qiagen, Germany) and eluted in 50 µl of nuclease-free water of which 5 µl was 
used in the PCR reaction. Plasma ncDNA was measured by PCR using the SYBR 
Green 480 Probes Master kit and analysed using a Light Cycler 480 (Roche, 
Switzerland).   
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Primer sets used to ncDNA was specific for the genes encoding β-globin: 
 Forward 5’-GTGCACCTGACTCCTGAGGAGA-3’ and reverse 5’-
CCTTGATACCAACCTGCCCAG-3’ 
Primer sets used to mtDNA was specific for the genes encoding cytochrome b: 
 Forward 5’-GTGCACCTGACTCCTGAGGAGA-3’ and reverse 5’-
CCTTGATACCAACCTGCCCAG-3’ 
Primers were synthesized by Eurofins MWG. Primer sequences have no 
significant homology with DNA found in any bacterial species published on 
BLAST. For concentration determination, a standard curve was created using 
purified ncDNA, isolated from K562 cells. Samples that produced no PCR 
products after 40 cycles were considered undetectable and the Ct number set to 
40 for statistical purposes (180). 
2.17 Quantification of DNAse activity in serum samples 
The protocol was adapted from a previous publication (237). Neutrophils were 
isolated from whole EDTA anticoagulated blood samples, from healthy volunteers, 
by Percoll density gradient centrifugation (Section 2.5). 5 x 104 neutrophils were 
seeded into each well of a 96 well flat bottom clear tissue culture plate. 
Neutrophils were stimulated with 25 nM PMA for 3 hours at 37oC in a 5% CO2 
atmosphere. Formed NETs were stored at 4oC for up to 24 hours ahead of 
degradation with serum, plasma or DNAse 1. 
Following stimulation, neutrophils were incubated for 6 hours with 5% serum or 
plasma from healthy volunteers or patients at 37oC in a 5% CO2 environment. 
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Serum was pre-diluted (1:4) in Hank’s Balanced Salt Solutions containing Mg2+ 
and Ca2+ (HBSS+) (Thermo Fisher, USA) before being diluted 1:5 directly into the 
NET containing wells. Following 6 hour incubation wells were fixed by adding 4% 
PFA for 30 minutes at 37oC in a 5% CO2 environment. Wells were washed gently 
with sterile PBS to remove residual serum and non-fixed cellular debris. NETs 
were incubated with 1 µM SYTOX® Green Dye for 10 minutes at RT in the dark. 
Fluorescence was measured using a BioTek® Synergy 2 fluorometric plate reader 
with excitation and emission set at 485 nm and 528 nm respectively. For analysis 
of DNAse activity in patient’s sera, NET degradation by the pooled-serum from 9 
healthy donors was defined as 100% activity. A calibration serum from a healthy 
individual and a buffer control were included on each assay plate. 
2.18 Visualisation of neutrophil extracellular traps degradation by 
fluorescent microscopy  
To visualise NET degradation by fluorescence microscopy, 5 x 104 isolated 
neutrophils, resuspended in 2 ml of RPMI media supplemented with 2 mM L-
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin, were seeded onto 13 
mm circular glass coverslips  and incubated for 30 minutes at 37oC in a 5% CO2 
atmosphere to allow cell adherence.  
Post incubation neutrophils were stimulated with 25 nM PMA for 3 hours (37oC 
and 5% CO2 atmosphere). All agonists were prepared from stock solutions in 
RPMI media, which alone served as buffer controls. Formed NETs were stored at 
4oC for up to 24 hours ahead of degradation with serum or plasma.  
Neutrophils were then incubated for 6 hours with 10 U/ml rhDNAse 1 (positive 
control), 5% serum from healthy volunteers or patients with thermal injuries. 
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rhDNAse 1 was chosen over other isoforms of DNAse as it is the predominant 
enzyme responsible for the degradation of circulating DNA. Serum was pre-diluted 
(1:4) in HBSS+ before being diluted 1:5 directly into the NET containing wells. 
Following stimulation cells were fixed with an additional 30 minute incubation with 
4% PFA (37oC and 5% CO2 atmosphere). Once fixed, slides were processed as 
detailed in Section 2.8. 
2.19 In Vitro inhibition of DNAse activity in serum samples 
NETs were generated as described in Section 2.17. Following generation NETs 
were stored at 4oC ahead of degradation with serum. To investigate the inhibition 
of DNAse activity, sera from healthy volunteers was incubated with either 1 µM, 2 
µM or 5 µM actin from rabbit muscle (Sigma-Aldrich, UK) to cause inhibition of 
serum DNase activity. Actin was diluted from a stock (11.63 µM) in HBSS+ which 
also served as a buffer control. Actin was added directly into wells with serum 
making a total well volume of 250 µl and protocol was followed as previously 
described (Section 2.17).  
2.20 Enzyme linked immunosorbent assay  
All enzyme linked immunosorbent assays (ELISA) were performed as per 
manufacturer’s instructions. 
2.20.1 Quantification of deoxyribonuclease (DNAse 1) by ELISA 
As DNAse 1 is the predominant enzyme responsible for the degradation of 
circulating DNA levels were quantified in PFP using a human DNASE1/DNAse I 
ELISA Kit, catalogue number LS-F4463 (LifeSpan BioSciences, Inc). Briefly, 
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samples were thawed at 37oC, 5% CO2 for 10 minutes before being gently mixed. 
Next, 10 µl of sample was added to 90 µl of Sample diluent (1:10 dilution) in a 
clear 96 well plate. Following initial dilution, 10 µl of diluted sample was added 
directly to assay plate which contained 90 µl of Sample diluent (1:10 dilution) 
making a final dilution of 1:100. Sample, standards and blanks were incubated for 
1 hour at 37oC. Wells were then aspirated and 100 µl of a biotin-conjugated 
detection antibody (Detection reagent A) is then added which binds to captured 
antigen. The plate was then aspirated and washed three times with 300 µl of wash 
buffer to remove any unbound Detection reagent A. Following washing, 100 µl of 
an avidin-HRP (Detection reagent B) conjugate which binds to the biotin added to 
each well. Plate was incubated for 30 minutes at 30oC. The plate was then 
aspirated and washed five times with 300 µl of wash buffer to remove any 
unbound Detection reagent B. Following washing, 90 µl of tetramethylbenzidine 
(TMB) substrate solution was added to each well and incubated for 10 minutes at 
37oC before adding 50 µl of a sulfuric acid stop solution to terminate the colour 
change. Optical density (OD) of each well is measured at a wavelength of 450 nm 
± 2 nm. In all assays samples were analysed in singlet, standards (ranging from 
5000 – 0 pg/ml) were analysed in duplicate and plasma from a known healthy 
volunteer was included to ensure reproducibility between plates. DNAse levels 
were extrapolated from standard curve values using GraphPad Prism® software 
(GraphPad Software Limited, USA). OD, for all assays, was measured using a 
BioTek® Synergy HT. 
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2.20.2 Quantification of vitamin D binding protein by ELISA  
VDBP levels were quantified in serum samples using a VDBP ELISA kit 
(catalogue number K2314, ImmunoDiagnostik, Germany). This assay does not 
measure VDBP complexed with actin. All serum samples were diluted 1:40000 
with SAMPLEBUF (sample dilution buffer). Firstly, 20 µl sample was added to 980 
µl SAMPLEBUF and mixed well (1:50 dilution 1). Next, 20 µl of dilution 1 was 
added to 980 µl SAMPLEBUF and mixed well (1:50 dilution 2). Finally, 20 µl of 
dilution 2 was added to 300 µl SAMPLEBUF and mixed well (1:16 dilution 3). Final 
dilution of 1:40000. For analysis, 100 µl of dilution 3 was added to each well. 
Before analysis each well was washed 5 times with 250 µl of wash buffer. 
Following washing, 100 µl of prediluted sample was added to each well and 
incubated at RT for 1 hour with shaking. Following incubation contents of the well 
were discarded and washed 5 times with 250 µl of wash buffer to remove any 
unbound material. Next, 100 µl of peroxidase-labelled antibody was added to each 
well and incubated for 1 hour at RT with shaking. Again, wells were washed 5 
times with 250 µl of wash buffer to remove unbound antibody. 100 µl of TMB 
solution was added to each well and incubated at RT for 10 minutes. Colour 
change was stopped by the addition of 100 µl of stop solution which was mixed 
briefly. Absorption was determined immediately with an ELISA reader at 450 nm 
against 620 nm (or 690 nm) as a reference. VDBP levels were extrapolated from 
standard curve values using GraphPad Prism® software. 
2.20.3 Quantification of human gelsolin by ELISA 
GSN levels in serum, from patients with thermal injuries, and plasma samples, 
patients with injuries caused by explosions, were quantified using LSBioTM 
 
90 
 
Human GSN/Gelsolin ELISA Kit, catalogue number LS-F5675 (LifeSpan 
BioSciences Inc, UK). Briefly, samples were thawed at 37oC, 5% CO2 for 10 
minutes before being gently mixed. Next, 1 µl of sample was added to 49 µl of 
Sample diluent (1:50 dilution) in a clear 96 well plate. Next, 1 µl of diluted sample 
was further diluted in 99 µl of assay buffer and mixed gently (1:100 dilution). 
Following dilution, 10 µl of diluted sample was added directly to assay plates 
which contained 90 µl of Sample diluent (1:10 dilution) making a final dilution of 
1:50000. Sample, standards and blanks were incubated for 2 hours at 37oC. Wells 
were then aspirated and 100 µl of a biotin-conjugated detection antibody 
(Detection reagent A) was then added which binds to captured antigen for 1 hour 
at 37oC. The plate was then aspirated and washed three times with 300 µl of wash 
buffer to remove any unbound Detection reagent A. Following washing, 100 µl of 
an avidin-HRP (Detection reagent B) conjugate which binds to the biotin was 
added to each well and plate was incubated for 60 minutes at 37oC. The plate was 
then aspirated and washed five times with 350 µl of wash buffer to remove any 
unbound Detection reagent B. Following washing, 90 µl of TMB substrate solution 
was added to each well and incubated for 20 minutes at 37oC before adding 50 µl 
of a sulphuric acid stop solution to terminate the colour change. OD of each well 
was measured at a wavelength of 450 nm ± 2 nm. In all assays samples were 
analysed in singlet, standards (ranging from 4000 – 0 pg/ml) were analysed in 
duplicate and plasma from a known healthy volunteer was included to ensure 
reproducibility between plates. GSN levels were extrapolated from standard curve 
values using GraphPad Prism® software. OD, for all assays, was measured using 
a BioTek® Synergy HT. 
 
91 
 
2.21 Isolation of nuclei and mitochondria from K562 cells 
Dr Jon Hazeldine isolated nuclei and mitochondria from K562 cells ahead of use 
during in vitro experiments. 
Firstly, RIPA lysis buffer (Thermo Fisher, USA) was diluted 1:10 in distilled water 
containing protease inhibitory cocktail to make 1 x RIPA buffer. Cells were 
transferred into a sterile 1.5 ml Eppendorf tube and pelleted by centrifugation at 
1500 x g for 2 minutes at RT. Post centrifugation, the supernatant was removed 
and cellular pellet was re-suspended in 1 ml 1 x RIPA lysis buffer. Eppendorf was 
left on ice for 10 minutes before the solution was transferred to a tight fitting 
homogeniser using a Pasteur pipette and 120 strokes were performed to lyse 
cells. Next, the solution was transferred to a fresh sterile 1.5 ml Eppendorf tube 
using a Pasteur pipette and centrifuged at 800 x g for 10 minutes at 4oC to pellet 
the nucleus. Post spin, the supernatant was carefully removed and placed into a 
new sterile 1.5 ml Eppendorf tube using a Pasteur pipette and centrifuged at 3000 
x g for 30 minutes at 4oC to pellet the mitochondria. Both the nuclear and 
mitochondria pellet were resuspended in 200 µl of sterile PBS. mtDNA and ncDNA 
were then isolated using a QIAamp DNA isolation kit (Section 2.15). 
2.22 mtDAMPs effects on neutrophil function and phenotype  
All experiments were performed in collaboration with Dr Jon Hazeldine (Institute of 
Inflammation and Ageing, University of Birmingham, UK). Dr Hazeline performed 
western blot analysis and assessment of neutrophil activation by surface 
phenotyping using flow cytometry. All other measurements and experiments were 
performed in collaboration between Dr Jon Hazeldine and Robert J Dinsdale.  
 
92 
 
2.22.1 Inhibition of neutrophil extracellular traps formation with isolated 
mtDAMPs 
Neutrophils were isolated from fresh blood by Percoll density gradient (Section 
2.5). Next, 2 x 105 were treated for 15 minutes, at 37oC and 5% CO2, with 40 or 
100 µg/ml mtDAMPs or vehicle control. Following incubation neutrophils (2 x 105) 
were then stimulated for 3 hours with 25 nM PMA. Post-treatment, supernatants 
were carefully collected and centrifuged at 2200 x g for 10 minutes at RT, after 
which the DNA content of cell-free supernatants was analysed using the SYTOX™ 
Green dye assay. Background fluorescence values acquired from SYTOX™ 
Green staining of mtDAMPs in the absence of neutrophils were subtracted from 
test readings. NET production is expressed as a fold increase compared to 
unstimulated neutrophils alone. 
For fluorescent microscopy, 2 x 105 neutrophils were seeded onto glass coverslips 
and stimulated with 40 or 100 µg/ml mtDAMPs, 40 µg/ml mtDNA or vehicle control 
for 15 minutes at 37oC in a humidified 5% CO2 atmosphere. Post treatment, 
samples were stimulated with 25 nM PMA for 3 hours (37oC, 5% CO2), after which 
samples were fixed for 30 minutes with 4% PFA (37oC, 5% CO2) and 
permeabilized with 0.1% Triton X-100. NETs were stained with 1 µg/ml of a rabbit 
polyclonal anti-histone H3 (citrulline R2, R8 and R17) antibody for 90 minutes, 
washed three times with PBS and stained for 90 minutes with 10 µg/ml of a goat 
anti-rabbit ALEXA Fluro-555 conjugated antibody. Following three washes in PBS, 
cells were stained with 1 µM SYTOX Green dye. Once stained, slides were 
mounted in fluoromount medium and visualized using a LEICA DMI 6000 B 
microscope at x20 objective. 
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2.22.2 Neutrophil transmigration following stimulation with mtDAMPs 
Neutrophils were isolated from whole blood by Percoll density gradient as 
previously described (Section 2.5). Freshly isolated neutrophils (1 x 107/ml) in 
HEPES buffer containing 1 mM Ca2+ were incubated for 30 minutes in a 370C 
water bath with 3 µg/ml calcein-acetoxmethyl ester (calcein-AM, Fisher Scientific 
UK, UK). Post incubation, neutrophils were treated for 15 minutes (370C, 5% CO2) 
with 40 or 100 µg/ml mtDAMPs or vehicle control, after which cells were pelleted 
by centrifugation at 1500 x g for 2 minutes at RT, supernatants removed and 
neutrophils re-suspended to a concentration of 1 x 107/ml in HEPES buffer 
containing 1 mM Ca2+. A total of 100 µl, containing 1 x 106 neutrophils, were then 
dispensed into the upper chambers of cell culture inserts (polycarbonate 
membrane, 3 µM pores, Corning, USA) that had been pre-loaded into wells of a 
24-well flat bottomed plate (BD Biosciences, UK) that contained pre-warmed 
phenol red free RPMI-1640 media supplemented with GPS, 10% heat inactivated-
FCS and 1 ng/ml leukotriene B4 (LTB4; R&D Systems, UK).   
Following a 90-minute incubation at 37oC in the dark, cell culture inserts were 
removed from plates without any attempt to dislodge adherent neutrophils and 
plates read immediately for calcein fluorescence using a BioTek Synergy 2 
fluorometric plate reader with excitation and emission set at 485 nm and 528 nm 
respectively. Fluorescent intensities were converted into neutrophil numbers via 
the use of a standard curve that was generated from calcein-AM loaded 
neutrophils that had been incubated alongside the test samples in the conditions 
described above. The number of neutrophils measured in media in which no 
chemokine was added was subtracted from the numbers calculated for wells that 
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contained 1 ng/ml LTB4 in order to determine specific chemokine-mediated 
migration. 
2.22.3 Assessment of neutrophil phenotype following stimulation with 
mtDAMPs 
Freshly isolated neutrophils (1 x 105) were stimulated with either 40 or 100 µg/ml 
of mtDAMPs or vehicle control for 15 minutes at 37oC in a humidified 5% CO2 
atmosphere. Post treatment, samples were placed on ice and stained for 20 
minutes with the following mouse anti-human monoclonal antibodies or their 
concentration-matched isotype controls: 2 µg/ml fluorescein isothiocyanate 
(FITC)-labelled CD62L (clone DREG56; eBioscience, UK), 1 µg/ml CXCR1-FITC 
(clone eBIO8F1-1-4; eBioscience, UK), 0.5 µg/ml R-phycoerythrin (PE)-labelled 
CXCR2-PE (clone eBio5E8-C7-F10; eBioscience, UK), 2.5 µg/ml allophycocyanin 
(APC)-labelled CD11b (clone ICRF44, BioLegend, UK) or 2 µg/ml CD16-APC 
(Clone 3G8; BD Biosciences, UK). Post incubation, cells were pelleted (250 x g, 5 
minutes, 4oC), supernatants discarded and neutrophils washed once in PBS 
containing 1% BSA. Following resuspension in PBS, samples were transferred to 
polypropylene FACS tubes for flow cytometric analysis, which was performed on 
an Accuri-C6TM bench top cytometer. 10,000 neutrophils, gated according to their 
forward scatter/sideward scatter properties were acquired for analysis, where 
receptor expression was measured as MFI values. 
2.22.4 Activation of ERK1/2 following stimulation with mtDAMPs 
To study mitogen activated protein kinase (MAPK) activation following mtDAMP 
stimulation, freshly isolated neutrophils (1 x 106 in RPMI + GPS + FCS media) 
were treated for 0, 2, 5, 10, 15 or 30 minutes (37oC, 5% CO2) with 100 µg/ml 
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mtDAMPs or vehicle control, after which cells were pelleted (1500 x g, 2 minutes, 
4oC) and supernatants removed.  
Cell lysates prepared by the addition of SDS sample buffer and boiled for 10 
minutes (Section 2.12). Lysates were separated on 12% SDS-PAGE and 
membranes probed with pERK1/2 (Cell Signalling Technology, USA) and ERK1/2 
antibodies overnight at 4oC (diluted 1:1000). Primary antibody was then removed 
and the membrane was washed three times (15 minutes each) with 1 x TBST. 
Membranes were incubated with secondary antibody goat anti-rabbit secondary 
antibody conjugated to HRP (diluted 1:4000 in TBST; GE Healthcare, UK) at RT. 
Following three washes of 15 minutes each with 1 x TBST, Amersham™ ECL Plus 
Western Blotting Detection System was applied directly to the membrane for 3 
minutes before it was developed using ChemiDoc™ Technology. 
2.22.5 Reactive oxygen species generation following stimulation with 
mtDAMPs 
100 µl aliquots of heparinised whole blood were treated for 15 minutes (37oC, 5% 
CO2) with 40 or 100 µg/ml mtDAMPs or vehicle control. Post-treatment, neutrophil 
ROS production in response to 1.62 µM PMA stimulation was assessed using the 
commercially available PhagoBURST® kit according to manufacturer’s 
instructions (Section 2.4). 10,000 neutrophils, gated according to their forward 
scatter/sideward scatter properties, were analysed on an Accuri C6 flow cytometer 
and data evaluated using CFlow software. Data are presented as MFI values, 
which reflect the enzymatic activity per cell. 
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2.23 Statistical analysis 
Data were analysed using GraphPad Prism® (GraphPad Software, Inc), SPSS 
(IBM) and R version 3.0.1 (http://www.r-project.org) together with the Ime4, 
effects, rms and pROC packages. All data within this thesis was checked for 
normality using the Kolmogorov-Smirnov test.  
2.23.1 Analysis of in vitro experiments  
If data was normally distributed the following statistical tests were performed; 
Unpaired t test was performed to analyse two independent groups. A paired t test 
was performed to analyse groups from paired samples. Not normally distributed 
paired groups were analysed by a Wilcoxon matched pairs signed rank test. If 
data was normally distributed and there was more than one matched group within 
the analysis a one-way analysis of variance (ANOVA) followed by the Bonferroni 
post hoc test was used. If data was not normally distributed and there was more 
than one matched group within the analysis a one-way analysis of variance 
(ANOVA) followed by the Friedman’s test followed by Dunn's Multiple Comparison 
Test post hoc test was used.  
2.23.2 Analysis of data generated from patients with thermal injuries  
When comparing to healthy individuals the level of statistical significance was 
adjusted manually for all analysis due to data not being equally distributed across 
all longitudinal time points. The threshold for significance was set at p < 0.005, 
unless otherwise stated within figure legend, as there are 10 longitudinal time 
points measured within this analysis. If data was normally distributed data was 
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analysed using an unpaired t test. If data was not normally distributed data was 
analysed using a Mann Whitney test. When analysis was performed on patient 
groups, e.g. sepsis and no sepsis, the threshold for significance was not adjusted 
(p < 0.05). If data was normally distributed data was analysed using an unpaired t 
test. If data was not normally distributed data was analysed using a Mann Whitney 
test. Categorical variables were compared using a Chi-squared test. 
2.23.3 Logistic regression analyses of potential biomarkers of sepsis 
Logistic regression analyses were conducted to examine the relationships 
between biomarkers at pre-specified sample times (e.g. day 7) and the presence 
of sepsis. Discriminatory power was assessed through the area under the receiver 
operator characteristic curve (AUROC). Longitudinal analyses were performed 
using linear mixed-effects models. Sample day was included in these models as a 
restricted cubic spline to allow for a flexible non-linear relationship between time 
and the response variable. Analysis was performed using the statistical software 
packages SPSS (IBM) and R version 3.0.1 (http://www.r-project.org) together with 
the Ime4, effects, rms and pROC packages. Analysis was performed by Dr 
Jonathon Bishop (University of Birmingham, UK). 
2.23.4 Analysis of data generated from patients with polytrauma 
As data was equally distributed amongst analysis groups the threshold for 
significance did not need to be adjusted manually (p < 0.05). When comparing to 
healthy controls, a one-way ANOVA followed by Bonferroni’s post hoc test was 
performed when data was normally distributed. If data was not normally distributed 
a one-way ANOVA followed by Dunn's Multiple Comparison Test was performed. 
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When analysis was performed between patient cohorts (blood products and no 
blood products) the threshold for significance was not adjusted (p < 0.05). If data 
was normally distributed an unpaired t test was performed. If data was not 
normally distributed a Mann Whitney test was performed. Categorical variables 
were compared using a Chi-squared test. 
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Chapter 3 
 
Neutrophil extracellular trap release following thermal 
injury 
  
 
100 
 
3.1 Introduction 
Neutrophils are essential effectors cells of the innate immune system and are 
equipped with a number of antimicrobial functions. In 2004, Brinkmann and 
colleagues defined a novel anti-microbial process in which neutrophils release 
their nuclear material to the outside of the cell in a ‘net-like’ structure which is 
designed to ensnare and trap bacteria (118, 119). This process is termed NET 
release or NETosis (178).  
The majority of research within the field of NETosis has focussed around their role 
during infection and sepsis. This is in part due to the specific functions of NETs in 
orchestrating the response to infection and due to their components being 
potential biomarkers (181, 192). Sepsis is a life threatening condition 
characterised by an imbalance in both the immune and haemostatic systems. It 
often results in cardiac dysfunction and acute respiratory distress syndrome, which 
are associated with MOF (46). Although accurate and early diagnosis of sepsis is 
crucial for determining patient outcomes, this is challenging as the criteria used 
are insensitive and nonspecific (47). 
A number of studies have concluded that NET production occurs in septic patients 
following traumatic injury (181, 215, 216). Furthermore, it has also been suggested 
that NETs can also be produced in response to sterile thermal and traumatic injury 
(111, 181, 215). However, many of the studies use quantification of plasma cfDNA 
alone as a marker of in vivo NETosis. This method is non-specific to NETosis as 
plasma cfDNA can originate from a number of sources including bacteria 
themselves (115). Therefore, to our knowledge, it has yet to be conclusively 
established whether NETosis occurs in patients following burn injury.   
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There is emerging evidence that neutrophil function is dysregulated following 
severe thermal injury (156, 159-161, 173, 174, 177). It has been proposed that 
this dysregulation of neutrophil function may underlie the increased incidence of 
nosocomial infections. Parment and colleagues have reported a reduced ability of 
neutrophils to generate ROS, an essential precursor of NETosis, following thermal 
injury (177). Although precursors of NET formation are reduced no group has 
investigated the effect severe thermal injury has on NET formation. Furthermore, if 
dysfunction exists no group has fully investigated the potential mechanisms 
responsible. Potential causes of neutrophil dysfunction include non-functioning 
immature neutrophils and circulating soluble mediators (40, 41, 45, 169). 
3.1.1 Aims 
The aims of this chapter were: 
 Conclusively investigate NET formation following severe thermal injury by 
the measurement of specific circulating biomarkers. 
 Investigate the association and predictive power of circulating NET 
components and secondary complications, e.g. sepsis. 
 Investigate the ability of neutrophils to form NETs ex vivo to understand if 
thermal injury results in impaired neutrophil function.  
 Investigate potential mechanisms responsible for the dysregulation of 
neutrophil function.  
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3.2 Results 
3.2.1 Study cohort  
All analysis was performed on adult patients (≥ 18 years of age) with burns ≥ 15% 
TBSA. The consort diagram for this analysis is included (Figure 3.1). Analysis was 
restricted to burns ≥ 15% TBSA to minimise the confounding bias of age and 
severity of injury in analysis. Furthermore, this has reduced the span and 
confounding bias of fluid resuscitation. Importantly, all patients were admitted 
within 24 hours of their injuries and all received standardised burn resuscitation 
protocols as per Parkland’s formula and as such have received equivalent fluid 
resuscitation: average = 5.4 mls/kg/%TBSA (Standard deviation = 2.1) (284, 285). 
In total there are 63 patients included in this analysis. The median age of the 
cohort was 39 years of age (range 16 - 88) and the median TBSA was 30% (range 
15 - 95%). Patients were further subcategorised into septic and non-septic 
according to the ABA sepsis scoring criteria (65). Of note, 6 patients died within 7 
days of injury from non-septic causes and were removed from the analysis, as it 
was not possible to determine whether these patients would have developed 
sepsis. Septic patients had significantly larger and more severe injuries (p < 
0.001) and consequently a higher mortality rate (p = 0.002). Full patient 
demographics are reported in Table 3.1.  
The incidence of sepsis was 61.4 % and the median time to first septic episode 
was 4 days (Interquartile range (IQR): 4, 8). The major source of sepsis in this 
cohort was pulmonary infection, accounting for 69%, and the most common 
colonising organism was Bacillus sp, accounting for 20%. Full details of colonising 
organisms and source can be found in Table 3.2. 
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Figure 3.1. CONSORT diagram showing the sub-classification and 
breakdown of numbers of study subjects. Data for surface area of burn is 
presented as median value (minimum-maximum value). 
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Characteristic Healthy 
Controls 
(n = 10) 
All 
Patients 
(n = 63) 
Sepsis 
(n = 35) 
No 
Sepsis 
(n = 22) 
p  
 
Age, years 58 (22-96) 39 (16-88) 41 (16-88) 31 (18-77) ns 
Gender (M:F) 6:4 42:21 23:12 14:8 < 0.05 
%TBSA (min-
max) 
 30 (15-95) 45 (16-95) 22 (15-31) < 0.0001 
ABSI (min-
max) 
 8 (4-14) 10 (4-14) 6 (4-8) < 0.0001 
Survived (Y:N)  43:20 21:14 22:0 < 0.001 
MOF (Y:N)  33:30 19:16 1:21 < 0.001 
 
Table 3.1. Patient Demographics (Chapter 3). Continuous data are quoted as 
median values with minimum to maximum values. Sepsis and no sepsis patient 
variables were compared using either a Mann-Whitney (continuous variable) or 
Chi-squared test (categorical variables). 
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 n=35 
Day of 1st septic episode, 
median (IQR) 
4 (4, 8) 
Source, n (%); 
Pulmonary Infection 
Wound Infection  
Central line associated blood 
stream infection 
 
24 (69) 
9 (26) 
1 (3) 
Organism, n (%); 
Bacillus sp. 
Staphylococcus sp. 
Enterobacter sp. 
Candida sp. 
E. Coli 
Haemophilus influenzae 
Acinetobacter sp. 
Klebsiella sp. 
Pseudomonas sp. 
Proteus mirabilis 
Pantoea sp. 
Serratia marcescens 
 
7 (20) 
4 (11.4) 
4 (11.4) 
4 (11.4) 
4 (11.4) 
3 (8.6) 
2 (5.7) 
2 (5.7) 
2 (5.7) 
1 (2.8) 
1 (2.8) 
1 (2.8) 
 
Table 3.2. Information on first septic episode. Continuous data are quoted as 
median values with interquartile range. Data has been published within ‘Neutrophil 
Dysfunction, Immature Granulocytes, and Cell-free DNA are Early Biomarkers of 
Sepsis in Burn-injured Patients: A Prospective Observational Cohort Study’ by 
Hampson and Dinsdale et al (180). 
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3.2.2 Assessment of neutrophil extracellular trap release in healthy controls 
Before investigating if thermal injury affects NET generation it was necessary to 
establish a number of techniques to measure NETs in vitro. To measure NET 
production in healthy controls two methods were established; quantification of 
cfDNA released during NETosis and visualisation of released NET structures by 
fluorescence microscopy, as previously described (283).  
Stimulation of neutrophils isolated from healthy controls with 25 nM PMA results in 
a significant release of cfDNA compared to unstimulated neutrophils (Figure 3.2). 
Stimulation of neutrophils with 100 ng/ml LPS did not cause an increase in cfDNA 
compared to unstimulated neutrophils (Figure 3.2).  
Analysis of NET formation by fluorescence microscopy showed that neutrophils 
isolated from healthy volunteers stimulated with 25 nM PMA are positive for both 
DNA (green stain) and Cit H3 (blue stain). Interestingly, Cit H3 is decorated across 
NETs but is more abundantly expressed within the remaining decondensed 
nuclear structure. All neutrophils in stimulated images also have decondensed 
nuclei which is a hallmark characteristic of NET formation. In contrast, 
unstimulated neutrophils retain their natural polymorphic nuclear morphology and 
do not release NETs following isolation (Figure 3.3). Stimulation of isolated 
neutrophils with LPS results in minor NET release and is characterised by few 
decondensed nuclei and a low number of neutrophils releasing DNA strands. 
Therefore, DNA and Cit H3 are components of NET formation and PMA is an 
appropriate in vitro stimulus to induce maximal NET formation. 
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Figure 3.2. Stimulation of neutrophils with 25 nM PMA results in robust NET 
formation. Ex vivo NET generation in response to 25 nM PMA or 100 ng/ml LPS 
by neutrophils isolated from healthy individuals. Data at each time point were 
compared with healthy control (HC) values using a repeated measures ANOVA 
and a Bonferroni post hoc test Test; *P < 0.05, **P < 0.01, ***P < 0.001. n = 5 for 
all experiments. Box and whisker plots represent minimum to maximum value and 
mean for each group.  
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Figure 3.3. Visualisation of ex vivo NET generation in response to 25 nM 
PMA or 100 ng/ml LPS by neutrophils isolated from a healthy control by 
fluorescence microscopy. DNA was stained by 1 µM SYTOX Green Dye (green 
stain) and Cit H3 was stained using 1 µg/ml AB5103 in addition to secondary 
antibody ALEXA Fluor 555 (blue stain). Slides were mounted in fluoromount 
medium and visualized using a LEICA DMI 6000 B microscope at X20 objective. 
Data shown is representative of 5 individual experiments. 
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3.2.3 Detection of circulating cell-free DNA in healthy controls 
To measure circulating levels of ‘NET markers’ an assay to quantify levels of 
plasma cfDNA was established from a previous publication (286). A ʎ-DNA 
standard curve was included in each assay which ranged from 1000 ng/ml – 0 
ng/ml. ʎ-DNA standard curves were linear, reproducible and accurate. Importantly, 
the inter-assay and intra-assay coefficients of variation for the assays were 5.3% 
and 5.1%, respectively. 
cfDNA could be detected in plasma from healthy volunteers but in low quantities 
(133.9 ng/ml) and comparable to that of previously published literature (109). 
Notably, cfDNA levels have been quantified in both plasma and serum (109, 111). 
Therefore to validate the assay, levels of cfDNA were measured in matched 
plasma and serum samples from healthy individuals. Levels of cfDNA were 
significantly higher in matched serum samples (188.5 ng/ml) when compared to 
plasma samples (133.9 ng/ml) (Figure 3.4). 
3.2.4 Analysis of plasma cell-free DNA levels following thermal injury 
It has previously been reported that levels of cfDNA are associated with poor 
outcome following major trauma and sepsis (109, 287). Therefore levels of cfDNA 
were analysed in patients with severe thermal injury.  
Levels of cfDNA in plasma taken within 24 hours following injury (Figure 3.5A), 
were not elevated (DNA = 153.46 ng/ml) compared to healthy control samples 
(161.04 ng/ml). This was unexpected as it has been previously published that 
thermal injury results in an initial increase in admission serum cfDNA levels (111). 
To try and explain the difference between the two studies, levels of cfDNA were 
also quantified in serum and compared to the matched plasma samples. 
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Admission levels of cfDNA were significantly higher in matched patient serum 
samples (439.38 ng/ml) compared to patient plasma samples (168.95 ng/ml) 
(Figure 3.6 A). Importantly the net change in cfDNA concentration between serum 
and plasma samples also correlated positively with WBC count (p = 0.0036, 
Spearman R = 0.6824, Figure 3.6 B). 
Levels of plasma cfDNA were significantly elevated at days 7 and 14 post-burn 
(Figure 3.5 A). Longitudinal analysis showed that plasma cfDNA levels were 
elevated in septic patients compared to non-septic patients from 7 days up to 2 
months post injury (Figure 3.5 B). In non-septic patients, there was a minimal 
increase in plasma cfDNA, being similar to levels found in healthy volunteers. 
In order to establish that our in house assay was comparable to that of a 
commercially available CE marked kit plasma samples were tested in both assays 
simultaneously. Importantly levels of cfDNA in our assay correlated with a 
commercially available kit (p < 0.0001, Spearman R = 0.78, Figure 3.7).  
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Figure 3.4. Levels of cfDNA are significantly higher in serum compared to 
plasma samples from healthy individuals. Levels of cfDNA were quantified in 
plasma and serum samples from healthy individuals (n = 12). Data was compared 
by a Wilcoxon matched pairs signed rank test. ***P < 0.001. Data is presented as 
before and after to depict changes within individual donors. 
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Figure 3.5. cfDNA is elevated post thermal injury and elevated in septic 
patients. (A) Plasma cfDNA levels (log scale) across time following burn injury    
(n = 50). Data at each time point were compared with healthy control (HC) (n = 10) 
values using a Mann-Whitney test; *P < 0.005. (B) Levels of cfDNA compared 
between septic and non-septic patients. Data was analysed using a Mann-
Whitney test; *P < 0.05. Box and whisker plots represent minimum to maximum 
value and median for each group. HC = healthy control, D = day, M = month. 
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Figure 3.6. Admission levels of cfDNA are higher in matched serum samples 
and correlate with WBC. (A) Levels of cfDNA in admission plasma and matched 
serum samples (n = 16). Data were compared using paired t-test; ***P < 0.001. 
Data is presented as before and after to depict changes within individual donors. 
(B) Correlation of WBC and change in DNA concentration between matched 
admission plasma and serum samples (n = 14). Data was analysed using 
Spearman’s rank. 
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Figure 3.7. Measurement of cfDNA by in house assay correlated positively 
with a commercially available kit. Correlation of plasma cfDNA levels using in 
house assay compared to Trillium Diagnostics kit to detect extracellular DNA       
(n = 32). Data was analysed using a Spearman’s rank (n = 32). 
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3.2.5 Diagnostic use of cell-free DNA in septic patients 
In order to investigate the potential diagnostic utility of plasma cfDNA during 
sepsis, we performed statistical regression analysis on the longitudinal kinetics for 
septic and non-septic patients (Table 3.3). There was a clear significant difference 
in plasma cfDNA trajectories following thermal injury between septic and non-
septic patients (Figure 3.5 B). On days 1 and 3 post injury the model gave 
reasonable discriminatory power between septic and non-septic patients with a c-
statistic of 0.691 (95% CI (0.542, 0.840)) and 0.640 (95% CI (0.479, 0.802)) 
respectively. Discriminatory power of the model increased with time with a c-
statistic of 0.775 (95% CI (0.604, 0.947)) on day 7 post injury. However, the 
maximal difference between the two patients groups was observed at day 14 
following injury. Levels of plasma cfDNA at day 14 following thermal injury provide 
good discriminatory power of whether an individual was in the septic group or not 
with a c-statistic of 0.883 (95% CI (0.767, 1.000)). 
3.2.6 Longitudinal analysis of nuclear and mitochondrial DNA 
In order to investigate the potential source(s) of circulating cfDNA, quantitative 
PCR analysis was performed to determine the concentration of ncDNA and 
mtDNA. Analysis of plasma levels of mtDNA revealed no significant elevation 
following thermal injury compared to healthy volunteers (Figure 3.8 A). However, 
there was a significant elevation of ncDNA between day 1 and day 28 post-injury 
(Figure 3.8 B). Plasma ncDNA levels had comparable kinetics to cfDNA, with 
levels peaking at day 7 and 14, and there was a strong positive correlation 
between the two measurements (r= 0.763, p < 0.001). However, there was a 
significant elevation of ncDNA at day 1-3 post-injury unlike plasma cfDNA. This is 
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most likely due to the higher sensitivity of the PCR assay compared to the 
fluorometric assay (lower limit of detection; 0.1 ng/ml vs.60 ng/ml).  
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Variable 
Number of 
Patients 
Number of 
Septic 
Patients 
 
AUROC (95% CI) 
Day 1    
cfDNA  50 19 0.691 (0.542, 
0.840) 
Day 3    
cfDNA  51 19 0.640 (0.479, 
0.802) 
Day 7    
cfDNA  35 12 0.775 (0.604, 
0.947) 
Day 14    
cfDNA  48 18 0.883 (0.767, 
1.000) 
 
 
Table 3.3. Discriminatory power of cfDNA for predicting sepsis at different 
time points was assessed through AUROC and 95% confidence intervals. 
Data is presented as c-statistic and 95% confidence intervals on each day tested.  
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Figure 3.8. Circulating DNA is predominantly of nuclear origin. (A) mtDNA 
levels (log scale) and (B) ncDNA levels (log scale) across time following burn 
injury (n = 50). Data at each time point were compared with healthy control (HC) 
(n = 10) values using a Mann-Whitney test; *P < 0.005. Box and whisker plots 
represent minimum to maximum value and median for each group. HC = healthy 
control, D = day, M = month. 
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3.2.7 Neutrophil extracellular trap formation following thermal injury   
Having found evidence of elevated levels of plasma cfDNA in septic patients, we 
investigated whether NETs could be a source of cfDNA. To confirm NETosis, 
plasma samples were analysed for the presence of Cit H3, which is a 
characteristic feature of NET generation (276). 
A western blot protocol was set up and validated along with a positive control for 
Cit H3 generated through HL-60 cells. Interestingly, following differentiation with 
DMSO, HL-60 cells retained their rounded morphology and do not exhibit a 
‘granulocyte like’ nuclear morphology. Western blot analysis of calcium ionophore 
stimulated HL-60 cells shows a concentration dependent decrease in signal with 
higher dilutions. As the 1:50 dilution of HL-60 gave a robust signal without 
saturating the blot this was used as a positive control for future measurements 
(Figure 3.9 A).  
Cit H3 was clearly detectable in the plasma of septic patients (Figure 3.9 B-C). 
The results obtained for two representative septic patients are shown in Figure 3.9 
B-C (representative of n = 9). The data presented here is for a patient with a 66% 
TBSA who was first diagnosed with sepsis on day 7 (Figure 3.9 B) and a patient 
with a 71% TBSA who was first diagnosed as septic on day 9 (Figure 3.9 C). Cit 
H3 was clearly detected in the plasma and coincided with the peak in cfDNA 
levels. Although this analysis included patients with severe thermal injuries there 
was only trace levels of Cit H3 found in the initial sample for one patient. However, 
Cit H3 was not detectable in any plasma sample obtained from non-septic patients 
or healthy controls (n = 10).  
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Figure 3.9. Longitudinal analysis of NET formation. In all experiments, Cit H3  
was detected in the plasma of septic patients as a 17kDa band by Western 
Blotting. (A) HL-60 positive control diluted 1:20, 1:50, 1:100, 1:150. (B-C) Two 
representative septic patients following thermal injury (data is representative of 9). 
Data presented includes longitudinal plasma cfDNA measurements (log scale) and 
corresponding Cit H3 blots. A positive control (generated in HL-60 cells) was 
included on all blots. HC = healthy control, D = day, MWM = molecular weight 
marker.  
 
121 
 
3.2.8 Ex vivo NETosis  
There is an increasing amount of evidence that thermal injury results in 
suppression or dysregulation of neutrophil functions (156, 173, 174). However, to 
date, no group has investigated if thermal injury also disrupts NET formation. 
Therefore, to investigate whether thermal injury affected NET production by 
circulating neutrophils, cfDNA release by isolated neutrophils stimulated with 
25nM PMA or 100 ng/ml LPS was quantified by fluorescent microscopy and 
fluorometry.  
Firstly, to investigate if neutrophils from patients with thermal injuries were primed 
and in turn released higher levels of NETs, neutrophils were stimulated with 100 
ng/ml LPS. In healthy individuals, neutrophils stimulated with LPS do not result in 
a significant increase in NET release compared to unstimulated neutrophils 
(Figure 3.2). Interestingly, we found that neutrophils from burn injury patients did 
not release more NETs when stimulated with 100 ng/ml LPS compared to healthy 
controls at all time points tested (Figure 3.10 A). 
To confirm maximal NET generation, neutrophils were stimulated with PMA for 3 
hours. Interestingly, neutrophils from burn injury patients released significantly 
lower levels of DNA compared to neutrophils isolated from healthy controls on 
days 3 and 7 post injury (Figure 3.10 B). Fluorescence microscopy imaging 
confirmed that neutrophils isolated from burn injury patients are partially resistant 
to NETosis induced by 25nM PMA, with the majority of the neutrophils from burn 
injury patients retaining their natural cell and nuclear morphology following 
stimulation (Figure 3.10 C). However, in healthy controls nearly all cells release 
NETs and have decondensed nuclei. 
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Figure 3.10. Ex vivo NET production in response to a biological stimulus, 
LPS, and a chemical stimulus, PMA. (A) Ex vivo NET generation in response to 
100 ng/ml LPS across time following burn injury (n = 24). (B) Ex vivo NET 
generation in response to 25 nM PMA across time following burn injury (n = 24).  
Data at each time point were compared with healthy control (HC) values by un-
paired t-test *P < 0.008. Ex vivo NET production in response to LPS was only 
measured for up to 21 days post injury due to the availability and number of 
neutrophils isolated. Data is presented as box and whisker plots and represents 
mean, minimum and maximum value (C) Ex vivo NET generation in response to 
PMA by neutrophils isolated from a healthy control or a burn patient. Slides were 
mounted in fluoromount medium and visualized using a LEICA DMI 6000 B 
microscope at X20 objective. Green stain = DNA. HC = healthy control, D = day. 
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3.2.9 Reactive oxygen species generation of neutrophils following thermal 
injury 
Analysis of ROS generation was performed in collaboration with Dr Peter 
Hampson as part of the SIFTI Trial (University of Birmingham, UK). Data has been 
published (180). 
Of note, we have shown that there is a significant reduction in the ability of 
neutrophils to phagocytose and ex vivo NETosis following thermal injury compared 
to healthy individuals (180). Thus, we investigated if neutrophils were 
dysfunctional in ROS production, suggesting a broader inhibition of neutrophil 
antibacterial functions. Compared to the levels measured in healthy volunteers, 
neutrophil ROS production was significantly reduced in patients with severe 
thermal injuries (Figure 3.11 A). This reduction ensued 3 days following injury and 
was lowest at 7 days post injury. The reduction in ROS formation persisted for up 
to a month following thermal injury (Figure 3.11 A).  
3.2.10 Neutrophil function is reduced to a greater degree in septic patients 
Analysis of ROS production in relation to sepsis status was performed to 
understand if dysregulated ROS production was responsible for the increased 
incidence of sepsis post thermal injury. ROS was reduced to a similar degree over 
the first 7 days following injury in both patient cohorts. However, ROS production 
was significantly lower in septic patients from day 14 – month 2 compared to non-
septic individuals (Figure 3.11 B).   
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Figure 3.11. Thermal injury results in a reduction in ROS production which is 
more pronounced in patients who develop sepsis. (A) Neutrophil ROS 
production longitudinally (n = 63). Data at each time point were compared with 
healthy control (HC) values using a Mann-Whitney test; *p < 0.005. (B) ROS 
production at each time points was compared between septic and non-septic 
patients using a Mann-Whitney test (n = 57). *p < 0.05. Box and whisker plots 
represent the median, minimum and maximum values. HC = healthy control, D = 
day, M = month.  
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3.2.11 White blood cell kinetics  
As neutrophil function is reduced following thermal injury we wanted to investigate 
if this was associated with a change in kinetics or phenotype of neutrophils. 
Thermal injury results in a significant elevation in the circulating levels of WBC 
compared to healthy individuals (Figure 3.12 A). WBC were elevated on day 1 
post-injury and again from day 14 to day 28 (Fig 3.12 A). Levels of WBC on day 1 
post-injury correlated positively with percentage TBSA (p < 0.001, r = 0.55, n = 
39).  
Levels of circulating neutrophils were also significantly elevated compared to the 
control cohort on day 1 and again from day 7 to month 2 post injury (Fig 3.13 A). 
Levels of circulating neutrophils on day 1 positively correlated with percentage 
TBSA (p < 0.001, r = 0.55, n = 39). Importantly, levels of WBC and neutrophils 
only differed between septic and non-septic patients at day 1 and day 28 following 
injury. Thus suggesting that alteration in the whole number is not fully responsible 
for the reduction in neutrophil function post thermal injury (Figure 3.12 B Figure 
3.13 B). 
Levels of IGs were quantified to investigate if a change in neutrophil phenotype 
was partly responsible for the reduction in neutrophil function. Levels of IGs were 
significantly elevated on day 1 post injury compared to healthy individuals (Figure 
3.14 A). There was also a secondary increase in IGs from 7 days to 2 months 
following injury compared to healthy individuals (Fig 3.14 A). Levels of IGs were 
significantly higher in septic patients compared to non-septic patients on days 1, 7, 
day 21 - 2 months following injury (Figure 3.14 B). Morphological analysis of 
isolated neutrophils confirmed the presence of immature cells with the appearance 
of the classical banded nuclear morphology (Figure 3.14 C, black arrows). The 
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image shown is from a patient with 45% TBSA thermal injury with neutrophils 
isolated on day 7 post injury during a known septic episode. 
  
 
127 
 
 
Figure 3.12. Circulating levels of WBC are elevated post thermal injury. (A) 
WBC across time (n = 39) compared to healthy controls (n = 40) using a Mann-
Whitney test *p < 0.005. (B) WBC count at each time points was compared 
between septic and non-septic patients using a Mann-Whitney test (n = 39)          
*p < 0.05. Box and whisker plots represent median, minimum and maximum 
values. HC = healthy control, D = day, M = month. 
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Figure 3.13. Circulating levels of neutrophils are elevated post thermal injury 
(A) Neutrophil count across time (n = 39) compared to healthy controls (n = 40) 
using a Mann-Whitney test *p < 0.005. (B) Neutrophil count at each time points 
was compared between septic and non-septic patients using a Mann-Whitney test 
(n = 39) *p < 0.05. Box and whisker plots represent median, minimum and 
maximum values. HC = healthy control, D = day, M = month. 
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Figure 3.14. Thermal injury results in the release of IGs which are associated 
with sepsis. (A) IGs across time (n = 39). Differences in kinetics were compared 
to data from control cohort (n = 40) using a Mann-Whitney test; *p < 0.005. (B) IG 
count at each time points was compared between septic and non-septic patients 
using a Mann-Whitney test (n = 39). *p < 0.05. (C) Giemsa stain of peripheral 
blood neutrophils on day 7 post burn injury. Arrows identify cells with immature 
banded nuclear morphology. Box and whisker plots represent median, minimum 
and maximum values. HC = healthy control, D = day, M = month, IGs = immature 
granulocytes. 
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3.2.12 Release of immature granulocytes post-burn injury is associated with 
reduced reactive oxygen species generation  
This data was performed in collaboration with Dr Hampson as part of the SIFTI 
Trial. Flow cytometric analysis of neutrophils following severe injury revealed a 
subset of neutrophils that exhibited greater forward-scatter and reduced sideward-
scatter properties when compared to the ‘normal’ neutrophils (Figure 3.15 A). The 
second population of neutrophils was termed a ‘dual population’. Of note, this dual 
population of neutrophils produced lower amount of ROS compared to ‘normal 
neutrophils’ (Figure 3.15 A).  
The ‘dual population’ of neutrophils were significantly elevated from day 3 – day 
28 post injury compared to healthy individuals (Figure 3.15 B). The kinetics of 
release were comparable to IG release, emphasised by the significant correlation 
(r = 0.65,    p < 0.0001) between the percentage of ‘dual population’ neutrophils 
and percentage of IGs (Figure 3.15 C).  
3.2.13 Immature granulocyte percentage is associated with reduced ex vivo 
neutrophil extracellular trap generation  
The ability of the ‘dual population’ to generate NETs could not be investigated 
directly. However, we used IGs percentage as a surrogate marker as there was a 
significant correlation between the percentage of neutrophils that fell within the 
‘dual population’ and IG frequency (Figure 3.15 C). As the appearance of IGs is in 
part responsible for the reduction in ROS generation, the ability to undergo ex vivo 
NETosis was correlated with IG percentage. Ex vivo NET production correlated 
negatively with IG percentage (n = 56, r = - 0.3517, p = 0.0079, Figure 3.16).  
 
131 
 
 
Figure 3.15. Burn injury leads to the release of a dual population of non-
functioning neutrophils into the circulation. (A) Presence of a neutrophil ‘dual 
population’ following burn injury which display reduced ROS production. (B) The 
percentage of cells within the ‘dual population’ as analysed by flow cytometry 
longitudinally compared to healthy individuals (n = 33).Data was compared to 
healthy controls (n = 15) by Mann Whitney test *p < 0.005. Box and whisker plots 
represent median, minimum and maximum values. (C) Correlation of percentage 
‘dual population’ and percentage of circulating IGs (n = 33), as determined by the 
Sysmex XN-1000 analyser. Data was analysed using a Spearman’s rank (n = 33). 
HC = healthy control, D = day, M = month, FSC = forward scatter, SSC = sideward 
scatter, IGs = immature granulocytes. 
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Figure 3.16. IGs are a potential contributor to the reduced ex vivo NETosis 
observed following thermal injury. Correlation of DNA release from isolated 
neutrophils following 3 hours of stimulation with 25 nM PMA with IG percentage. 
Data was analysed by Spearman’s rank (n = 56).  
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3.2.14 Thermal injury results in a change in extended neutrophil parameters 
Following severe thermal injury the circulating pool of neutrophils is 
heterogeneous and measurement of IGs alone does not fully investigate the total 
changes in granulocyte phenotype. Therefore, a more comprehensive analysis of 
neutrophil phenotype and maturity was performed. These include neutrophil 
granularity index (NEUT GI), neutrophil reactive intensity (NEUT RI), neutrophil 
fluorescence intensity and the width of dispersion (NEUT WY), neutrophil 
complexity and width of dispersion (NEUT WX) and neutrophil cell size and the 
width of dispersion (NEUT WZ). 
NEUT WY was significantly elevated on day 1 to day 21 post-injury compared to 
levels in healthy individuals (Figure 3.17 A). NEUT WY was significantly higher in 
septic patients compared to non-septic patients from day 3 – day 21 post injury 
(Fig 3.17 B). In contrast, NEUT RI was significantly elevated from day 3 to month 
2 post injury compared to healthy individuals (Fig 3.18 A). NEUT RI was 
significantly elevated in the septic patients from day 3 to day 28 post injury 
compared to the non-septic patients (Figure 3.18 B). Unlike with NEUT WY and 
NEUT RI, NEUT WX was not significantly different from the control cohort at any 
time point. NEUT WZ was only significantly elevated at day 14 (Figure 3.19 A-B).  
3.2.15 Extended neutrophil parameters correlate with reduced neutrophil 
function 
Levels of ex vivo NET production were correlated with NEUT WY and NEUT RI to 
investigate if a change in neutrophil phenotype was partly responsible for the 
reduced neutrophil function. Levels of DNA release negatively correlated with 
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NEUT WY (R = -0.4494, p = 0.0036, n = 41, Figure 3.20 A) and NEUT-RI (R = -
0.7368, p < 0.0001, n = 41, Figure 3.20 B).  
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Figure 3.17. Burn injury results in increased NEUT WY. (A) NEUT WY across 
time   (n = 39) compared to healthy volunteers. Differences in kinetics were 
compared to data from control cohort (n = 40) using a Mann-Whitney test *p < 
0.005. (B) NEUT WY at each time points was compared between septic and non-
septic patients using a Mann-Whitney test (n = 39) *p < 0.05. Box and whisker 
plots represent median, minimum and maximum values. HC = healthy control, D = 
day, M = month. 
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Figure 3.18. Burn injury results in increased NEUT RI. (A) NEUT RI across 
time (n = 39) compared to healthy volunteers. Differences in kinetics were 
compared to data from control cohort (n = 40) using a Mann-Whitney test;           
*p < 0.005. (B) NEUT RI at each time points was compared between septic and 
non-septic patients using a Mann-Whitney test (n = 39). *p < 0.05. Box and 
whisker plots represent median, minimum and maximum values. HC = healthy 
control, D = day, M = month. 
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Figure 3.19. Burn injury does not result in dynamic changes in NEUT WX 
and NEUT WZ. (A) NEUT WX (n = 39) and (B) Vector sum of NEUT WX and 
NEUT WY (NEUT WZ) across time (n = 39). Differences in kinetics were 
compared to data from control cohort (n = 40) using a Mann-Whitney test; *p < 
0.005. Box and whisker plots represent median, minimum and maximum values. 
HC = healthy control, D = day, M = month.  
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Figure 3.20. Changes in neutrophil nucleic acid content potentially 
contribute to reduced ex vivo NETosis observed following thermal injury. (A) 
Correlation of ex vivo NETosis and NEUT WY (n = 39). (B) Correlation of ex vivo 
NETosis and NEUT RI (n = 39). Data was analysed by Spearman’s rank. 
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3.2.16 mtDAMPs activate neutrophils  
This work was performed by Dr Jon Hazeldine (University of Birmingham, UK) as 
part of a collaboration and joint first authorship manuscript (in preparation). 
An additional mechanism for reduced neutrophil function post thermal injury is 
direct immune suppression by mtDAMPs. To confirm previous observations that 
mtDAMPs could induce neutrophil activation (43), we investigated the surface 
expression of CD62L, CD11b, CXCR1 and CRX2 on human neutrophils following 
15-minute stimulation with 40 or 100 µg/ml mtDAMPs.  
Treatment of neutrophils with both 40 and 100 µg/ml of mtDAMPs resulted in a 
significant reduction in surface density of CXCR1, CXCR2 and CD62L, compared 
to control neutrophils stimulated with vehicle buffer (Figure 3.21 A-C).  Neutrophils 
treated with 40 and 100 µg/ml mtDAMPs had significantly higher levels of CD11b 
surface expression compared to control neutrophils (Figure 3.21 D). Activation of 
neutrophils was further confirmed by western blotting for MAPK ERK1/2. 
Neutrophils simulated for up to 30 minutes with 100 µg/ml mtDAMPs had 
detectable phosphorylation of ERK1/2 within 2 minutes of stimulation (Figure 3.21 
E). Total EKR1/2 was included as a loading control for all experiments (Figure 
3.21 E). 
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Figure 3.21. mtDAMPs induce neutrophil activation. Neutrophils were 
stimulated with 40 or 100 µg/ml mtDAMPs for 15 minutes. (A) Surface CXCR1 
expression on neutrophils following pre-treatment with mtDAMPs. (B) Surface 
expression of CXRC2 expression on neutrophils pre-treated with mtDAMPs. (C) 
Surface CD62L expression on neutrophils following pre-treatment with mtDAMPs. 
(D) Surface CD11b expression on neutrophils following pre-treatment with 
mtDAMPs. Data is presented as MedFI and was compared to neutrophils pre-
treated with buffer control via paired t test. *p < 0.05, **p < 0.01 and ***p < 0.001.  
Data is presented as mean +/- SEM (E) Western blotting for MAPK ERK1/2 and 
phosphorylated MAPK ERK1/2 following pre-treatment with 100 µg/ml mtDAMPs.  
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3.2.17 mtDAMPs pre-treatment results in impaired neutrophil extracellular 
trap generation upon secondary stimulation 
To investigate if mtDAMPs were in part responsible for the reduced ex vivo NET 
generation, neutrophils were pre-treated with mtDAMPs and then stimulated with 
PMA to induce maximal NETosis. Neutrophils which had been pre-treated with 40 
or 100 µg/ml mtDAMPs produced significantly fewer NETs compared to 
neutrophils pre-treated with vehicle control (Figure 3.22 A). This inhibition of NET 
formation was confirmed by fluorescence microscopy with neutrophils pre-treated 
with mtDAMPs displaying lower NET release. Of note, nuclei of pre-treated 
neutrophils do decondense suggesting initiation of NETosis process but an 
inability to release the decondensed nuclear material (Figure 3.22 B-C). 
Importantly, mtDAMPs alone do not induce decondensation of nucleus without 
secondary stimulation with PMA (Figure 3.22 C) 
mtDAMPs are a collection of endogenous cytosolic, mitochondrial and nuclear 
derived proteins and DNA detected in high circulating concentrations following 
major trauma (40, 41). The two major components include fMLP and mtDNA.  
Neutrophils were pre-treated with mtDNA in order to investigate what component 
of the mtDAMPs was causing the inhibition of NET production. Only 40 µg/ml 
could be used in this experiment due to the availability of mtDNA. Neutrophils pre-
treated with 40 µg/ml mtDNA had no inhibition of NET formation relative to control 
neutrophils pre-treated with vehicle control when visualised by fluorescence 
microscopy (Figure 3.23). 
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3.2.18 Effect of mtDAMP pre-treatment on PMA-induced neutrophil reactive 
oxygen species production and citrullination of histone H3 
Two processes central to the formation of NETs are the generation of ROS and 
the citrullination of histone H3 (189-191). The effect of mtDAMPs on ROS 
production was examined to investigate if this was the mechanism responsible for 
the reduced NET formation. Pre-treatment of neutrophils with 40 µg/ml of 
mtDAMPs did not affect ROS production following secondary stimulation. Pre-
treatment of neutrophils with 100 µg/ml of mtDAMPs resulted in an increase in 
ROS production relative to neutrophils pre-treated with buffer control (Figure 3.24 
A). 
The activation of intracellular NADPH and the formation of ROS is a prerequisite 
for the citrullination of histone H3, a specific marker of NETosis (189-191). As we 
had found no inhibition of ROS production we investigated if Cit H3 production 
was affected. Cit H3 was localised in the nucleus and dispersed on the NETs of 
vehicle control neutrophils stimulated with PMA (Figure 3.24 B). Furthermore, Cit 
H3 was detectable in the nucleus of PMA stimulated neutrophils pre-treated with 
40 and 100 µg/ml mtDAMPs (Figure 3.24 B). This is consistent with the 
appearance of the decondensed nuclear structure. Although visible, Cit H3 
appeared to be expressed in lower quantities in PMA stimulated neutrophils pre-
treated with 100 µg/ml compared to 40 µg/ml mtDAMPs (Figure 3.24 B).   
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Figure 3.22. Pre-treatment of neutrophils with 40 or 100 µg/ml mtDAMPs 
inhibits NET formation. (A) Fold increase in DNA release following pre-treatment 
with 40 or 100 µg/ml mtDAMPs and secondary stimulation with PMA. Data was 
compared to unstimulated neutrophils via paired t test (**p < 0.01). Data is 
presented as mean +/- SEM (B) Fluorescence microscopy displaying neutrophils 
pre-treated with, either, buffer control or 40 or 100 µg/ml mtDAMPs followed by 
secondary stimulation with PMA. Images at 20x (C) Fluorescence microscopy 
displaying neutrophils pre-treated with, either, buffer control or 40 or 100 µg/ml 
mtDAMPs followed by secondary stimulation with. Images are taken at 63x 
magnification. (B-C) Data is representative of 3 independent experiments. 
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Figure 3.23. Pre-treatment of neutrophils with 40 µg/ml mtDNA does not 
inhibit NET formation. Fluorescence microscopy displaying neutrophils pre-
treated with, either, buffer control or 40 µg/ml mtDNA followed by second 
stimulation with 25 nM PMA. Images are taken at 20x magnification and data is 
representative of 3 independent experiments.  
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Figure 3.24. Pre-treatment of neutrophils with 100 µg/ml mtDAMPs augments 
ROS production but reduces citrullination of histone H3. (A) Quantification of 
ROS production in whole blood following pre-treatment of neutrophils with, either, 
40 or 100 µ/ml mtDAMPs and a secondary stimulation of 25 nM PMA. Data was 
compared to neutrophils pre-treated with buffer control via paired t-test (**p < 
0.01). Data is presented as mean +/- SEM (B) Fluorescence microscopy 
displaying neutrophils pre-treated with, either, buffer control, 40 or 100 µg/ml 
mtDAMPs followed by secondary stimulation with 25nM PMA. Green stain is for 
DNA stained by SYTOX Green Dye. Blue stain is for Cit H3. All images are taken 
at 20x magnification. Data is representative of n = 3. 
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3.2.19 Exposure to mtDAMPs suppresses neutrophil migration to LTB4 
Suppression or dysregulation in various neutrophil functions have been reported 
following thermal injury including chemotaxis and migration (159-161, 171, 172). 
We aimed to investigate if mtDAMPs could cause a broad inhibition of neutrophil 
function. Therefore, neutrophils were pre-treated with mtDAMPs and their ability to 
transmigrate to the arachidonic acid-derived fatty acid LTB4, a chemotactic signal, 
was investigated. Neutrophils pre-treated with both 40 and 100 µg/ml of mtDAMPs 
had a significant reduction in their migratory activity towards LTB4 compared to 
vehicle control treated neutrophils (Figure 3.25). 
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Figure 3.25. Pre-treatment with 40 and 100 µg/ml mtDAMPs reduced 
migratory activity of neutrophils towards the arachidonic acid-derived fatty 
acid LTB4. Neutrophils were pre-treated with 40 or 100 µg/ml mtDAMPs and the 
amount of neutrophils which transmigrated towards to LTB4 was quantified. Data 
was analysed via repeated measures ANOVA and Bonferroni test compared to 
vehicle control neutrophils (Unt). ***p < 0.001 
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3.3 Discussion 
When first described, NETs sparked a change in the traditional paradigm of 
neutrophil biology (118). NETs are comprised of DNA, granular proteins and 
modified histones and function to ensnare, trap and potentially kill invading 
pathogens (118, 119). Multiple groups have used quantification of DNA and 
histones as a method for quantifying NET release in vivo and in vitro (288). Here 
we report, consistent with previous literature, neutrophils stimulated in vitro with 
PMA results in maximal NET formation which can be characterised by increased 
release of DNA from neutrophils. One limitation of studying DNA release as a 
single entity of NET release is the lack of specificity as DNA can originate from a 
number of sources including apoptosis and necrosis (115). Therefore, specific 
markers of NETosis, e.g. Cit H3 which decorates the remaining decondensed 
nuclear structure and extruded NET structures, need to be investigated to confirm 
NETosis (289). In this thesis, it has been shown that NETs are decorated with Cit 
H3, consistent with previous literature (181, 190, 233). 
In vitro NETosis is further limited by the stimulus used. The use of PMA is 
commonly criticised because it lacks biological relevance as a stimulus. Therefore, 
additional stimuli including IL-8, fMLP and LPS have been shown to induce NET 
formation in vitro following initial priming of neutrophils (9). Here we report that 
LPS alone does not induce NETosis in isolated neutrophils from healthy 
individuals. Therefore, stimulation of neutrophils isolated from patients with 
thermal injuries with LPS allows the investigation of priming status of neutrophils 
and their propensity to undergo NETosis.  
NETosis is a conserved and active cell death pathway which forms a fundamental 
part of innate immunity. NETs are released from neutrophils in an attempt to 
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ensnare, trap and potentially kill invading bacteria (118, 119). Previous groups 
have shown that NETs are implicated in the response to sterile traumatic injury, 
consequent infection and sepsis in various disease pathologies (111, 290). It has 
been proposed that NETosis can be induced rapidly by a number of soluble 
mediators released following tissue damage (9). Moreover, Branzk and colleagues 
demonstrated that neutrophils were able to adapt and tailor their host defensive 
functions based upon the pathogenic challenge. If the challenge is too large in 
size to be engulfed by phagocytosis, then a pro-NETosis phenotype was adopted 
(188). In our patient cohort the most colonising bacteria was Bacillus sp. 
Interestingly, when neutrophils are incubated with Mycobacterium bovis bacillus 
Calmette-Guérin they formed NETs in preference to phagocytosis (188). 
Therefore, given the nature and sources of infections in patients with thermal 
injuries it is not unreasonable to hypothesise that patients will have a pro-NETosis 
phenotype.  
Elevation in circulating cfDNA post thermal injury has been attributed to in vivo 
NET formation (111, 215, 290). However, this method alone is non-specific and 
circulating DNA can originate from a number of sources including cellular damage, 
apoptotic cells, necrosing cells, NETosis and bacteria themselves (115). A specific 
marker of NET formation is the presence of Cit H3 which is facilitated by the 
activation of the enzyme PAD4. This mediates the decondensation of nuclear 
chromatin and extrusion of NETs to the outside of the cell decorated in Cit H3 
(189).  
Hirose and colleagues detected the presence of Cit H3 in the blood stream of 
critically ill patients following traumatic injury (181) thus confirming NET formation. 
Here, we expand upon this and demonstrate that Cit H3 is detectable in the 
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plasma of patients following thermal injury during sepsis and coinciding with 
elevated levels of cfDNA. Thus, we propose that NETosis is a contributing factor 
to the increase in cfDNA detectable in septic patients. Importantly, Cit H3 was only 
detectable in trace quantities immediately following injury in one patient. Hence, 
the initial sterile injury does not induce NET formation following thermal injury. 
Data presented in this thesis would suggest that NETs are a defensive action of 
neutrophils to control and eliminate infection post thermal injury rather than a 
response initiated by the sterile injury.  
In contrast, Hazeldine et al report NET formation within 60 minutes of sterile 
traumatic injury. This occurs in the absence of an infectious stimulus and appears 
to be mediated by a different mechanism of NET generation following thermal 
injury. Thus, there appears to be a difference between burn and general traumatic 
injury in the generation of NETs (291). However, variations in results may be 
attributed to differences and difficulties in methodologies used to study NET 
formation. Namely, current Western blotting assays, for Cit H3, are limited due to 
its semi-quantitative nature and trace quantities of Cit H3 may be below the limit of 
detection in plasma samples of patients with thermal injuries. Advancements in 
ELISA based technologies may aid in the sensitive quantification of Cit H3 and 
further its validation as a biomarker of sepsis, NETosis and secondary 
complications (292). Nevertheless, measurements of Cit H3 in conjunction with 
cfDNA have provided important information on the kinetics and timing of NETosis 
following thermal injury. 
NETosis was long regarded as process localised to tissues at sites of infection 
and injury (293-295). However, recent evidence has implicated NETosis as a 
process which can occur within the circulation, resulting in formation and 
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propagation of thrombosis in a mouse model of DVT (233). Hence, it is plausible 
that thermal injury results in both NET formation within the tissues and circulation. 
This is one potential explanation for the detection of NET components in plasma 
following thermal injury. 
NETosis can be initiated in vivo by a plethora of mechanisms. One of which is 
neutrophils directly interacting with circulating bacteria and the formation of NETs 
during sepsis (225). Furthermore, neutrophils can also bind to inflammatory cells 
which initiate and amplify neutrophil response and function. In addition to their 
central role in haemostasis, platelets are key players in host defence against 
infection in a process termed ‘immunothrombosis’ (296, 297). Of particular interest 
is ‘vital NETosis’ governed by the interaction between activated platelets and 
neutrophils (178). In our cohort of patients, Montague et al report activation of 
platelets, by measurement of circulating sGPVI, at the later time points correlating 
with NET production (Montague et al, manuscript submitted). Thus, it is 
reasonable to hypothesise that activated platelets are also in part responsible for 
the NETosis in patients following thermal injury.  
In addition to their procoagulant activity, it has been reported that heme-related 
molecules can induce rapid NETosis in vitro (58). In a murine model of sickle cell 
anaemia, heme causes NET release and is associated with increased mortality 
(298). Thermal injury results in the production of FRCs (282), which will potentially 
carry heme-related molecules, which could bind to and activate neutrophils to 
induce NETosis. Future studies should focus on the mechanism(s) driving 
NETosis post thermal injury to better understand their role during in vivo 
responses. 
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Severe sepsis and septic shock remain a global health care challenge with a 
systematic review, published in 2012, reporting sepsis as the major cause of 
mortality in burn injury patients (38). Accurate and early diagnosis of sepsis still 
remains challenging with many of the diagnostic criteria being non-specific in 
patients with burns. This is due to many of the classically used diagnosis criteria 
being masked by the ongoing SIRS which occurs immediately following severe 
thermal injury. The Surviving Sepsis Campaign published guidelines, in 2012, 
which recommends administration of antibiotics within 60 minutes of diagnosis of 
sepsis (299). Furthermore, a delay in diagnosis of sepsis is associated with 
significantly increased mortality (300). In 2016, the Surviving Sepsis Campaign 
stressed the importance of antibiotic stewardship aided by further testing to ensure 
infection and in turn reduce overuse of antibiotics (301). This is in an effort to 
overcome the growing problem of antibiotic resistance. Blood cultures remain the 
gold standard for diagnosis of sepsis even though many problems including 
specificity and time required to process have been reported (302, 303). Hence, the 
identification and development of novel and accurate biomarkers of sepsis is 
imperative.  
Recent literature has shown a potential role for cfDNA in the diagnosis of sepsis 
(109, 304-306). Quantification of cfDNA in serum samples, taken within 6 hours of 
injury, from patients with burns correlated with injury severity and outcome (111). 
Surprisingly, we report no elevation in plasma cfDNA within 24 hours of injury 
compared to levels detected in healthy individuals. There are a number of possible 
explanations for these discordant observations. Firstly, a difference in the timing of 
the first sample could explain the results. In our analysis, the median time to first 
blood sample following burn injury was 9 hours. As it has previously been shown 
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that cfDNA is cleared within 30 minutes of appearance in circulation this may 
result in clearance and reduced levels of cfDNA (307-309). Another key difference 
between the two studies is in the preparation of blood samples. In our analysis 
cfDNA was quantified in plasma samples were as Shoham and colleagues 
measured cfDNA in serum (111). Analysis of matched plasma and serum samples 
shows that levels of cfDNA are significantly higher in admission serum samples 
compared to matched plasma samples from burn injury patients. Furthermore, the 
change in DNA between matched samples positively correlated with WBC count. 
In addition, levels of cfDNA were significantly higher in serum samples compared 
to matched plasma samples from healthy volunteers. Interestingly, the ‘net’ 
change in DNA was much lower in healthy individuals compared to the ‘net’ 
change observed in patients. As the ‘net’ change of DNA correlates with WBC, we 
propose that this increase is mediated by the significant increase in WBC count in 
patients following thermal injury compared to healthy individuals. Therefore, the 
false elevation in serum could be a consequence of in vitro clotting, cell death or 
non-specific binding of SYTOX™ Green dye to any residual WBC. This is not only 
an important standardization issue but is also in agreement with previously 
published data (310). 
It has been suggested that plasma cfDNA is a potential novel biomarker of sepsis. 
Consistent with previous publications (109, 220), longitudinal analysis of cfDNA 
levels in our cohort of patients revealed a potential diagnostic use for this 
biomarker. Levels of cfDNA are significantly higher in septic individuals and 
AUROC analysis showed good discriminatory at days 7 and day 14 post injury. 
Quantification of cfDNA by fluorometric analysis has a number of advantages. 
Firstly, the process is rapid and requires no isolation of DNA. Unlike Cit H3, 
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plasma cfDNA can be quantified which allows for evaluation of the marker in 
multiple clinical settings. Finally, the assay is relatively cheap, requires a small 
volume of blood and is rapid to perform. In all, this makes the assay applicable as 
a point of care test to quickly identify patients with infection. Conversely, there are 
a number of limitations of the assay and cfDNA as a biomarker. It is possible that 
DNA binding dyes such as SYTOX Green™ could bind non-specifically to other 
charged molecules in the plasma samples causing false elevation. Additionally, 
cfDNA lacks specificity as it can originate from a number of sources (115). Hence, 
it is important to consider the source of circulating DNA. 
Using a murine cecal ligation model of sepsis it has been reported that the major 
source of elevated cfDNA during sepsis is host tissue damage and not NETs 
(311). Thus, the elevation in cfDNA reported in our cohort could be caused by an 
accumulation of DNA from initial tissue damage and consequential tissue damage 
that occurs during sepsis and MOF. Hamaguchi and colleagues went on to show 
that depletion of neutrophils only had a minor effect upon cfDNA levels confirming 
an insignificant role of neutrophils in mediating the elevation in cfDNA (311). Thus, 
the contribution of NETs in the elevation of cfDNA may be minor following thermal 
injury but still may explain some of the later elevation in cfDNA reported within this 
thesis.  
Circulating DNA can also be of bacterial origin (312, 313). Here, PCR analysis 
was performed to determine the source of cfDNA. Analysis shows that the 
predominant source of circulating DNA is nuclear in origin and not mitochondrial 
following thermal injury. Importantly, the primers used shared no homology with 
any bacterial species and therefore the ncDNA must, therefore, be host derived; 
either from host tissue damage, apoptosis, necrosis or NETosis. However, we 
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cannot exclude the possibility that bacterial DNA is a contributing factor to the total 
cfDNA measured. 
ncDNA levels were significantly elevated within 24 hours of injury relative to 
healthy individuals which was contradictory to the cfDNA results. The significant 
elevation of ncDNA at day 1 – 3 following injury is in part due to the higher 
sensitivity of the PCR assay. As the lower limit of detection of the PCR assay was 
0.1 ng/ml and the lower limit of detection for the fluorometric based assay was 60 
ng/ml. Still, ncDNA followed comparable kinetics to total cfDNA and they 
correlated strongly with each other (r = 0.763). 
mtDNA is derived from the mitochondria of cells and can act as a DAMP (314). 
Elevated levels of mtDNA are associated with secondary complications following 
traumatic injury (314-317). This is attributed to their direct interactions with 
immune cells and damage to host tissue due to their cytotoxic nature (314, 317, 
318). Itagaki and colleagues reported an association between mtDNA levels and 
NET formation following traumatic injury. Consistent with their previous findings, 
trauma patients had a significant elevation in mtDNA compared to healthy 
individuals and incubation of isolated neutrophils with mtDNA resulted in the 
induction of NET release (315). This may in part be attributable to DAMP induced 
activation of neutrophils, however the exact mechanism remains unknown (319). 
Conversely, in our analysis we report no significant elevation in mtDNA 
concentrations in patients with severe thermal injuries compared to healthy 
individuals. It is currently unknown if this is a contradictory finding perhaps due to 
the different mechanism(s) of injury. However, it could be in part explained by 
differences in timing of blood sampling resulting in clearance of mtDNA or pre-
analytical variables by which centrifugation has removed the larger microvesicles 
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containing mitochondria and hence mtDNA (320). Finally, higher levels of mtDNA 
are detected in elderly trauma patients compared to young trauma patients (315). 
As the mean age of our cohort was 39 years this may result in the lower levels of 
mtDNA detected. As we have few elderly patients with burns ≥ 15% TBSA it was 
not possible to investigate this hypothesis within our cohort. Thus, further research 
is required to investigate mtDNA concentrations following thermal injury in relation 
to outcome, age and secondary complications. 
Itagaki and colleagues report preliminary evidence showing a reduced ability of 
neutrophils from elderly trauma patients to form NETs ex vivo relative to age 
matched controls and young trauma patients (315). Given the high incidence of 
infections post burn injury and apparent reduced neutrophil function it has led to 
the investigation of this relationship (38, 172, 174, 321). 
As early as 1985, Arturson et al reported, in a cohort of 50 patients with thermal 
injuries, a reduction in chemotaxis, phagocytosis and impaired killing of bacteria 
(175). As recently as 2014, a spontaneous migratory phenotype for neutrophils 
isolated from patients with severe thermal injuries was observed. This migratory 
phenotype was present 1 - 2 days prior to clinical diagnosis of sepsis and was not 
present in healthy or non-septic individuals (172). Whilst these studies 
documented a dysregulation in neutrophil function following severe thermal injury, 
they have only studied this in the early days post injury. Thus, the longitudinal 
neutrophil response has not been thoroughly examined. Whilst the ability of 
neutrophils to generate NETs post trauma has been investigated no group has 
investigated the effect thermal injury has on this NET production (315). 
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Traumatic injury results in the systemic priming of neutrophils which has been 
attributed to the enormous release of soluble mediators (322, 323). Zhang et al 
reported a link between initial traumatic injury and consequent immune cell 
activation and inflammation (42). Further research has shown that adenosine 
triphosphate (ATP) and N-formyl peptides can stimulate ROS production, 
degranulation and cytokine secretion in neutrophils (43, 324, 325). Due to the 
elevated levels of NET components in the circulation we had hypothesised that 
neutrophils from patients following thermal injury would be primed and in turn 
would overproduce NETs rapidly with ex vivo stimulation. To test this hypothesis, 
neutrophils isolated from patients with burn injury were stimulated with LPS alone 
to investigate their priming status and ability to form NETs ex vivo (9, 293). 
However, neutrophils from patients following thermal injury did not generate NETs 
when stimulated with 100 ng/ml LPS. This would suggest that neutrophils are not 
primed or have a reduced ability to form NETs following thermal injury.  
We expanded upon this finding and report that neutrophils stimulated with 25 nM 
PMA release significantly lower amounts of NETs on day 3 – 7 post thermal injury 
relative to healthy individuals. This was further confirmed by fluorescent 
microscopy in which minimal release of DNA was observed from neutrophils 
isolated from patients. These findings are consistent with previous literature which 
reports a reduction in maximal NET generation in patients with traumatic injuries 
(326). In a number of patients it was clear that neutrophils also retained their 
natural morphology following stimulation without significant decondensation of 
nuclei. As PMA is not receptor dependent this indicates a clear defect in later 
signalling cascades. Thus, there appears to be a reduction in the ability to form 
NETs following thermal injury which may leave patients at risk of nosocomial 
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infections. One limitation of this data is the absence of a second marker of NET 
formation, e.g. neutrophil elastase, in our fluorescence microscopy based assay. 
However, within this analysis we use an isolated in vitro system to induce maximal 
NET formation. Thus, DNA released from neutrophils following stimulation with 
PMA can be regarded as a surrogate marker of NET formation. Therefore, we 
would propose that the lack of a more comprehensive staining panel does not 
affect our conclusions.  
Initially a reduction in ex vivo NETosis appears to contradict our in vivo data. 
However, there are a number of possible explanations for NET markers detected 
in vivo and reduced ex vivo NETosis. One possible explanation is that functional 
neutrophils have migrated and are generating NETs in the damaged tissues and 
thus leaving non-functional neutrophils in the circulation. Secondly, there may be a 
dysregulation in the breakdown and clearance of NETs allowing for the build-up of 
NET components. One limitation of our current data is the inability to investigate 
the relationship between ex vivo NETosis and susceptibility to infection post 
thermal injury due to limited sample size. Thus, further studies are required to fully 
understand the clinical relevance of this finding post thermal injury and to 
investigate if reduced ex vivo NETosis is associated with an increased incidence 
of infection and a potential therapeutic target. 
Whilst a reduction in NET formation has been shown post traumatic injury (315), to 
our knowledge no groups have studied potential mechanisms for this 
dysregulation in the same patient cohort. ROS are a heterogeneous collection of 
molecules which form an important link between cellular activation and NET 
formation. Production of ROS is controlled by NADPH oxidase complex which 
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produces O2- and H2O2 upon activation. ROS induced decondensation of nuclear 
chromatin precedes NETosis and is facilitated by the activity of PAD4 (189-191).  
There are contradicting data regarding ROS production following traumatic injury. 
Namely, it has been shown that baseline ROS production is increased and may be 
contributing to host tissue damage (137, 138). Conversely, Parment and 
colleagues report a reduction in oxidative capacity for up to 3.5 months post 
thermal injury (177). In agreement with Parment and colleagues, we report a 
significant reduction in ROS formation following thermal injury relative to healthy 
individuals. Furthermore, in our analysis septic patients had significantly lower 
levels of ROS production than non-septic patients. This highlights the immediate 
and sustained immunosuppression induced by thermal injury in septic patients. 
Given that ROS production is regarded as a prerequisite of NETosis, this may be 
a potential mechanism by which neutrophils have a reduced ability to generate 
NETs ex vivo. However, ROS independent mechanisms of NET formation must 
also be considered. Hence, given the limited sample size, further research is 
required to fully study in vivo reduced ROS formation and ex vivo NETosis 
following thermal injury.  
Independent of NETosis, ROS also forms a key component of host defence 
against engulfed pathogens (134). Neutrophils are essential effector cells of innate 
immunity and function to clear invading pathogens. Dysfunction or dysregulation 
of neutrophil functions may leave the host immunocompromised as highlighted in 
CGD patients who are incapable of forming ROS due to the absence of NADPH 
(153). Moreover, phagocytosis is significantly reduced following thermal injury and 
is more pronounced in septic individuals (180). This may be contributing to the 
increased incidence of infection as septic patients with thermal injuries have 
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reduced ROS formation and phagocytosis following thermal injury. In addition, it 
has recently been suggested that pathogens can use evasion strategies to avoid 
killing by neutrophils. Laskay et al suggest an evasion strategy, by Leishmania, 
that allows pathogens to use granulocytes as host cells and replicate. As ROS is a 
critical effector of intracellular killing and reduced post thermal injury, this process 
may be occurring. Therefore, pathogens may be using neutrophils as a ‘Trojan 
horse’ to aid in their dissemination due to the inability to kill engulfed pathogens 
(327). 
Given that NETosis can also be mediated through ROS independent mechanisms 
it is important to consider additional mechanisms by which dysregulation in NET 
formation may occur (186). IGs are released prematurely from the bone marrow in 
response to stress and infection (96). Although they can still phagocytose and 
migrate, it is reduced compared to mature neutrophils (169). In addition, immature 
cells are termed ‘band cells’ due to their classical banded morphology and 
increased nuclear content. Here we show that neutrophils which are banded in 
morphology are present in isolated neutrophil preparations from patients. Analysis 
of neutrophils following severe thermal injury also revealed a ‘dual population’ of 
neutrophils which have distinct forward and sideward scatter properties 
comparable to data published by Pillay et al in 2011 (158). The kinetics of the 
‘dual population’ of neutrophils correlated with the appearance of IGs and in our 
analysis this ‘dual population’ of neutrophils was defective in generating ROS and 
phagocytosis (180). IG frequency correlated with reduced ex vivo NETosis and 
therefore immature cells may be contributing to the reduced neutrophil function 
post burn. 
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It is important to consider the heterogeneous nature of the circulating population of 
neutrophils. Quantification of IGs alone is therefore limited as it does not account 
for phenotypical changes in the total neutrophil population. We performed a more 
comprehensive analysis of neutrophil phenotype by quantifying five additional 
novel parameters; NEUT WY, NEUT WX, NEUT WZ, NEUT GI and NEUT RI. 
Here we report a significant increase in NEUT WY and NEUT RI post thermal 
injury. The elevation is potentially caused by the cumulative release of IGs and 
promyelocytes, myelocytes or metamyelocytes.  Moreover, the presence of IGs 
and extended measurements of neutrophil phenotype correlated with reduced ex 
vivo NETosis. Thus, changes in neutrophil maturity and morphology could be in 
part responsible for the reduced neutrophil function observed following severe 
thermal injury.  
Quantification of circulating IGs is able to discriminate between septic and non-
septic patients with a sensitivity of 89.2% and a specificity of 79.4% (96). Here we 
show that in addition to their potential mechanistic role in sepsis, IGs have a 
potential diagnostic use as they are significantly higher in septic patients 
compared to non-septic individuals. Further investigation and formal statistical 
analysis on the kinetics of IGs release in relation to infection is required to fully 
understand the diagnostic potential of this marker.  
Recently it has been reported that quantification of extended neutrophil 
parameters could predict an increase in circulating IGs and discriminate between 
IG release from infectious or non-infectious causes (328). Therefore a combination 
of IG number and extended neutrophil parameters may provide a novel panel of 
biomarkers to discriminate between sterile injury and infection following burn. In a 
recent study by Luo et al, NEUT X, NEUT Y and NEUT Z could identify septic 
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patients (329). In our analysis only NEUT WY and NEUT RI, measurements of 
nucleic acid content, demonstrated any significant and dynamic changes in 
thermal injury patients compared to control cohort. The differences may be 
mediated by methodology as, NEUT-Y, NEUTX and NEUT-Z do not account for 
width of dispersion unlike NEUT-WY. Stiel et al have reported that an increase in 
nucleic acid content had a strong discriminatory power for diagnosing sepsis with 
sensitivity equal to 90.91% and specificity equal to 80.60% (330). In agreement, 
septic individuals had higher NEUT WY and NEUT RI values compared to non-
septic patients. Quantification of immature neutrophils and measurement of 
nucleic acid content may be a potential novel biomarker of sepsis following 
thermal injury. Furthermore, measurement of the extended neutrophil parameters 
of maturity and phenotype may have better potential compared to quantifying IGs 
alone.  
Although quantification of novel biomarkers is showing promise in the early 
diagnosis of sepsis in patients with thermal injuries, understanding the 
mechanisms responsible for the immunosuppression offers the opportunity to 
explore novel therapeutic interventions. However, current mechanisms 
responsible for immunosuppression are poorly understood. One potential source 
of immediate immunosuppression is the release of mtDAMPs. 
mtDAMPs are comprised of a heterogeneous mixture of molecules including; 
mtDNA, cytochrome C, N-formyl peptides and ATP (331). However, fMLP and 
mtDNA are regarded as the two major effectors on neutrophils. This was 
demonstrated in 2015 by Hazeldine et al who report neutrophil activation through 
N-Formyl peptides within mtDAMPs (43). 
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Once released into the circulation from damaged tissues and cells, mtDAMPs can 
activate and induce a state of tolerance in immune cells (42, 45, 332). In 2014, 
Fernández-Ruiz et al defined endotoxin tolerance in monocytes induced by 
circulating mtDAMPs. Notably, this phenomenon of tolerance was associated with 
an increased infection rate (45). In a more recent study, the authors report that 
patients with ischemic stroke display this endotoxin tolerance phenotype and it is 
association with elevated circulating mtDNA. Furthermore, monocytes from 
healthy individuals developed this endotoxin tolerance phenotype when cultured 
with serum from patients with ischemic stroke or elevated levels of mtDNA (332). 
Whilst this refractory state has been described in monocytes it is possible that 
circulating mtDAMPs induce a comparable phenotype in neutrophils following 
thermal injury and maybe responsible for the reported dysfunction.  
Following severe traumatic injury mtDAMPs, including N-formyl peptides and 
mtDNA, are released into the circulation (42, 333). Whilst here we report no 
significant elevation in mtDNA following thermal injury the difference may be 
caused by a number of factors including pre-analytical variables, time to blood 
sampling and mechanism of injury. Furthermore, we have been unable to measure 
circulating levels of fMLP due to lack of sample availability. Therefore, further 
study is warranted to fully investigate mtDAMP kinetics post thermal injury and 
their association with neutrophil function. Of note, in septic patients or patients 
with DIC, elevated levels of circulating high mobility group box 1 protein (HMGB1) 
have been observed (334, 335). Thus, one would hypothesise that fMLP is 
released in response to consequent host tissue damage and infection following 
thermal injury in a similar manner to HMGB1 (42, 333). 
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In 2015, Hazeldine et al reported activation of human neutrophils following 
stimulation with 40 or 100 µg/ml mtDAMPs. The authors showed for the first time 
that activation of neutrophils by mtDAMPs was dependent upon signalling through 
the MAPK p38 and ERK 1/2. Selective inhibition of the formyl peptide receptor-1 
inhibited this activation and the group concluded that N-formyl peptides are the 
main constituents driving mtDAMP-induced neutrophil activation (43). Consistent 
with their findings we report that mtDAMPs result in activation of neutrophils 
characterised by CD62L shedding and phosphorylation of ERK 1/2 (43). Here we 
expand upon this observation by investigating CXCR1 and CXCR2 surface 
expression on neutrophils following 15 minutes incubation with mtDAMPs. 
Following activation of neutrophils, CXCR1 and CXCR2 are internalised resulting 
in a decrease in their surface expression (336, 337). Here, we report that 
stimulation with mtDAMPs results in a rapid decrease in both CXCR1 and CXCR2 
surface expression. The decrease in CXCR2 is more pronounced than CXCR1 
which may be explained by CXCR2 being rapidly internalised following activation 
compared to CXCR1 (337). 
Various endogenous and exogenous inhibitors of NET release have been reported 
(338-341). Although dysregulation in NET formation has been reported following 
major trauma (180, 315), the mechanisms driving this dysregulation are poorly 
understood. Furthermore, the role mtDAMPs and inhibition NET formation has yet 
to be fully explored. Pre-treatment of neutrophils with either 40 or 100 µg/ml of 
mtDAMPs results in a significant reduction in NET formation following secondary 
stimulation with PMA. To investigate the component responsible for inhibition of in 
vitro NET formation neutrophils were pre-treated with mtDNA. Consistent with 
previous findings we report no inhibition of NET formation when neutrophils are 
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pre-treated with mtDNA (315). Hence, an additional component of mtDAMPs that 
is not mtDNA is potentially responsible for the inhibition of PMA induced NET 
formation. Thus data presented within this thesis does not contradict previous 
observations (315). 
Neutrophils pre-treated with mtDAMPs and then stimulated with PMA had 
decondensed chromatin and nuclear structure and did not retain their natural 
polymorphic nuclear structure. This is indicative of dysregulation of NET release 
rather than recognition of stimulus. Since PMA activity is not dependent upon 
receptor activation it appears that inability to release NETs is mediated by 
dysregulation in a downstream cascade. This is different to our ex vivo data in 
which neutrophils do not decondense following stimulation with PMA. However, 
this difference may be explained by cumulative dysregulation in our ex vivo data 
caused by a change in phenotype and abnormal ROS production. Importantly, this 
is not accounted for in our in vitro analysis of mtDAMPs functions.  
Formation of NETs is generally NADPH oxidase-dependent with many activators 
of ROS being reported as inducers of NETosis (189-191, 342). In addition, mice 
with NADPH oxidase deficient neutrophils are not able to form NETs (342). To 
investigate if a dysregulation in ROS production was responsible for inhibition of 
NETosis, levels of ROS were quantified following pre-treatment with mtDAMPs 
and secondary stimulation with PMA. Of note, Hazeldine et al have previously 
reported that stimulation of neutrophils with mtDAMPs results in a significant 
increase in ROS production from resting neutrophils (43). Here we expand upon 
this and show that pre-treatment of neutrophils with mtDAMPs and a secondary 
stimulation with PMA results in a significant increase in ROS production compared 
to vehicle control neutrophils. ROS induced decondensation of nuclear chromatin 
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precedes NETosis and is facilitated by the activity of enzyme PAD4 (189-191, 
343). Here we report, although reduced, neutrophils still have Cit H3 detectable 
and a decondensed nuclear structure. As ROS formation can mediate citrullination 
of histones by PAD4 and eventual chromatin decondensation this may explain our 
results (135, 189, 208, 343). 
It is important to consider the limitations of these experiments. As we are 
measuring ROS production in whole blood we cannot eliminate that mtDAMPs are 
indirectly increasing neutrophil ROS production via activation and interaction with 
other inflammatory cells. However, our data suggest that a reduction in ROS is not 
causing inhibition of NETosis following pre-treatment with mtDAMPs. 
Multiple groups, including ourselves, have reported a reduction in neutrophil ROS 
production following severe thermal injury (175-177). Here we report that pre-
treatment of neutrophils with mtDAMPs increases ROS production following 
secondary stimulation. Therefore, mtDAMPs are probably not responsible for the 
in vivo reduction in ROS production reported in this thesis. As discussed earlier, 
this reduction in ROS formation is most likely caused by a change in neutrophil 
maturity, phenotype or an unknown soluble mediator.  
Ramijsen et al report that the formation of NETs is dependent upon both ROS 
generation and autophagy (208). Autophagy is an essential cellular mechanism for 
cellular homeostasis and is regulated by activation of the mammalian target of 
rapamycin (mTOR). Pharmacological inhibition of mTOR accelerated NETosis 
following stimulation with fMLP and is therefore a negative regulator of autophagy. 
Inhibition of autophagy by wortmannin abolishes citrullination of histones induced 
by co-treatment of neutrophils with rapamycin and fMLP (344). We hypothesise 
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that mtDAMPs may be activating mTOR which inhibits autophagy and in turn 
prevents NET production. Therefore, one may hypothesise that the reduction in Cit 
H3 staining observed is in part caused by mtDAMP inhibition of autophagy. 
However, this is only a hypothesis and further study is required to fully understand 
the effect mtDAMPs have on autophagy and consequently NET formation. 
For neutrophils to function in tissues they must migrate towards the site of 
infection before phagocytosing or generating NETs against the pathogen. One 
hypothesis speculates if the dysfunctional pool of circulating neutrophils consists 
of cells which are unable to migrate to sites of injury and in turn leaving the patient 
immunocompromised. Hence this may manifest as the clear dysregulation in 
migratory phenotype of neutrophils observed following severe thermal injury (159-
161, 171, 172). In addition, studies have reported impaired migration, of 
neutrophils isolated from trauma patients, towards IL-8 and LTB4 (326, 345). In 
this thesis, pre-treatment of neutrophils with mtDAMPs causes a reduction in 
neutrophils ability to migrate towards LTB4. Suggesting that mtDAMPs may be a 
contributory factor to the dysregulated chemotaxis and migration reported 
following severe thermal and traumatic injury. 
We propose that the reduced migration of neutrophils is mediated by both mtDNA 
and fMLP. Firstly, Li et al have reported using an ex vivo model that pre-treatment 
of neutrophils with 10 nM fMLP resulted in reduced transmigration in response to 
both 1 and 10 nM LTB4 (326). This was earlier shown by Campbell et al who 
reported decreased migration towards IL-8 following pre-treatment with 10 nM 
fMLP (346). Furthermore, mtDNA contains CpG DNA repeats as mitochondria 
evolved from bacteria (347, 348). Incubation of neutrophils with CpG DNA 
significantly impairs migration towards LTB4 which occurred simultaneously to a 
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reduction in BLT1, a high affinity receptor for LTB4 (349). In addition, the authors 
show a reduction in migration towards IL-8 following pre-treatment with CpG DNA. 
Again, this reduction occurred simultaneously to a reduction in the IL-8 specific 
receptor, CXCR1 (349). In our studies, pre-treatment of neutrophils with mtDAMPs 
results in a significant reduction in both CXCR1 and CXCR2. Therefore, whilst we 
have yet to investigate an ability to migrate towards IL-8, it is possible that 
mtDAMPs may result in disrupted transmigration towards this chemokine. Finally, 
reduced transmigration towards LTB4 may be caused by internalisation of BLT1 
receptors following treatment with mtDAMPs. 
In conclusion, this data supports the hypothesis that mtDAMPs may induce a state 
of neutrophil dysregulation and may be responsible, in part, for the reduced ex 
vivo NETosis and dysregulated migration reported following thermal injury (159, 
161, 171, 172). These results may provide a novel area of research linking the 
initial traumatic injury, subsequent suppression of neutrophil function and 
increased incidence of nosocomial infections. Following further studies, this may 
identify therapeutic targets to manipulate and correct the reduced neutrophil 
function following thermal injury. However, it is important to consider that all of 
these experiments are performed in isolation without any potential cellular 
interactions or additional soluble mediators. However, we propose that the 
reduced neutrophil function is in part mediated by the initial and rapid release of 
mtDAMPs.  
In summary, data presented in this chapter show NETs are generated following 
thermal injury. Consistent with previous literature (181, 350, 351), NETs are 
generated during the infectious phase and are most likely forming a key part of 
host defence against invading pathogens. Shoham et al have previously reported 
 
169 
 
an increase in serum cfDNA and NET markers immediately post thermal injury 
(111). However, our data suggests that this was caused by an artefactual increase 
in cfDNA induced by blood clotting in the preparation of serum. Thus, there is a 
need for standardisation of cfDNA and NET marker measurements in clinical 
samples.  
Furthermore, data presented in this chapter reports a dysfunction in the ability of 
neutrophils to form NETs following thermal injury. Whilst preliminary evidence has 
reported this dysfunction following trauma (315), to our knowledge it has yet to be 
reported following thermal injury. As shown in Figure 3.26, the reduced ability to 
generate NETs may be attributed to three main causes. Firstly, septic patients 
have significant changes in the maturity phenotype of circulating neutrophils which 
are known to be dysfunctional (169). mtDAMPs, and other soluble mediators, 
which are released immediately following thermal injury are potential contributors 
of the reduced ability to generate NETs. This provides a link between the initial 
traumatic injury, subsequent suppression on innate immunity and provides an 
explanation for the increased incidence of nosocomial infections following thermal 
injury. Whilst still a hypothesis it is possible that functioning neutrophils have 
migrated to sites of injury within the tissues, in turn leaving behind non-functioning 
circulating neutrophils. In conclusion, this research reports both novel biomarkers 
of sepsis and potential mechanisms of reduced neutrophil function following 
thermal injury which may be therapeutic targets. 
  
 
170 
 
 
  
Figure 3.26. Mechanisms by which neutrophil dysfunction, including 
reduced NET formation, may occur following severe thermal injury. Following 
severe thermal injury there is a heterogeneous pool of circulating dysfunctional 
neutrophils which may underlie the increased infection rate. Dysfunction may 
occur by a change in neutrophil phenotype, tolerance induced by prior stimulation 
with soluble mediators (e.g. mtDAMPs) or due to functioning neutrophils migrating 
to the tissues leaving behind non-functioning circulating neutrophils. 
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Chapter 4 
 
Reduced DNAse activity in burns patients is associated 
with compromise to the blood-based actin scavenging 
system and increased risk of multiple organ failure 
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4.1 Introduction  
Sepsis is a life threatening condition characterised by an imbalance in both the 
immune and haemostatic systems, which results in cardiac dysfunction and acute 
respiratory distress syndrome. Without intervention, sepsis can lead to MOF, 
which is a leading cause of delayed mortality following major trauma and is 
characterised by tissue hypoxia, tissue damage and organ dysfunction (59). 
Although it is well recognised that damage to vital organs occurs during MOF, the 
mechanisms mediating this damage and progression remain poorly understood 
(352). Understanding the pathogenesis of MOF and organ damage has the 
potential to improve patient outcome following major injury including burns. 
Immunothrombosis is a recently described phenomenon in which thrombosis 
forms a vital part of host protection against invading pathogens (296). This 
process is supported by innate immune cells and forms a matrix upon which 
recognition and elimination of pathogens can occur. Of note, neutrophils have a 
multifaceted role in coagulation and are implicated in thrombosis, tissue damage 
and various disease pathologies (229, 230, 237, 353). One proposed mechanism 
by which this occurs is through the generation of NETs which are comprised of 
DNA, histones, granule-derived peptides and enzymes and have been shown both 
in vitro and in vivo to ensnare, trap and in some instances directly eliminate 
pathogens (119). 
Recent studies have shown that NETs and their components can initiate a 
procoagulant phenotype and cause tissue and organ damage (195, 223, 224). 
NET induced thrombi have decreased permeability, decreased susceptibility to 
fibrinolysis and increased clot stability (235). Build-up of circulating NET 
components may occur due to overproduction of NETs, due to systemic priming, 
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or a reduced ability to degrade and breakdown NETs. As described in an earlier 
chapter (3.2.8 Ex vivo NETosis, Figure 3.10), neutrophils isolated from burn-
injured patients are dysfunctional in producing NETs ex vivo compared to healthy 
individuals. Therefore, we hypothesise that the accumulation of NET components 
following injury is likely caused by impairment in clearance mechanisms.  
DNAse 1 is the major extracellular endonuclease found in blood and functions to 
break down chromatin and DNA that are released following cellular damage, cell 
death and NETosis. Reduction in DNAse activity is associated with the 
pathogenesis of autoimmune disease through physical inhibition of the enzyme by 
circulating antibodies (237). DNAse activity is also indirectly regulated by the actin 
scavenging system that prevents the formation of DNAse and actin complexes. 
The system is comprised of two key proteins; GSN and VDBP (237, 240, 245, 
246). Whilst it has been shown that reduced levels of GSN are associated with 
mortality, development of sepsis and MOF (254). No group has studied dynamic 
changes in GSN and VDBP levels in relation to DNAse activity and build-up of 
circulating toxic NET components following severe thermal injury.  
4.1.1 Aims 
The aims of this chapter were: 
 Investigate if clearance of DNA was dysfunctional following thermal injury.  
 Investigate if a reduction in DNAse activity was associated with secondary 
complications namely, sepsis and MOF.  
 Investigate if reduced DNAse activity is a potential therapeutic target to 
reduce secondary complications. 
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4.2 Results 
4.2.1 Study cohort  
Consistent with Chapter 3, all analysis was performed on adult patients (≥ 18 
years of age) with burns ≥ 15% TBSA. The consort diagram for this analysis is 
included (Figure 4.1). Analysis was restricted to burns ≥ 15% TBSA to minimise 
the confounding bias of age and severity of injury in analysis. Furthermore, this 
has reduced the span and confounding bias of fluid resuscitation (284, 285). 
Patient and healthy controls demographics are shown in Table 4.1. A total of 64 
adult burns patients were included in the study, with a mean age of 43 years 
(range 16 - 88) and mean burn size of 35% TBSA (range 15 - 95). In addition, 19 
healthy controls were included in this analysis with a mean age of 44.5 years 
(range 20 - 95.9). The incidence of sepsis was 59%, with 38 patients experiencing 
one or more episodes during their hospital stay. The median time to first septic 
episode in this cohort was 5 days post-injury (IQR 4 - 7). The incidence of MOF in 
the cohort was 37.5% (24/64), with the median time to first episode 4 days post-
injury (IQR 2 - 11). A significantly greater injury severity, incidence of sepsis and 
mortality rate was recorded in those patients who developed MOF (p < 0.05). All 
patients received standardised burn resuscitation protocols as per Parkland 
Formula and as such received equivalent fluid resuscitation (average = 5.4 
mls/kg/%TBSA, standard deviation = 2.1).  
Different from Chapter 3, all patients were included in the analysis within this 
chapter irrelevant of time to mortality as no attempt to evaluate the diagnostic or 
prognostic accuracy of biomarkers using AUROC was made.  
 
175 
 
 
 
 
 
 
 
Characteristic Healthy 
Controls 
(n = 18) 
All 
Patients 
(n = 64) 
MOF 
(n = 24) 
No MOF 
(n = 40) 
p  
 
Age, years 44.5 (20-95.9) 43 (16-88) 44 (24-77) 42 (16-88) ns 
Gender (M:F) 9:9 43:21 12:12 31:9 < 0.05 
%TBSA (min-
max) 
 35 (15-95) 48 (17-95) 27 (15-58) < 0.0001 
ABSI (min-
max) 
 8 (4-14) 10 (6-14) 7 (4-11) < 0.0001 
Survived (Y:N)  44:20 10:14 34:6 < 0.001 
Sepsis (Y:N)  38:26 22:2 16:24 < 0.0001 
 
Table 4.1. Patient demographics (Chapter 4). MOF and no-MOF variables were 
analysed by Mann-Whitney (continuous variables) or Chi-squared test (categorical 
variables). Abbreviations: ABSI, %TBSA = percentage TBSA. 
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Figure 4.1. CONSORT diagram showing allocation and disposition of study 
subjects. 
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4.2.2 Nuclear DNA levels are elevated in patients with multiple organ failure 
Firstly, it was essential to understand if an elevation in NET markers was 
associated with the development of MOF or sepsis. Analysis of ncDNA was 
chosen due to the lower limit of detection compared to cfDNA alone. Therefore, 
changes within 24 hours following thermal injury and its relation to MOF and 
sepsis could be investigated.  
Longitudinal changes in the kinetics of ncDNA were compared between patients 
who did or did not develop MOF. Levels of ncDNA were significantly elevated on 
day 1 – day 3 post-burn in patients who developed MOF compared to those who 
did not (Figure 4.2 A). This was followed by a secondary significant elevation in 
ncDNA between day 14 and month 2 in patients with MOF. ncDNA levels returned 
to values comparable to that of healthy controls 3 months post-injury (Figure 4.2 
A). 
4.2.3 Nuclear DNA levels are elevated in patients who develop sepsis 
Longitudinal changes in the kinetics of ncDNA were compared between patients 
who did or did not develop sepsis. ncDNA was significantly elevated on day 14–
month 2 post-burn in patients who developed sepsis compared to those who did 
not (Figure 4.2 B). This was followed by a secondary significant elevation in 
ncDNA at month 12 in patients who had developed sepsis which is most probably 
caused by small sample number at this time point within the analysis. 
Elevation in ncDNA at later time points coincides with NET generation as 
determined by the presence of Cit H3. The representative western blot (Figure 
4.3) is for a 55 year old male patient who had a 65% TBSA burn who survived 
their injury but developed both sepsis and MOF. Cit H3 is detectable at both day 
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21 and day 28 post thermal injury coinciding with infection and elevation in ncDNA 
post thermal injury. Therefore, it is highly likely that NETs are contributing to the 
increase in ncDNA at the later time points post injury (Figure 4.3). Of note, levels 
of ncDNA within 24 hours following thermal injury significantly correlated with 
TBSA burn, ABSI and rBaux score (R = 0.42, 0.31 and 0.37 respectively, Figure 
4.4 A-C). 
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Figure 4.2. Patients with MOF and sepsis have higher levels of circulating 
ncDNA. (A) ncDNA across time (n = 64) differences in kinetics were compared 
between patients who did and did not develop MOF using a Mann-Whitney test;      
*p < 0.05. (B) ncDNA across time (n = 64) differences in kinetics were compared 
between patients who did and did not develop sepsis using a Mann-Whitney test;    
*p < 0.05. Both panels are presented on a log scale. Box and whisker plots 
represent median, minimum and maximum values. HC = healthy control, D = day, 
M = month. 
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Figure 4.3. Cit H3 coincides with elevations in ncDNA following thermal 
injury. ncDNA (log scale) and Cit H3 western for a representative patient: 55 year 
old male patient who had a 65% TBSA burn who survived their injury but 
developed both sepsis and MOF. Positive control = Calcium ionophore stimulated 
HL-60 cells (Section 2.10), HC = healthy control, D = day. 
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Figure 4.4. Levels of ncDNA correlate with severity and size of injury. (A) 
Correlation of ncDNA and TBSA burn (%) (n = 64) (B) Correlation of ncDNA and 
ABSI (n = 64). (C) Correlation of ncDNA and rBaux score (n = 64). All 
measurements were taken within 24 hours of injury. Data was compared by 
Spearman’s rank. 
  
 
182 
 
4.2.4 Patients with thermal injury have reduced DNAse activity 
To investigate if the accumulation of ncDNA was associated with reduced 
clearance, DNAse activity was quantified in serum samples. There was a 
significant reduction in DNAse activity, from day 1 – day 28 post-injury compared 
to healthy individuals (Figure 4.5). Interestingly, DNAse activity on day of injury did 
not correlate with size of thermal injury (TBSA %), severity of injury (ABSI) or 
rBaux (Figure 4.6 A-C).  
Reduced DNAse activity was confirmed by fluorescence microscopy with NETs 
still visible in slides treated with patient serum (Figure 4.7). Conversely, all healthy 
control serum samples digested NETs completely (Figure 4.7). Data presented is 
from 5 independent experiments and is representative of 10 experiments. DNAse 
activity significantly and inversely correlated with ncDNA levels across all time 
points (n = 64, r = -0.3574, p < 0.0001). 
4.2.5 DNAse activity is lower in patients who develop multiple organ failure 
or sepsis 
To understand if a reduced DNAse activity was associated with MOF, by 
facilitating the accumulation of ncDNA, patients were split into those who did and 
those who did not develop MOF. Importantly, patients who developed MOF had 
significantly lower DNAse activity at day 28 and month 2 post injury compared to 
patients who did not develop MOF (Figure 4.8).  
Patients were further subcategorised according to their sepsis status to investigate 
if infection had any effect on DNAse activity. Patients who developed sepsis had 
significantly lower DNAse activity at day 21 to month 2 post injury compared to 
patients who did not develop sepsis (Figure 4.9).  
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4.2.6 DNAse-1 antigen levels are elevated following thermal injury 
As we have reported a sustained elevation in NET markers in the presence of an 
inability to produce NETs in vivo we investigated if clearance was impaired. Levels 
of DNAse 1 were quantified to understand if the reduction in DNAse activity from 
day 1 – day 28 post injury was mediated by a reduction in circulating DNAse 
antigen. Levels were quantified in 24 patients who had reduced DNAse activity 
(below 50% compared to healthy controls) within 24 hours of injury. Interestingly, 
there was no significant difference in DNAse antigen levels from day 1 – day 3 
post injury. However, there was a significant increase in DNAse antigen levels 
from day 7 – day 14 and on day 28 post injury compared to levels measured in 
healthy volunteers (Figure 4.10).  
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Figure 4.5. Thermal injury results in reduced DNAse activity. DNAse activity 
following thermal injury (n = 64). Differences in kinetics were compared to data 
from control cohort (n = 10) using a Mann-Whitney test; *p < 0.005. Box and 
whisker plots represent median, minimum and maximum values. HC = healthy 
control, D = day, M = month. 
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Figure 4.6. DNAse activity within 24 hours of injury does not correlate with 
severity and size of injury. (A) Correlation of DNAse activity and TBSA burn (%) 
(n = 64) (B) Correlation of DNAse activity and ABSI (n = 64). (C) Correlation of 
DNAse activity and rBaux (n = 64). All measurements were taken within 24 hours 
of injury. Data was compared by Spearman’s rank. 
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Figure 4.7. Thermal injury results in reduced DNAse activity visualised by 
fluorescence microscopy. Fluorescence microscopy imaging of NET 
degradation of preformed NETs. DNA is stained green with SYTOX™ Green Dye. 
A buffer control (PMA control) was included in every experiment to show maximal 
NET generation without degradation. NETs treated with serum from patients 
(Thermal Injury Patients), healthy individuals (Healthy Control) or 10 units/ml 
DNAse 1 (DNAse 1 Positive Control). Data presented here is for 5 independent 
experiments and is representative of 10 independent experiments. All images 
were taken at 20x magnification. 
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Figure 4.8. Patients with MOF exhibited lower DNAse activity. Comparison of 
DNAse activity (n = 64) between patients with (n = 24) and without MOF (n = 40);    
*p < 0.05. Data was compared between patient groups at time points using a 
Mann-Whitney test. Box and whisker plots represent median, minimum and 
maximum values. HC = healthy control, D = day, M = month. 
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Figure 4.9. Patients who developed sepsis have lower DNAse activity. 
Comparison of DNAse activity (n = 64) between patients diagnosed with (n = 38) 
and without sepsis (n = 26); *p < 0.05. Data was compared between patient 
groups at time points using a Mann-Whitney test. Box and whisker plots represent 
median, minimum and maximum values. HC = healthy control, D = day,               
M = month. 
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Figure 4.10. Thermal injury significantly increases DNAse 1 antigen levels. 
DNAse 1 antigen levels following thermal injury (n = 24). DNAse 1 antigen 
compared to healthy controls (n = 10). Differences in kinetics were compared to 
data from control cohort (n = 10) using an unpaired t test (*p < 0.008). Box and 
whisker plots represent mean, minimum and maximum values. HC = healthy 
control, D = day. 
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4.2.7 Actin is released following thermal injury  
Actin, an inhibitor of DNAse activity, was measured in plasma to determine the 
potential mechanism behind reduced in vivo DNAse activity following thermal 
injury. Sterile injury results in the immediate release of cellular actin which was 
detected in 8 out of 9 patient samples taken within 24 hours of injury (Figure 4.11 
A).  This data is representative of 20 individual patients in which actin is present in 
16 out of 20. Actin was not detected in plasma from 2 healthy controls, this data is 
representative of n = 5 in which no actin was detectable. 
Actin was measured longitudinally in 6 patients to understand the kinetics of actin 
release. Importantly, actin was detectable up to day 28 post injury in patients. 
Western blot data presented is for three patients: Patient 10 had a 66% TBSA 
burn who developed MOF. Actin was detected within 24 hours and up to 3 days 
following thermal injury. Interestingly, actin was also detectable at later time 
points, day 20 – day 23. Patient 11 had a 53.5% burn TBSA who developed 
sepsis. A weak actin band was detected on days 19 and day 28 post injury. 
Patient 12 had a 65% TBSA burn who developed sepsis. Actin is detected only on 
day 1 following injury. Western blot analysis for 4 patients shows that actin is 
detectable at day 21 following injury in Patient 11 and 12 whilst being absent on 
day 14 and day 28 in patient 13 and 14 (Figure 4.11 B) 
4.2.8 Actin inhibits DNAse activity in vitro 
Healthy control serum was incubated with increasing concentrations of actin in 
order to understand the potential in vivo mechanism of reduced DNAse activity. 
Incubation with 1, 2 or 5 µM actin resulted in a significant decrease in DNAse 
activity compared to buffer control (Figure 4.12). 
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Figure 4.11. Thermal injury causes the release of circulating actin. (A) 
Western blot of actin in plasma samples from 9 patients (P 1 - 9) taken within 24 
hours of injury. Actin was not detected in plasma from healthy controls (HC) n = 2. 
(B) Western blot for Patient 10 with a 66% TBSA who developed MOF. Patient 11 
had a 53.5% burn TBSA who developed sepsis. Patient 12 had a 65% TBSA burn 
who developed sepsis. Western blot analysis for 4 individual patients (P13-16). 
HC = healthy control, D = day. 
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Figure 4.12. Actin inhibits DNAse activity in vitro. Actin inhibition of DNAse 
activity in serum by 1, 2 or 5 µM actin. Differences in kinetics were compared to 
data from control serum (n = 8) using a Friedman’s test followed by Dunn's 
Multiple Comparison Test; *p < 0.05. Box and whisker plots represent median, 
minimum and maximum values. Pooled serum from 9 healthy volunteers was used 
to calibrate 100% degradation.  
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4.2.9 Thermal injury results in a decrease in circulating vitamin d binding 
protein and gelsolin levels  
Levels of VDBP were quantified by Dr Khaled Altarrah (University of Birmingham, 
UK) as part of the SIFTI Trial. All data was analysed by Robert J Dinsdale. 
The actin scavenging system is controlled by two proteins; VDBP and GSN. 
Levels of VDBP were quantified in patients with burns ≥ 20% TBSA (n = 50) to 
establish the effect thermal injury has on the actin scavenging system. 
Thermal injury resulted in a rapid and significant reduction in VDBP from day 1 - 
day 3 post injury compared to levels in healthy controls (Figure 4.13 A). There was 
a significant increase in VDBP levels at month 3 post thermal injury relative to 
healthy individuals (Figure 4.13 A).  
Levels of VDBP weakly correlated with DNAse activity across all time points (r = 
0.15, p = 0.013). However, there was no significant difference in VDBP kinetics 
between patients with and without MOF (Figure 4.13 B).  
4.2.10 Thermal injury results in a decrease in circulating gelsolin levels  
Levels of GSN were quantified to fully investigate the effect severe thermal injury 
has on the actin scavenging system. Levels of GSN were measured in all 64 
patients.  
Thermal injury resulted in a significant reduction in GSN from day 1 - day 14 post 
injury (n = 64) compared to levels in healthy control (Figure 4.14 A). Additionally, 
kinetics of GSN was comparable between patients with and without MOF (Figure 
4.14 B). Levels of GSN also weakly correlated with DNAse activity across all time 
points (r = 0.1331, p = 0.0058). There were no significant differences in circulating 
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VDBP and GSN levels between septic and non-septic patients following thermal 
injury (Figure 4.15 A-B) 
4.2.11 In vitro actin inhibition of DNAse activity can be corrected by gelsolin 
As we have shown reduced DNAse activity in patients who developed MOF and 
an association between serum GSN levels and DNAse activity, we next 
investigated if administration of GSN could potentially reverse the in vitro inhibition 
of DNAse activity caused by raised actin levels. Incubation of actin spiked serum 
(5 µM) with 100 µg/ml GSN resulted in a significant increase in DNAse activity 
comparable with that of actin free serum (Figure 4.16).  
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Figure 4.13. Levels of VDBP are reduced following thermal injury. (A) VDBP 
across time (n = 50). Differences in kinetics were compared to data from 10 
healthy volunteers using a Mann-Whitney test; *p < 0.005. (B) VDBP across time 
(n = 50) between patients with (n = 18) and without MOF (n = 32) using a Mann-
Whitney test; *p < 0.05. Data is presented as a box and whisker plots and 
represents median, minimum and maximum values. HC = healthy control,            
D = day, M = month. 
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Figure 4.14. Levels of GSN are reduced following thermal injury. (A) GSN 
levels across time (n = 64) compared to healthy controls (n = 10). Data was 
analysed by Mann-Whitney test compared to healthy controls *p < 0.005. (B) GSN 
levels across time comparing those who did (n = 24) and those who did not          
(n = 40) develop MOF. Differences in kinetics were compared between patient 
groups using a Mann-Whitney test; *p < 0.05. Data is presented as a box and 
whisker plots and represents median, minimum and maximum values. HC = 
healthy control, D = day, M = month. 
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Figure 4.15. GSN and VDBP levels are not significantly different between 
septic and non-septic patients. (A) GSN levels across time according to sepsis 
status (n = 64). Differences in kinetics were compared between patient groups 
using a Mann-Whitney test; *p < 0.05. (B) VDBP levels across time according to 
sepsis status (n = 50). Differences in kinetics were compared between patient 
groups using a Mann-Whitney test; *p < 0.05. Data is presented as a box and 
whisker plots and represents median, minimum and maximum values.                 
HC = healthy control, D = day, M = month.  
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Figure 4.16. GSN recovers actin inhibition of DNAse activity in vitro. DNAse 
activity following incubation of actin spiked serum with vehicle control or 100 µg/ml 
GSN (n = 8). Data was analysed using a paired t test (*p < 0.05). Data is 
presented as before and after to display changes within independent experiments. 
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4.2.12 Patient demographics for patients with severe injuries caused by 
explosions 
To investigate if blood products, namely fresh frozen plasma (FFP), can potentially 
increase DNAse activity by correcting the blood based actin scavenging system, 
levels of GSN, VDBP and DNAse activity were quantified in plasma from patients 
following severe traumatic injury caused by explosions. This cohort was split into 
patients who had (n = 6) or had not received FFP (n = 6) prior to hospital 
admission and blood sampling. There was no significant difference in ISS, NISS 
and time to admission following injury between the 2 groups. Full patient 
demographics can be found in Table 4.2. On average patients received 3 units of 
blood products before admission to hospital. Due to the nature of this work and 
the cohort it was not possible to obtain clinical data on outcomes or secondary 
complications.  
4.2.13 Fresh frozen plasma increases gelsolin levels and DNAse activity 
following severe injury caused by explosion but has no effect on vitamin d 
binding protein levels 
All patients in this analysis were matched for clinical scores of severity and 
admission times. In the total cohort (n = 12), DNAse activity and VDBP levels were 
comparable between healthy controls and patients with severe injuries caused by 
explosions (Figure 4.17 A, C). However, GSN levels were significantly lower in 
patients with severe injuries caused by explosions when compared to healthy 
individuals (Figure 4.17 B).  
Patients who did not receive blood products before hospital admission had 
significantly lower DNAse activity and plasma GSN levels compared to healthy 
controls (Figure 4.18 A-B). However, there was no difference when comparing 
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plasma VDBP levels (Figure 4.18 C). DNAse activity, GSN and VDBP were 
comparable between patients who received blood products and healthy controls 
(Figure 4.18 A-C). 
Administration of blood products and FFP before admission to hospital 
significantly increased DNAse activity compared to patients who had not received 
blood products upon admission to hospital (Figure 4.19 A). Furthermore, 
administration of blood products and FFP before admission to hospital significantly 
increased circulating GSN levels compared to patients who had not received blood 
products and FFP (Figure 4.19 B).  Finally, administration of blood products and 
FFP did not affect circulating levels of VDBP in both patient groups (Figure 4.19 
C). 
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Characteristic No FFP pre admission 
 (n = 6) 
FFP pre admission  
(n = 6) 
p 
ISS (min-max) 27 (17-59) 22 (16-42) ns 
NISS (min-max) 36 (18-75) 35 (16-66) ns 
Minutes to admission (min-max) 75 (30-135) 83 (50-130) ns 
 
Table 4.2. Patient demographics for patients with severe injuries caused by 
explosions (Chapter 4). FFP post or pre admission variables were analysed by 
Mann-Whitney (continuous variables) or Chi-squared test (categorical variables). 
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Figure 4.17. Severe injury caused by explosion caused a significant 
reduction in circulating GSN levels compared to healthy controls. (A) Plasma 
DNAse activity in healthy individuals (n = 10) and patients with severe injuries 
caused by explosions (n = 12). (B) Circulating plasma GSN levels in healthy 
individuals (n = 10) and patients with severe injuries caused by explosions           
(n = 12). (C) Circulating plasma VDBP levels in healthy individuals (n = 10) and 
patients with severe injuries caused by explosions (n = 12). All data was 
compared by Mann-Whitney test *p < 0.05. Data is presented as a box and 
whisker plots and represents median, minimum and maximum values.                 
HC = Healthy control. 
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Figure 4.18. Patients who do not receive blood products before admission to 
hospital have significantly lower DNAse and GSN levels compared to 
healthy individuals. (A) Plasma DNAse activity in healthy individuals (n = 10) and 
patients who did and did not receive blood products before admission (n = 6). (B) 
Circulating plasma GSN levels in healthy individuals (n = 10) and patients who did 
and did not receive blood products before admission (n = 6). (C) Circulating 
plasma VDBP levels in healthy individuals (n = 10) and patients who did and did 
not receive blood products before admission (n = 6). All data was compared by 
one way ANOVA and Dunn's multiple comparison test *p < 0.05. Data is 
presented as a box and whisker plots and represents median, minimum and 
maximum values. HC = Healthy control. 
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Figure 4.19. Blood products increase circulating GSN levels and protects 
against inhibition of DNAse activity. (A) Comparison of DNAse levels at 
hospital admission between patients with (n = 6) or without (n = 6) prior blood 
product administration. (B) GSN levels at hospital admission between patients with 
(n = 6) or without (n = 6) prior blood product infusion at time of blood sampling. (C) 
Comparison of VDBP activity levels at hospital admission from patients with          
(n = 6) or without (n = 6) prior blood product infusion at time of blood sampling. For 
panel A and C data was analysed by unpaired t-test. For panel B data was 
analysed by Mann-Whitney test. *p < 0.05. For panel A and C, data is presented 
as a box and whisker plots and represents mean, minimum and maximum values. 
For panel B, data is presented as a box and whisker plots and represents median, 
minimum and maximum values. HC = Healthy control. 
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4.3 Discussion  
Circulating levels of cfDNA have been described as a novel biomarker of 
secondary complications and mortality with studies reporting positive prognostic 
and diagnostic utility (109, 180, 220, 304-306). In a cohort of 67 patients with 
severe sepsis, quantification of ncDNA showed positive prognostic utility for 
predicting 24 hours mortality in patients who presented to the emergency 
department (354). 
Circulating DNA can arise from a number of sources including tissue damage, 
apoptosis, necrosis and NETosis (114). In our analysis levels of ncDNA within 24 
hours of injury correlated with measurements of burn size and severity. Therefore, 
we propose that the initial elevation in ncDNA is originating from tissue damage 
caused by the burn injury. Due to the cytotoxic nature of DNA (355, 356), the initial 
elevation in circulating ncDNA may be contributing to the immediate host tissue 
and organ damage which occurs in patients with burn injuries. Consistent with 
previous literature (354), ncDNA levels are significantly higher in septic patients 
compared to non-septic individuals. We propose that tissue damage, surgery and 
NETosis may also be contributing to this secondary increase. Interestingly, levels 
of ncDNA are significantly higher at 12 months following injury in patients who 
developed sepsis compared to those who didn’t. This elevation is either caused by 
lower sample numbers in the analysis for 12 month samples, a reactive response 
by the body in which DNA cannot be cleared or further release from tissue 
remodelling and scar formation. 
NETs and histones form key components of host defence and innate immunity 
(118, 355, 357). Engelmann and Massberg described an innate immune response 
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in which coagulation is activated in an attempt to ensnare, recognise and remove 
bacteria (296, 358, 359). This process is termed immunothrombosis and is in part 
mediated by the production of NETs (296). NETs are capable of providing both a 
stimulus to and scaffold for thrombus formation. Uncontrolled or excessive NET 
generation and immunothrombosis can result in increased risk of thrombosis, host 
tissue damage and the accumulation of pathogenic components, including DNA, 
in the microvasculature (226).  
Fuchs and colleagues demonstrated that NETs perfused with blood caused 
recruitment of red cells, increased fibrin deposition, platelet adhesion and 
activation. Importantly, this could be prevented by incubation with DNAse which 
promotes NET breakdown (232). In a murine model of DVT, Cit H3 was found in 
close proximity to thrombi. Furthermore, DNA and histones form components of 
the scaffold required for the pathogenesis of DVT (233). In addition to promoting 
thrombosis, elevated levels of NET components are cytotoxic and can result in 
host tissue damage. For example, incubation of activated endothelial cells with 
NETs results in cell damage which, again, can be prevented by degrading NETs 
with DNAse (360).  
Here, we report that ncDNA was elevated from day 1 to day 3 and again at day 14 
to 2 months post-injury in patients who developed MOF compared to those who 
did not. Here we report an accumulation of circulating ncDNA for up to 28 days 
following injury. We hypothesised that clearance of host and NET derived DNA 
was dysregulated. Multiple groups have shown that degradation of NETs with 
DNAse can protect against tissue damage, thrombosis and procoagulant 
interactions (232, 360). Furthermore, elevated levels of circulating DNA are also 
associated with and contribute to the progression of autoimmune diseases, 
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notably SLE (237, 238). This build-up of circulating DNA can be explained in part 
to the impaired DNAse activity caused by the presence of ‘DNAse inhibitors’ or 
inhibitory antibodies in these patients (237). 
As we report a build-up of circulating DNA and reduced ex vivo NET formation we 
next investigated DNAse activity in patient samples. Here we report a reduction in 
DNAse activity from day 1 – day 28 post injury in the total cohort. Of note, there 
was large variation in DNAse activity within the whole cohort at all time points. 
Furthermore, levels of DNAse activity did not correlate with injury severity. This 
may be explained by timing of sample, clinical intervention or heterogeneity within 
the patient cohort. Importantly, DNAse activity was lower in patients who 
developed MOF or sepsis compared to those who did not develop either. Both 
groups had comparable reduction in DNAse activity for the first 14 days following 
thermal injury. Therefore, one might hypothesise that the initial injury causes the 
immediate reduction in activity reported in both groups and the later reduction may 
be caused by further tissue damage or surgical procedures. Within this cohort the 
average amount of individual septic episodes was 2.5 episodes per patient. The 
average time to first episode was 5 days following injury (range 3 – 70 days) and 
the time to last episode was 23 days following injury (range 3 – 130 days). 
Furthermore, whilst most patients underwent surgery within the first 5 days for 
debridement and immediate treatment of burn wounds, patients did have further 
surgical procedures if required, e.g. skin graft rejection. Thus, the variation within 
DNAse activity at the later time points following thermal injury may be explained by 
the ongoing tissue damage from surgical procedures and sporadic infectious 
episodes. 
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It is important to consider the mechanism by which DNAse activity inhibition 
occurs. Here, we report that levels of total DNAse antigen are increased post 
thermal injury, which is consistent with existing literature (239). Therefore, the 
apparent reduction in DNAse activity is indicative of inhibition of enzymatic activity. 
In this thesis, only levels of DNAse 1 antigen were quantified as this is the 
predominant enzyme responsible for the degradation of circulating DNA. However, 
there are different isoforms of DNAse, including DNAse-γ, therefore we cannot 
exclude the possibility that the reduction in DNAse activity may be mediated in 
part by reduced DNAse-γ antigen levels. Thus, further study of DNAse isoforms 
and their contribution to reduced DNAse activity following injury is required. 
A naturally occurring inhibitor of DNAse activity is actin, which is an abundant 
protein in mammalian cells (240). Actin exists in a balance between monomeric 
and filamentous actin, which is essential for cellular function (241, 242). However, 
this predisposition of actin to rapidly polymerise is extremely dangerous if it occurs 
in the circulation. Actin is recognised as a DAMP due to its rapid release, 
immunostimulatory actions and conserved structure (361). Polymerised actin, F-
actin, binds to the DNGR-1 receptor (CLEC9A) and primes cytotoxic T-cells 
against dead cell antigens (362-364). In addition to its DAMP properties, 
extracellular actin can cause direct damage to the microvasculature, impair clot 
lysis and activate platelets (240, 243, 244).  
Actin can bind to DNAse forming a stoichiometric 1:1 complex which inhibits 
enzymatic activity (245, 365). In this analysis circulating actin is detected in 
patients immediately following and for up to 28 days post-injury. The initial release 
of actin most likely originates from the extensive tissue damage occurring 
following severe thermal injury. This will not only inhibit DNAse activity but may 
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also be responsible for the immediate stimulation of the immune system and host 
tissue damage that occurs following thermal injury due to its DAMP properties and 
cytotoxic nature (240, 243, 244, 361-364). 
Here we show that actin is detectable for up to 28 days post injury. In Patient 10 
(Figure 4.11 B) actin is cleared at day 10 and is then detectable at day 20 - day 
23. Therefore, this secondary appearance of actin is not from the initial tissue 
damage and may be caused by further host tissue damage during surgery, 
infection or MOF. Patient 10 has been chosen as a representative of this study 
due to quality of blot. However, this appearance of actin at the later time points is 
present in multiple patients. This is consistent with previous literature reporting 
elevated levels of actin in septic individuals (246). This prolonged appearance of 
actin may be in part responsible for the prolonged inhibition of DNAse activity and 
may also be responsible for host tissue damage and a pro-thrombotic phenotype 
associated with actin toxicity. One limitation of these data is the inability to quantify 
circulating actin by an ELISA based method. Thus, within this analysis we make 
no attempt to relate circulating levels of actin with DNAse activity, nor do we 
suggest there is an increase in circulating levels at different time points tested. 
Further studies are warranted to investigate the relationship between exact actin 
concentrations and secondary complications in order to study the dynamic kinetic 
changes and interactions. Furthermore, performing western blot analysis on 
plasma is extremely difficult and challenging due to the increased concentration of 
high molecular weight proteins which distort gels and cause high background 
signal. This has affected the quality of western blot produced and prevents further 
analysis of blots by densitometry. Therefore, novel and more accurate 
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methodologies are required to quantify levels of actin in blood products from 
patients.  
Many of the detrimental effects of circulating levels of actin are attributed to 
saturation of the actin scavenging system. Control of the actin scavenging system 
is mediated by two key proteins; GSN and VDBP (240). GSN is normally found in 
high quantities in healthy individuals and can bind to both monomeric and 
filamentous actin (246, 247). GSN functions to clear circulating actin via 2 distinct 
processes; preventing further polymerisation or severing existing filamentous actin 
(240, 249-251). It is therefore not surprising that studies have reported a decrease 
in circulating levels of GSN in a number of disease pathologies connected with 
actin release (252-259). Of note, Huang et al reported in 95 patients with thermal 
injuries that plasma GSN levels were reduced and associated with mortality, 
development of sepsis and MODS (254). In a rat burn model, plasma GSN levels 
decreased within 12 hours to 6 days post-injury. This was accompanied by 
increased pulmonary microvasculature permeability, which was corrected by 
administration of recombinant plasma GSN prior to burn injury (261). Moreover, 
administration of GSN can also reverse actin inhibition of lung macrophage 
binding and uptake of bacteria (260). As GSN functions may extend beyond 
simply actin scavenging, GSN levels may not only serve as a biomarker of poor 
outcomes but could also be a potential therapeutic target to reduce or prevent 
secondary complications.  
VDBP is an abundant circulating protein that is a key component of vitamin D 
transport (262, 263). Unlike GSN, VDBP binds to monomeric actin only (264, 265). 
Binding of VDBP to actin prevents further polymerisation by rapidly clearing 
residual monomeric actin from the circulation (266, 267). Levels of VDBP have 
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been suggested as good prognostic markers of outcome and organ damage 
following severe trauma (268-271).  
Following severe thermal injury there is an immediate and transient decrease in 
both VDBP, up to 3 days post injury, and GSN, up to 14 days post injury, 
compared to levels quantified in healthy volunteers. Thus, severe thermal injury 
results in dysregulation of the actin scavenging system which will facilitate the 
accumulation of monomeric and polymerised circulating actin which can then 
cause host damage and inhibit DNAse activity (240, 243, 244, 361-364). Of note, 
patients with thermal injuries have significantly higher levels of VDBP at 3 months 
following injury compared to healthy individuals. This overproduction is consistent 
with previous publications (271) and suggests a reactive response mediated 
potentially by the injury, recovery, medications or diet.  
The decrease in both VDBP and GSN may be caused by a number of 
mechanisms which include; loss of protein through endothelium dysfunction, 
dilution during fluid resuscitation or saturation through elevated levels of actin. 
Severe thermal injury results in systemic endothelial dysfunction and capillary leak 
(366). Like albumin, it is possible that VDBP and GSN may be lost by this 
mechanism. However, it is reported that endothelial dysfunction and capillary leak 
are only present for up to 5 hours post-injury (367). Therefore, this would not 
explain the decrease seen at 48 hours post-injury in this analysis as capillary leak 
and endothelial dysfunction will have been corrected. It is also possible that fluid 
resuscitation may cause the immediate decrease in both GSN and VDBP. All 
patients received a standardised burn resuscitation protocol as per the Parkland 
Formula thus this would not fully explain the difference in the later kinetics of GSN 
and VDBP. Of note, the VDBP ELISA does not bind to VDBP complexed with 
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actin. Hence, this may explain the initial reduction in VDBP reported within this 
thesis.  
In addition to their mechanistic functions, GSN and VDBP have been proposed as 
biomarkers of poor outcomes following trauma and burns (254, 268-271). In our 
cohort, there are no differences in VDBP and GSN levels or kinetics between 
patients who did and did not develop MOF or sepsis. This is surprising and 
contradictory to existing literature; however, there are a number of potential 
explanations. The significant reduction in VDBP and GSN occurred before the 
onset of sepsis and MOF in this cohort. Therefore, the decrease may solely be 
caused by immediate actin release following injury due to the severe nature of the 
injuries included within this analysis. Furthermore, differences may not have been 
seen due to the severity of injuries included within this analysis, low numbers of 
patients or differences in timing of sample between studies.  
From this analysis, we have developed a hypothesis model depicting how patients 
are predisposed to the pathogenesis of MOF following severe thermal injury 
(Figure 4.20). We hypothesise that following severe thermal injury there is the 
initial release of both monomeric and polymeric actin which results in the rapid 
consumption of circulating GSN and VDBP, potentially due to extensive tissue 
damage and actin release. This reduction facilitates the rapid accumulation of 
circulating actin and binding to DNAse and inhibition of enzymatic activity. All 
patients are then predisposed to the development of MOF following severe 
thermal injury but that a second stimulus is required to elevate DNA and reveal 
this susceptibility. This could arise through repeated surgery with resultant tissue 
damage or through NETosis in septic patients. This is supported by the growing 
amount of evidence reporting the involvement of NETs in immunothrombosis (273, 
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368). This phenotype will facilitate the build-up of circulating DNA and NET 
components which further the pathogenesis of MOF by promoting impaired 
fibrinolysis, thrombotic complications, tissue damage and occlusion of the 
microvasculature (195, 224, 235, 236). This hypothesis model provides a novel 
mechanistic link between the initial traumatic injury and subsequent infection in 
potentially mediating the pathogenesis of MOF. 
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Figure 4.20. Hypothesis model: The link between severe thermal injury and 
pathogenesis of MOF through disruption of the actin scavenging system. 
Following severe thermal injury polymerised and monomeric actin is released 
which immediately reduces VDBP and GSN levels. The polymerised actin can 
then bind to DNAse and inhibit its activity. Following infection, NETs are released 
and accumulate due to reduced degradation. This increases the pathogenesis of 
MOF. 
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In 2011, Cohen and colleagues demonstrated the therapeutic potential of GSN in 
a rat model of sepsis caused by double puncture of the cecum. Administration of 1 
mg/ml recombinant human GSN, only once, resulted in significantly improved 
survival and reduced tissue damage compared to sham animals (369). The group 
concluded that administration of GSN is a potential therapy to reduce the severity 
of illness caused by infection and sepsis. They propose that GSN may have an 
effect on expression and regulation of pro-inflammatory cytokines. However, we 
would suggest that GSN is having a multifaceted role by regulating cytokine 
release (369), inflammatory cell function (260) and readdressing the overwhelmed 
actin scavenging system. We show that administration of GSN in vitro can restore 
DNAse activity in actin spiked serum, providing further evidence that GSN is a 
potential therapy. However, this experiment is performed in vitro with no 
contribution from VDBP or any other cellular interactions. Therefore, further 
experiments are required to investigate the potential of GSN and VDBP combined 
in vivo.  
To investigate this possibility we performed a preliminary retrospective analysis in 
samples from military patients following severe injury caused by explosions 
receiving FFP prior to first blood sampling and hospital admission. Severe trauma 
caused by explosions is becoming an increasingly common form of injury due to 
conflicts and terrorism. Injuries can be classified into primary to quaternary injuries 
depending upon severity and mechanism of blast injury (370). Burn injuries are 
also common among patients with injuries caused by explosions and therefore 
clinical treatment is comparable.  
Patients with severe injury caused by explosions who are hemodynamically 
unstable receive packed red blood cells and FFP in a 1:1 ratio immediately 
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following their injuries. By definition, FFP contains high levels of GSN and VDBP 
which may explain some of the known therapeutic potential in the context of 
traumatic injury by boosting the depleted levels of the actin scavenging proteins 
(371). In our preliminary analysis, we have split our cohort into two groups who did 
or did not receive blood products before admission to hospital. The decision to 
give blood products was based upon resources available during transportation 
from the battlefield and not injury severity or mechanism of injury. Importantly, 
subgroups within this analysis are matched for ISS, NISS and time to admission 
following injury. Theoretically, the only difference between the two groups is the 
infusion of blood products. 
Here we provide preliminary data showing that early administration of blood 
products significantly increases GSN levels immediately post severe trauma 
caused by explosion. This increase in GSN was also accompanied by a significant 
increase in DNAse activity. However, VDBP levels were not affected. This data 
would suggest that an early increase in circulating GSN is able to improve DNAse 
activity rapidly following injury independently of VDBP. In 2005, Chhabra et al 
showed that the N-terminal fragment of GSN could bind to and disrupt actin-
DNAse complexes, in turn, restoring enzymatic activity (372). Therefore, this may 
be a potential mechanism by which GSN can rapidly restore or enhance DNAse 
activity independently of VDBP. However, it is important to note that blood 
products will contain many other soluble factors which may enhance DNAse 
activity, including DNAse 1 itself. Therefore, the restoration of DNAse activity may 
not be solely attributed to the increases in GSN. Thus, further studies are required 
to investigate all components within blood products to fully understand if they are 
contributing any therapeutic benefit. 
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Although not common, patients recruited within our primary analysis did receive 
blood products but only when clinically required. In total 21 patients received at 
least 1 unit (220 ml) FFP following injury which may be an important confounder in 
this study. This may also contribute to the variation and lack of difference between 
patients who did and did not develop MOF. The median time to first unit received 
was 3 days post injury (range 1 – 57 days post injury) with 4 patients received FFP 
during the first 24 hours post injury. However, as not all patients received FFP, 
coupled with the sporadic nature and lack of sustained administration we cannot 
study any differences between patients who did and did not receive FFP following 
thermal injury.  
These data provide preliminary evidence that early administration of FFP to 
patients with severe injuries may offer a simple way of boosting the depletion of 
actin scavenging system and therefore improve DNAse activity. Larger studies are 
therefore required to fully investigate the therapeutic potential of both FFP and 
GSN alone post major trauma and severe thermal injury. Given the extensive 
literature and ongoing debate on the utility of FFP in trauma and resuscitation it 
may be more applicable to utilise GSN in isolation to scavenge excess actin (373-
375). GSN is unlikely to be immunogenic due to the high concentrations found in 
healthy individuals. Therefore, we propose that administration of FFP (containing 
GSN) or GSN alone immediately to patients with severe thermal injuries may be a 
potential safe therapeutic which addresses dysregulation of the actin scavenging 
system. In turn, reducing the accumulation of DNA and NET components and 
potentially protecting against the pathogenesis of MOF. 
In summary, this chapter presents data of several novel findings and a model of 
post-injury complications in which DNAse activity is reduced following thermal 
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injury, driven most likely by raised circulating actin and acute reductions in the 
actin scavengers GSN and VDBP. The reduced DNAse activity may be 
contributing to the pathogenesis of MOF by mediating the sustained elevation of 
circulating DNA from the injury and secondary complications. In addition, two 
potential therapeutic agents, FFP and GSN, been identified which have the 
potential to restore DNAse activity and thus protect against host tissue damage 
associated with MOF.  
  
 
219 
 
 
 
 
 
 
 
 
Chapter 5 
 
General Discussion 
  
 
220 
 
General Discussion 
5.1 Limitations  
Despite showing for the first time the association between and potential 
mechanisms responsible for dysregulated NET release following severe thermal 
injury, there are a number of limitations which must be considered.  
This study was designed to be exploratory and hypothesis generating in nature 
and not confirmatory. Hence we cannot estimate a specific outcome or obtain a 
pre-determined level of precision from our results. Data generated should be 
regarded as a pilot to obtain data to inform a potential larger confirmatory study. 
Furthermore, in this thesis, clinical samples were obtained and analysed at fixed 
time points. Whilst this remains a strength of the current study it limits the ability to 
study the full kinetics of many in vivo markers and their relation to secondary 
complications or clinical treatments. A second study has been established in which 
blood samples are taken daily over the first 14 days which will allow us to 
investigate and characterise the daily kinetics of neutrophil function, NET release 
and diagnostic utility of described biomarkers. 
Whilst we have shown the protective role of immediate administration of blood 
products in patients with severe injuries caused by explosions it remains extremely 
preliminary data in a small population of patients. Due to the nature of injuries and 
sensitivity of data it has not been possible to correlate increases in DNAse activity 
and GSN with improved outcome in this patient cohort. In addition, in this analysis 
only GSN, VDBP and DNAse activity have been quantified and investigated. 
Blood products contain many soluble mediators, including DNAse, and therefore 
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the protection against reduced DNAse activity cannot be solely attributed to 
increases in GSN levels. Therefore, further characterisation of blood products or 
the use of GSN and/or VDBP in isolation is required. 
5.2 Future Work 
Severe thermal injuries constitute a major form of traumatic injury (1). 
Advancements in the initial care of patients with burns have dramatically improved 
immediate survival (18, 19, 31). However, delayed mortality associated with sepsis 
and MOF remain a significant health care problem (38, 47). Although sepsis and 
MOF are well characterised the mechanisms mediating the increased 
susceptibility to infection and the pathogenesis of MOF are poorly understood. 
This thesis has investigated and identified a number of potential mechanisms, 
therapeutic targets and biomarkers which have the potential to improve patient 
outcome following severe thermal injury. 
Infection and sepsis remain a major clinical burden in patients with severe thermal 
injuries. Whilst this has been reported, the mechanisms responsible for the 
increased susceptibility and incidence are poorly understood. Data from this thesis 
reports a reduction in ex vivo NET production and intracellular ROS formation 
which may underlie the inability to clear pathogens and be in part responsible for 
the increased incidence of infections (Figure 5.1 A). The exact mechanism by 
which this occurs is yet to be described but possible factors include; abnormal 
neutrophil maturity phenotype or release of soluble mediators (e.g. mtDAMPs) 
(Figure 5.1 B). Thus, understanding the mechanisms responsible for reduced 
neutrophil function may aid in both the early identification of at risk patients and 
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development of novel therapeutics which reduce infection and secondary 
complication rates following severe thermal injury.  
Furthermore, data within this thesis identifies a major biological mechanism driving 
MOF after major trauma, namely the compromise to the actin scavenging system 
which leads to reduced DNAse activity and a build-up of cfDNA. NETs are 
generated during sepsis in patients with thermal injuries. The exact mechanism of 
NETosis reamins to be identified, however, potential mechanisms include direct 
interactions with bacteria or inflammatory cells (Figure 5.1 C). Included in this 
thesis is a model of post-injury complications in which DNAse activity is reduced 
following thermal injury caused by actin release from host tissue damage and 
dysregulation of the actin scavenging system (Figure 5.1 D). Our data provide a 
novel mechanistic link between the initial traumatic injury and subsequent infection 
in potentially mediating the pathogenesis of MOF (Figure 4.20). Although our 
study is based in burns patients it is likely to have relevance to all major trauma 
and to support this, pilot observational trial data from patients with severe injuries 
caused by explosions suggests that DNAse activity can be restored by the 
prehospital administration of FFP. MOF is a leading cause of mortality following 
severe thermal injury and data within this thesis identifies several potential novel 
therapies to overcome the suppression of DNAse activity and improve outcomes 
after trauma.  
Future work investigating potential therapeutics to modulate abnormal neutrophil 
function and the actin scavenging system is described below in priority order. 
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Figure 5.1. Hypothesis model: Linking initial injury to secondary 
complications following severe thermal injury. (A) Severe thermal injury 
significantly reduces, both, ex vivo NET formation and ROS generation. (B) This 
reduction is potentially mediated by a phenotypical change in the circulating 
neutrophil pool, soluble mediators e.g. mtDAMPs or functional neutrophils have 
potentially migrated to the tissues leaving a non-functioning pool of circulating 
neutrophils. (C) During infection, NETs are generated following thermal injury. 
Potential mechanisms include direct induction through bacteria or through 
neutrophil interactions with inflammatory cells. (D) Thermal injury results in 
dysregulation of the actin scavenging system which facilitates the build-up of 
circulating DNA, from initial injury and NETs, which are potentially responsible for 
the pathogenesis of MOF. Panel D has been presented earlier in this thesis 
(Figure 4.20).  
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5.2.1 In vivo characterisation of NETosis 
Levels of cfDNA are associated with cellular damage and secondary complications 
in a number of disease pathologies (108, 376). However, it is important to consider 
the nature and structure of circulating DNA as it is released, complexed with 
histones, in nucleosomes following NETosis. Whilst this is known, the broad 
effects of free histones, free DNA and nucleosomes are described interchangeably 
whereas there is a clear difference in their biological activity (377).  
Free histones are cationic, highly conserved between species and orchestrate 
gene transcription. Intravenous administration of free histones results in rapid 
mortality of animals which can be prevented using an anti-histone antibody (198). 
Histones can also mediate cytotoxic damage to endothelial and epithelial cells via 
activation of TLRs (197). Whilst the mechanism by which histones are cytotoxic 
remains unclear, studies have proposed that their cationic nature facilitates the 
direct binding of histones to cells resulting in perforation, cell death and damage 
caused by calcium influx (195, 196). 
One potential therapeutic to reduce histone cytotoxicity is the administration of 
negatively charged molecules such as heparins (378, 379). The non-anticoagulant 
form of unfractionated heparin, for example, has been trialled as a novel 
therapeutic in sepsis (378). Whilst this study did not report an improvement in 28 
day mortality, Wildhagen and colleagues report a beneficial effect of this novel 
therapy in mediating the inhibition of histone cytotoxicity (378). During sepsis there 
is an abnormal consumption coagulopathy and thus an increased risk of bleeding. 
Hence, administration of a non-anticoagulated form of heparin may have 
promising effects on reducing tissue damage mediated by histones during sepsis 
without potentiating bleeding. 
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DNA is regarded as a DAMP due to its rapid release and stimulation of immune 
processes (199). The origin of DNA, nuclear, mitochondrial or bacterial, affects its 
biological activity. In 2015, Bhagirath and colleagues isolated DNA from septic 
patients and determined the different function of nuclear, mitochondrial and 
bacterial DNA on coagulation and inflammation. All three sources of DNA were 
capable of inducing thrombin formation, by an intrinsic dependent pathway 
mechanism, and activation of platelets by platelet integrin αIIbβ3. Although, all 
three have similar procoagulant properties, their functions in initiating inflammation 
differ. Whilst, ncDNA and mtDNA prolonged in vitro neutrophil life, bacterial DNA 
did not. However, only bacterial DNA promoted in vitro secretion of IL-6 (206).  
Due to their opposing charges, DNA and histones will bind together and form a 
nucleosome complex with an overall neutral charge. Like free histones and DNA, 
nucleosomes can activate neutrophils (380). However, nucleosomes have 
different cytotoxic properties compared to free histones and DNA. Unlike free 
histones, administration of nucleosomes does not result in a significant increase in 
mortality (204, 205). This may be explained by the inability of nucleosomes, unlike 
histones, to cause direct damage or cell death to cultured endothelial cells. 
However, subsequent physical or enzymatic degradation of nucleosomes then 
resulted in damage to endothelial cells (381). Thus components of nucleosomes, 
histones and DNA, are then responsible for the cellular damage and this effect is 
nullified when components are complexed. In this thesis, we have investigated 
three potential sources of DNA; nuclear, mitochondrial, and NET derived. 
However, the status by which they exist, free or complexed, has not been fully 
investigated. Thus, further study is required to investigate the relationship between 
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free histones, DNA and nucleosome complexes with secondary complications and 
host tissue damage.  
In 2013, Abrams et al reported the potential therapeutic benefit of CRP in 
neutralising in vivo and in vitro histone induced endothelial damage, enhanced 
coagulation and increased vascular permeability (381). Supported by earlier work 
(382, 383), CRP is able to compete with phospholipid-containing liposomes and 
form CRP-histone complexes, confirmed using immunofluorescence staining and 
a gel overlay assay. The formation of CRP-histone complexes reduced integration 
of histones into the cellular wall of endothelial cells and in turn cellular damage. 
The exact mechanism of binding between CRP and histones remains to be 
identified, however, the authors propose that the positively charged histones are 
likely binding the negatively charged central pore of the CRP pentamer (381). 
Interestingly, it has yet to be established if CRP-histone complexes have 
increased clearance. Thus, Abrams and colleagues demonstrated, for the first 
time, that CRP is a conserved mechanism which protects the body against histone 
toxicity in the acute phase following trauma and illness (381). Hence, it may be 
possible to use CRP, or a therapeutic mimicking CRPs mechanism of action, as 
an intervention to neutralise the cytotoxic effect of circulating histones following 
severe thermal injury. 
As described above cfDNA can originate from a number of sources (114). In 2016, 
Lehmann-Werman and colleagues described a novel technique by which the 
tissue specific origin of cfDNA could be elucidated (384). It is likely that following 
thermal injury circulating DNA is heterogeneous in origin given the severe nature 
of injury, surgical procedures, infection, host tissue damage and NET release. 
Despite the shared homology in nucleotide sequences, DNA also has unique 
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methylation patterns depending upon the cell or tissue of origin (385). Thus, it is 
possible to infer cell death within specific organs and its contribution to the 
circulating cfDNA. As proof of principle, Lehmann-Werman and colleagues 
detected pancreatic β-cell DNA in patients with diagnosed type-1 diabetes and 
islet-graft recipients, neuronal or glial DNA in patients with traumatic brain injury or 
cardiac arrest and exocrine pancreas DNA in pancreatic cancer or pancreatitis 
patients (384). Given the exploratory nature of this study, however, they were 
unable to conclusively evaluate the diagnostic or prognostic utility of methylation 
patterns. However, investigation of methylation patterns in patients following 
thermal injury may have the potential to aid in the accurate diagnosis of specific 
organ dysfunction and responses to clinical treatment. 
5.2.2 DNAse isoforms and their functions 
In 1997, Rodriguez and colleagues described three members of a DNAse 1 family. 
All three displayed similarity in their nucleotide, amino acid sequences (386) and 
biochemical properties, dependency on Ca2+ and Mg2+ (387). DNAse 1 is the 
major endonuclease responsible for the breakdown of circulating nucleic acids. 
However, in recent years groups have begun investigating the physiological roles 
of DNAse-γ (386-388). Like our analysis, many assays established to measure 
DNAse activity, therefore, quantify total DNAse. Furthermore, most groups focus 
upon the role of DNAse 1 alone and thus do not investigate the role of DNAse-γ 
(237, 353, 389). 
As it functions internucleosomally and degrades nuclear chromatin, DNAse-γ was 
originally reported to be involved in apoptotic DNA fragmentation (390-392). 
However, cells transfected with DNAse-γ can secrete this enzyme thus suggesting 
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a mechanism by which exocytosis can occur (393). Consequently, DNAse-γ, 
potentially from monocytes (394), may contribute to total circulating DNAse 
activity.  
DNAse 1 and –γ function synergistically to clear total circulating DNA through 
distinct substrate consumption and degradation. DNAse 1 has a higher affinity and 
accelerated clearance of free DNA compared to DNAse-γ which is more efficient 
at degrading chromatin (387, 395). 
Recent studies report a clear link between genetic mutations of DNAse-γ and 
development multiple autoimmune diseases (396-398). Highlighted in DNAse-γ 
mice which develop an SLE phenotype associated with the presence of 
autoantigens against chromatin (399). Although DNAse-γ has been related to 
autoimmunity, there have there have been no investigations into its function and 
potential role in secondary complications following trauma or severe burn. Thus, 
further work could investigate the combined and individual functions of DNAse-1 
and –γ activity in the degradation of chromatin and DNA release following severe 
thermal injury. This may reveal additional mechanistic information and/or novel 
therapeutics to reduce secondary complications driven by elevated circulating 
DNA or chromatin.  
5.2.3 Targeting the build-up of toxic and pro-thrombotic DNA following 
thermal injury 
Following thermal injury, there is the disruption of the actin scavenging system 
which predisposes patients to the accumulation of tissue derived and NET derived 
DNA (Figure 4.20). This can then facilitate further host tissue damage, obstruct 
blood flow and induce thrombosis (233, 236, 360). Modulation of this system by 
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targeting DNAse, GSN or VDBP has the potential to protect against this pro-
thrombotic and host cytotoxic phenotype. 
5.2.4 DNAse as a therapy 
DNAse is the major extracellular endonuclease found in a number of bodily fluids 
and is responsible for the breakdown and clearance of circulating chromatin and 
DNA. Severe thermal injury results in the immediate release of DNA which is 
followed by a secondary release during infection. Both populations of DNA are 
implicated in the generation of thrombosis, host tissue damage, endothelial 
damage and secondary complications in trauma patients and animal models of 
thrombosis (232, 233, 356, 400). Thus, targeting total DNA accumulation by 
administration of DNAse may provide therapeutic benefit.  
Using a murine model of DVT, extracellular chromatin formed a scaffold upon 
which venous thrombosis could occur and was involved in the pathogenesis of the 
DVT. Administration of DNAse 1 was capable of protecting animals from DVT 
(233). Furthermore, PAD4 deficient mice form fewer thrombi after inferior vena 
cava stenosis compared to wild-type animals (401). Thus confirming the role of 
NET derived DNA in the propagation of venous thrombus formation. In addition to 
their procoagulant activity, DNA, derived from NETs, can also cause direct 
damage to endothelial cells (360). Interestingly, coculture of neutrophils with 
activated endothelial cells results in NETosis which caused direct cellular damage 
thus it appears to be self-propagating. This could also be abrogated by the 
degradation of NETs using DNAse (360). These data provide evidence that 
administration of DNAse to target host derived and NET derived DNA may have 
potential to alleviate host tissue damage and reduce the pro-thrombotic 
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phenotype. Importantly, administration of DNAse 1 is a licenced therapeutic in 
patients with cystic fibrosis and used to reduce the viscosity of sputum through 
direct degradation of NET derived DNA.  
It is also very important to consider the potential complications associated with 
DNAse. Administration of DNAse in a murine model of sepsis resulted in an 
increased pro-inflammatory response along with increased colonisation of bacteria 
and mortality (221). This was further confirmed by Mai et al who highlighted the 
importance of timing when targeting NETs. Early administration of DNAse resulted 
in increased mortality, whereas later administration reduced tissue damage and 
decreased circulating DNA levels resulting in improved survival (402). These data 
provide evidence that DNA should only be broken down when in excess and 
contributing an enhanced pro-inflammatory and thrombotic phenotype. Given the 
clinical complexity and heterogeneous nature of patients following severe burns 
this may be challenging. Furthermore, as actin is released following severe 
thermal injury this may inhibit any administered DNAse, rendering the therapy 
potentially non-effective. Hence, a more targeted approach towards NETs or 
modulation of the actin scavenging system may be more applicable. 
5.2.5 Inhibition of PAD4 
NETosis can also be prevented by inhibition of PAD4. Indeed, PAD4 knockout 
mice are totally protected against venous thrombosis formation and tissue damage 
following liver injury (225, 275). However, these studies do not take into account 
the pre-existing immunosuppression which occurs following thermal injury. 
Therefore, elimination of NETs completely could leave, an already 
immunocompromised patient, susceptible to further infection. Moreover, PAD4 
 
231 
 
deficient mice are more susceptible to necrotizing fasciitis infection than wild-type 
mice and this susceptibility is attributed to the inability to form NETs (276).  
5.2.6 Modulation of actin scavenging system 
The actin scavenging system is comprised of two key proteins; VDBP and GSN. 
Following severe thermal injury, there are reductions in circulating levels of both 
proteins which predispose patients to reduce DNAse activity and the build-up of 
circulating DNA (Figure 4.13 - 4.14). As both VDBP and GSN are extremely 
abundant within the blood they are unlikely to be toxic if used as direct 
therapeutics.  
One potential mechanism to replenish depleted VDBP and GSN is through 
administration of blood products, namely FFP. Although not known, replenishment 
of the actin scavenging system may play a role in a number of the reported 
therapeutic benefits of using blood products following major trauma (371). In this 
thesis, administration of FFP during transportation from site of injury to hospital in 
major trauma victims improved DNAse activity in addition to increasing circulating 
GSN levels but without increasing circulating VDBP levels (Figure 4.19). Whilst 
this data suggests a role of GSN in recovery of DNAse activity any improvement 
by FFP will be multifactorial and caused by a number of soluble factors which may 
enhance DNAse activity, including DNAse 1 itself. Therefore, the restoration of 
DNAse activity cannot be solely attributed to the increase in GSN. Thus, further 
studies are required to investigate whether other components within blood 
products are contributing.  
Whilst VDBP remains a potential therapy, to date, no group has investigated the 
effect of administration of VDBP on outcome following trauma or burns. Despite 
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this, large quantities of protein can be produced from plasma fractions (403). 
Following thermal injury GSN and VDBP both become saturated, most likely 
caused by the release of monomeric and polymeric actin. Administration of GSN 
and VDBP as a combination therapy may therefore aid in the rapid recovery of the 
actin scavenging system.  
There is growing evidence for the use of GSN in the treatment of infection, trauma 
and burns (261, 404-406). In 2007, Lee and colleagues reported a reduction in 
mortality and a dynamic change in cytokine release in GSN depleted mice that 
were given 20 mg/mL recombinant human plasma GSN after challenge with 
endotoxin. Although the mechanism responsible remains unclear, improvements 
in outcome were associated with depolymerisation of actin in these animals (404). 
Interestingly, levels of total circulating actin did not decrease which suggests that 
GSN can modulate the activity of actin independent of VDBP which is consistent 
with previous literature (407, 408). 
A clinical trial has been established to assess the pharmacokinetics and safety of 
recombinant plasma GSN given to patients admitted to an ICU, including patients 
with trauma, infection and burns. The hypothesis of the study states that 
administration of GSN will increase circulating GSN levels and decrease the 
incidence of secondary complications, e.g. MOF or death (Trial Number: 
NCT00671307). Results for this study are not currently available, however, a 
second study may be warranted to focus upon patients admitted to an ICU with a 
dysregulated actin scavenging system.  
Whilst the beneficial effects of GSN alone have been described (261, 404-406), 
the cumulative benefit of GSN with VDBP or DNAse have not. Given the 
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saturation and dysregulation of the actin scavenging system, one might 
hypothesise that a combination therapy may be more appropriate. Furthermore, it 
may be possible to produce novel therapies which contain the active N-terminal 
fragment of GSN which is responsible for its ability to restore DNAse activity 
independently of VDBP (372). Therefore, one might propose the development of a 
novel compound which mimics the N-terminal fragment of GSN for its use in a 
clinical trial investigating early and sustained administration of GSN and its effects 
on DNAse activity and outcome following severe thermal injury. Of note, GSN 
function also extends beyond control of actin homeostasis and as a potential use 
as a biomarker of poor outcome as it also exhibits various anti-inflammatory 
activities (260, 408). Thus, understanding the mechanism(s) by which GSN 
provides benefit is fundamental to its development as a therapy.   
5.2.7 Targeting reduced neutrophil function following thermal injury 
The association between severe thermal injury and abnormal neutrophil function 
has been well reported (156, 159-161, 173, 174, 177). Furthermore, this reduction 
or dysregulation in neutrophil function may underlie the increased incidence of 
nosocomial infections reported within these patient cohorts. In this thesis, it has 
been shown that measurements of abnormal neutrophil function are potential 
biomarkers of sepsis, in addition to being novel therapeutic targets.  
5.2.8 Granulocyte colony-stimulating factor and neutrophil maturity  
Traumatic injury induces marked alterations in haematopoiesis which is 
characterised by a repolarisation towards a myeloid lineage (409, 410). Production 
and maturation of neutrophils is multifaceted with the principle regulator of 
granulopoiesis being G-CSF (162, 163) which causes activation of signal 
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transducer and activator of transcription 3 (STAT3), via MEK-1/-2 and ERK-1/-2 
(411, 412). 
Severe thermal injury results in the release of IGs/neutrophils which are 
associated with sepsis status and reduced neutrophil function (Chapter 3, Figure 
3.14, 3.17 and 3.18). One limitation of the work presented in this thesis is the lack 
of mechanistic insight responsible for the release of IGs following thermal injury. 
This release may be induced by emergency granulopoiesis caused by excessive 
stress from immediate injury and consequent infectious episodes. In a study which 
included 83 severely injured patients, sustained elevation in G-CSF was 
associated with the release of immature cells and increased risk of infection (157). 
In addition, Ertel and colleagues report an inhibition of neutrophil apoptosis 
caused by local G-CSF which propagates damage caused by neutrophils at sites 
of injury (413). Therefore, one might propose that inhibition of G-CSF can 
potentially reduce circulating IGs and protect against, neutrophil mediated, 
immunosuppression.  
Conversely, administration of G-CSF has positive effects in mice (168, 414). 
Namely, an increase in neutrophil chemotaxis in animals who received 
recombinant G-CSF following burn injury which was attributed to a combination of 
myeloid expansion and direct enhancement of neutrophil function (414). Gardner 
et al report a key role for G-CSF/STAT3 axis in providing protection against post-
traumatic infection which was consistent with human gene analysis. Paradoxically, 
thermal injury resulted in protection from a lethal Klebsiella pneumoniae 
pulmonary challenge. Inhibition of G-CSF reduced STAT3 activation and 
diminished this protective response by preventing myeloid differentiation and 
neutrophil release (168). Thus, caution must be advised when targeting G-CSF 
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following severe thermal injury as it potentially exhibits multiple roles in host 
protection and innate immunity (157, 168, 413, 414). Therefore a more targeted 
approach modulating neutrophil maturation may be more applicable.  
5.2.9 Resolvins 
Acute inflammation is necessary for the host to respond to initial tissue damage or 
invading pathogens and is required to maintain host protection and homeostasis. 
However, if inflammation is prolonged or uncontrolled it can lead to host tissue 
damage and secondary complications (415). Resolution of inflammation was long 
characterised as an eventual reduction of pro-inflammatory mediators by a 
passive process. As reviewed by Serhan and colleagues, resolution of 
inflammation is now considered an active and responsive process controlled by 
the release of a number of negative regulators (416). Resolvins, protectins and 
lipoxins are three examples of anti-inflammatory mediators which induce 
resolution and containment of acute inflammation (417, 418). 
Resolvins are named after their role in the resolution of inflammation and 
produced from eicosapentaenoic or docosahexaenoic acid, the most abundant 
omega-3 polyunsaturated fatty acids (417, 419). Administration of resolvin D2 
(RvD2) can enhance both neutrophil phagocytosis and killing of engulfed E.Coli 
(420). In a cecal ligation and puncture model of sepsis, treatment with RvD2 
causes a reduction in leukocyte-endothelial interactions, cytokine production, and 
a reduction in local and systemic bacterial burden (420). Furthermore, Kurihara et 
al reported a restoration of neutrophil chemotaxis following burn injury when 
animals were administered RvD2 which was attributed to the direct action of RvD2 
on neutrophils (421). Whilst it is known that resolvin D1 can act through ALX/FPR2 
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and GPR32 G-protein coupled receptors (422), the receptors responsible for RvD2 
actions are currently unknown. Hence, further characterisation of RvD2 and its 
receptors is essential to understand the mechanisms by which immunoregulation 
and enhancement of neutrophil function occur. Nevertheless, RvD2 may be a 
potential therapeutic to reduce both the uncontrolled inflammation and reduced 
neutrophil function which occurs following severe thermal injury.  
5.2.10 Haemoperfusion therapy 
Direct haemoperfusion therapy can filter cells or soluble mediators from the blood 
of patients. This results in reduced uncontrolled activation of the immune system 
and a reduction in host tissue damage (423, 424). Whilst direct haemoperfusion 
therapy is a recognised treatment for septic shock in Japan, only parts of Western 
Europe currently use this technology (425). Direct haemoperfusion therapy using a 
polymixin-B immobilized fibre cartridge (PMX-DHP) primarily works by removal of 
endotoxin from the blood. However, recent evidence has shown a broader 
mechanistic role for PMX-DHP in the removal of activated neutrophils which can 
cause endothelial damage (424). Whilst the mechanism responsible for selective 
removal of activated cells remains unclear the authors propose that it is caused by 
a direct interaction between activated neutrophils and polymixin-B located on the 
fibres of the filter (424). Thus, depletion of activated neutrophils by PMX-DHP may 
help to control inflammation in patients with septic shock. 
More recently, Lee and colleagues developed a microfibre mesh decorated in 
polythylenimine and polyamidoamine dendrimers which can capture DAMPs, 
including extracellular DNA. In vitro immobilisation of DAMPs located within blood 
from trauma patients results in reduced activation of toll-like receptor (TLR) -2, 3, 4 
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and 9 compared to unfiltered serum in a monocyte derived reporter cell line. 
Furthermore, immobilisation of DAMPs in hearts transplanted in vivo abrogated 
thrombus formation (423). In this thesis, DAMPs cause dysregulation of neutrophil 
function in vitro which mimics our in vivo findings in patients with severe thermal 
injuries (Figure 3.21 - 3.25). Hence, immobilisation of DAMPs using the microfibre 
mesh decorated in polythylenimine and polyamidoamine dendrimers has the 
potential to protect against dysregulation of neutrophil function following thermal 
injury and reduce thrombotic complications associated with elevated DNA and 
histones. However, direct haemoperfusion therapy using polythylenimine and 
polyamidoamine dendrimers remains experimental with limited translation to 
clinical practice due to difficulty in integrating these microfibre meshes into 
available technology.  
  
  
 
238 
 
Bibliography 
1. Department for the Management of Noncommunicable Diseases D, Violence and 
Injury Prevention. World Health Organisation Injuries and Violence: The Facts (2014) 
2014 [cited 2017 28/07/2017]. Available from: 
http://apps.who.int/iris/bitstream/10665/149798/1/9789241508018_eng.pdf?ua=1&ua=1&
ua=1. 
2. Haagsma JA, Graetz N, Bolliger I, Naghavi M, Higashi H, Mullany EC, et al. The 
global burden of injury: incidence, mortality, disability-adjusted life years and time trends 
from the Global Burden of Disease study 2013. Inj Prev. 2016;22(1):3-18. 
3. Sanchez JL, Pereperez SB, Bastida JL, Martinez MM. Cost-utility analysis applied 
to the treatment of burn patients in a specialized center. Arch Surg. 2007;142(1):50-7; 
discussion 7. 
4. Stylianou N, Buchan I, Dunn KW. A review of the international Burn Injury 
Database (iBID) for England and Wales: descriptive analysis of burn injuries 2003-2011. 
BMJ Open. 2015;5(2):e006184. 
5. Santaniello JM, Luchette FA, Esposito TJ, Gunawan H, Reed RL, Davis KA, et al. 
Ten year experience of burn, trauma, and combined burn/trauma injuries comparing 
outcomes. J Trauma. 2004;57(4):696-700; dicussion -1. 
6. Wilson D, Jackson T, Sapey E, Lord JM. Frailty and sarcopenia: The potential role 
of an aged immune system. Ageing Res Rev. 2017;36:1-10. 
7. Kling KM, Lopez-Rodriguez E, Pfarrer C, Muhlfeld C, Brandenberger C. Aging 
exacerbates acute lung injury-induced changes of the air-blood barrier, lung function, and 
inflammation in the mouse. Am J Physiol Lung Cell Mol Physiol. 2017;312(1):L1-L12. 
8. Hazeldine J, Lord JM. The impact of ageing on natural killer cell function and 
potential consequences for health in older adults. Ageing Res Rev. 2013;12(4):1069-78. 
9. Hazeldine J, Harris P, Chapple IL, Grant M, Greenwood H, Livesey A, et al. 
Impaired neutrophil extracellular trap formation: a novel defect in the innate immune 
system of aged individuals. Aging Cell. 2014;13(4):690-8. 
10. Pham TN, Kramer CB, Wang J, Rivara FP, Heimbach DM, Gibran NS, et al. 
Epidemiology and outcomes of older adults with burn injury: an analysis of the National 
Burn Repository. J Burn Care Res. 2009;30(1):30-6. 
11. El-Helbawy RH, Ghareeb FM. Inhalation injury as a prognostic factor for mortality 
in burn patients. Ann Burns Fire Disasters. 2011;24(2):82-8. 
12. Jackson DM. [The diagnosis of the depth of burning]. Br J Surg. 
1953;40(164):588-96. 
13. Hettiaratchy S, Dziewulski P. ABC of burns: pathophysiology and types of burns. 
BMJ. 2004;328(7453):1427-9. 
14. Wolf SE, Rose JK, Desai MH, Mileski JP, Barrow RE, Herndon DN. Mortality 
determinants in massive pediatric burns. An analysis of 103 children with > or = 80% 
TBSA burns (> or = 70% full-thickness). Ann Surg. 1997;225(5):554-65; discussion 65-9. 
15. Du Y, Wang L, Shi H, Gao M. Comparison of clinical effect of dopamine and 
norepinephrine in the treatment of septic shock. Pak J Pharm Sci. 2015;28(4 Suppl):1461-
4. 
16. Nielson CB, Duethman NC, Howard JM, Moncure M, Wood JG. Burns: 
Pathophysiology of Systemic Complications and Current Management. J Burn Care Res. 
2017;38(1):e469-e81. 
17. Ahrns KS. Trends in burn resuscitation: shifting the focus from fluids to adequate 
endpoint monitoring, edema control, and adjuvant therapies. Crit Care Nurs Clin North 
Am. 2004;16(1):75-98. 
18. Mann R, Heimbach D. Prognosis and treatment of burns. West J Med. 
1996;165(4):215-20. 
 
239 
 
19. Jackson PC, Hardwicke J, Bamford A, Nightingale P, Wilson Y, Papini R, et al. 
Revised estimates of mortality from the Birmingham Burn Centre, 2001-2010: a 
continuing analysis over 65 years. Ann Surg. 2014;259(5):979-84. 
20. Monafo WW. Initial management of burns. N Engl J Med. 1996;335(21):1581-6. 
21. Barrow RE, Jeschke MG, Herndon DN. Early fluid resuscitation improves 
outcomes in severely burned children. Resuscitation. 2000;45(2):91-6. 
22. Snell JA, Loh NH, Mahambrey T, Shokrollahi K. Clinical review: the critical care 
management of the burn patient. Crit Care. 2013;17(5):241. 
23. Tan A, Smailes S, Friebel T, Magdum A, Frew Q, El-Muttardi N, et al. Smoke 
inhalation increases intensive care requirements and morbidity in paediatric burns. Burns. 
2016;42(5):1111-5. 
24. Sakallioglu AE, Haberal M. Current approach to burn critical care. Minerva Med. 
2007;98(5):569-73. 
25. Sheridan RL. Fire-Related Inhalation Injury. N Engl J Med. 2016;375(5):464-9. 
26. Rehberg S, Maybauer MO, Enkhbaatar P, Maybauer DM, Yamamoto Y, Traber 
DL. Pathophysiology, management and treatment of smoke inhalation injury. Expert Rev 
Respir Med. 2009;3(3):283-97. 
27. Dries DJ, Endorf FW. Inhalation injury: epidemiology, pathology, treatment 
strategies. Scand J Trauma Resusc Emerg Med. 2013;21:31. 
28. Taylor FW, Gumbert JL. Cause of Death from Burns: Role of Respiratory Damage. 
Ann Surg. 1965;161:497-501. 
29. Walker PF, Buehner MF, Wood LA, Boyer NL, Driscoll IR, Lundy JB, et al. 
Diagnosis and management of inhalation injury: an updated review. Crit Care. 
2015;19:351. 
30. Schwacha MG, Thobe BM, Daniel T, Hubbard WJ. Impact of thermal injury on 
wound infiltration and the dermal inflammatory response. J Surg Res. 2010;158(1):112-
20. 
31. Kasten KR, Makley AT, Kagan RJ. Update on the critical care management of 
severe burns. J Intensive Care Med. 2011;26(4):223-36. 
32. Xiao-Wu W, Herndon DN, Spies M, Sanford AP, Wolf SE. Effects of delayed 
wound excision and grafting in severely burned children. Arch Surg. 2002;137(9):1049-54. 
33. Toussaint J, Chung WT, Osman N, McClain SA, Raut V, Singer AJ. Topical 
antibiotic ointment versus silver-containing foam dressing for second-degree burns in 
swine. Acad Emerg Med. 2015;22(8):927-33. 
34. Sevgi M, Toklu A, Vecchio D, Hamblin MR. Topical antimicrobials for burn 
infections - an update. Recent Pat Antiinfect Drug Discov. 2013;8(3):161-97. 
35. Farina JA, Jr., Rosique MJ, Rosique RG. Curbing inflammation in burn patients. 
Int J Inflam. 2013;2013:715645. 
36. Balk RA. Systemic inflammatory response syndrome (SIRS): where did it come 
from and is it still relevant today? Virulence. 2014;5(1):20-6. 
37. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al. A genomic 
storm in critically injured humans. J Exp Med. 2011;208(13):2581-90. 
38. Mann EA, Baun MM, Meininger JC, Wade CE. Comparison of mortality associated 
with sepsis in the burn, trauma, and general intensive care unit patient: a systematic 
review of the literature. Shock. 2012;37(1):4-16. 
39. Binkowska AM, Michalak G, Slotwinski R. Current views on the mechanisms of 
immune responses to trauma and infection. Cent Eur J Immunol. 2015;40(2):206-16. 
40. Sharma SK, Naidu G. The role of danger-associated molecular patterns (DAMPs) 
in trauma and infections. J Thorac Dis. 2016;8(7):1406-9. 
41. Lam NY, Rainer TH, Chiu RW, Joynt GM, Lo YM. Plasma mitochondrial DNA 
concentrations after trauma. Clin Chem. 2004;50(1):213-6. 
42. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating 
mitochondrial DAMPs cause inflammatory responses to injury. Nature. 
2010;464(7285):104-7. 
 
240 
 
43. Hazeldine J, Hampson P, Opoku FA, Foster M, Lord JM. N-Formyl peptides drive 
mitochondrial damage associated molecular pattern induced neutrophil activation through 
ERK1/2 and P38 MAP kinase signalling pathways. Injury. 2015;46(6):975-84. 
44. Simmons JD, Lee YL, Mulekar S, Kuck JL, Brevard SB, Gonzalez RP, et al. 
Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in 
severely injured human subjects. Ann Surg. 2013;258(4):591-6; discussion 6-8. 
45. Fernandez-Ruiz I, Arnalich F, Cubillos-Zapata C, Hernandez-Jimenez E, Moreno-
Gonzalez R, Toledano V, et al. Mitochondrial DAMPs induce endotoxin tolerance in 
human monocytes: an observation in patients with myocardial infarction. PLoS One. 
2014;9(5):e95073. 
46. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 
2013;369(21):2063. 
47. Paratz JD, Lipman J, Boots RJ, Muller MJ, Paterson DL. A new marker of sepsis 
post burn injury?*. Crit Care Med. 2014;42(9):2029-36. 
48. Baue AE. Multiple, progressive, or sequential systems failure. A syndrome of the 
1970s. Arch Surg. 1975;110(7):779-81. 
49. Penner JA. Disseminated intravascular coagulation in patients with multiple organ 
failure of non-septic origin. Semin Thromb Hemost. 1998;24(1):45-52. 
50. Kidokoro A, Iba T, Hong J. Role of DIC in multiple organ failure. Int J Surg 
Investig. 2000;2(1):73-80. 
51. Vincent JL, De Backer D. Does disseminated intravascular coagulation lead to 
multiple organ failure? Crit Care Clin. 2005;21(3):469-77. 
52. Toh CH, Alhamdi Y, Abrams ST. Current Pathological and Laboratory 
Considerations in the Diagnosis of Disseminated Intravascular Coagulation. Ann Lab 
Med. 2016;36(6):505-12. 
53. Levi M, Toh CH, Thachil J, Watson HG. Guidelines for the diagnosis and 
management of disseminated intravascular coagulation. British Committee for Standards 
in Haematology. Br J Haematol. 2009;145(1):24-33. 
54. Bick RL. Disseminated intravascular coagulation: a review of etiology, 
pathophysiology, diagnosis, and management: guidelines for care. Clin Appl Thromb 
Hemost. 2002;8(1):1-31. 
55. Wada H, Hasegawa K, Watanabe M. DIC: an update on diagnosis and treatment. 
Rinsho Ketsueki. 2017;58(5):523-9. 
56. Yanagida Y, Gando S, Sawamura A, Hayakawa M, Uegaki S, Kubota N, et al. 
Normal prothrombinase activity, increased systemic thrombin activity, and lower 
antithrombin levels in patients with disseminated intravascular coagulation at an early 
phase of trauma: comparison with acute coagulopathy of trauma-shock. Surgery. 
2013;154(1):48-57. 
57. Dobson GP, Letson HL, Sharma R, Sheppard FR, Cap AP. Mechanisms of early 
trauma-induced coagulopathy: The clot thickens or not? J Trauma Acute Care Surg. 
2015;79(2):301-9. 
58. Kono M, Saigo K, Takagi Y, Takahashi T, Kawauchi S, Wada A, et al. Heme-
related molecules induce rapid production of neutrophil extracellular traps. Transfusion. 
2014;54(11):2811-9. 
59. Nguyen LN, Nguyen TG. Characteristics and outcomes of multiple organ 
dysfunction syndrome among severe-burn patients. Burns. 2009;35(7):937-41. 
60. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. 
Surviving sepsis campaign: international guidelines for management of severe sepsis and 
septic shock: 2012. Crit Care Med. 2013;41(2):580-637. 
61. Castellanos-Ortega A, Suberviola B, Garcia-Astudillo LA, Holanda MS, Ortiz F, 
Llorca J, et al. Impact of the Surviving Sepsis Campaign protocols on hospital length of 
stay and mortality in septic shock patients: results of a three-year follow-up quasi-
experimental study. Crit Care Med. 2010;38(4):1036-43. 
62. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, Bion J, et 
al. The Surviving Sepsis Campaign: results of an international guideline-based 
 
241 
 
performance improvement program targeting severe sepsis. Crit Care Med. 
2010;38(2):367-74. 
63. Ferrer R, Artigas A, Suarez D, Palencia E, Levy MM, Arenzana A, et al. 
Effectiveness of treatments for severe sepsis: a prospective, multicenter, observational 
study. Am J Respir Crit Care Med. 2009;180(9):861-6. 
64. Orban C. Diagnostic criteria for sepsis in burn patients. Chirurgia (Bucur). 
2012;107(6):697-700. 
65. Greenhalgh DG, Saffle JR, Holmes JHt, Gamelli RL, Palmieri TL, Horton JW, et al. 
American Burn Association consensus conference to define sepsis and infection in burns. 
J Burn Care Res. 2007;28(6):776-90. 
66. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, 
et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-
3). JAMA. 2016;315(8):801-10. 
67. Blair JM, Webber MA, Baylay AJ, Ogbolu DO, Piddock LJ. Molecular mechanisms 
of antibiotic resistance. Nat Rev Microbiol. 2015;13(1):42-51. 
68. van Langeveld I, Gagnon RC, Conrad PF, Gamelli RL, Martin B, Choudhry MA, et 
al. Multiple-Drug Resistance in Burn Patients: A Retrospective Study on the Impact of 
Antibiotic Resistance on Survival and Length of Stay. J Burn Care Res. 2017;38(2):99-
105. 
69. Assicot M, Gendrel D, Carsin H, Raymond J, Guilbaud J, Bohuon C. High serum 
procalcitonin concentrations in patients with sepsis and infection. Lancet. 
1993;341(8844):515-8. 
70. Mehanic S, Baljic R. The importance of serum procalcitonin in diagnosis and 
treatment of serious bacterial infections and sepsis. Mater Sociomed. 2013;25(4):277-81. 
71. von Heimburg D, Stieghorst W, Khorram-Sefat R, Pallua N. Procalcitonin--a sepsis 
parameter in severe burn injuries. Burns. 1998;24(8):745-50. 
72. Sachse C, Machens HG, Felmerer G, Berger A, Henkel E. Procalcitonin as a 
marker for the early diagnosis of severe infection after thermal injury. J Burn Care 
Rehabil. 1999;20(5):354-60. 
73. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY. Procalcitonin as a 
diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic 
review and meta-analysis. Crit Care Med. 2006;34(7):1996-2003. 
74. Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve 
antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit 
Care. 2013;19(5):453-60. 
75. Cabral L, Afreixo V, Almeida L, Paiva JA. The Use of Procalcitonin (PCT) for 
Diagnosis of Sepsis in Burn Patients: A Meta-Analysis. PLoS One. 
2016;11(12):e0168475. 
76. Seoane L, Pertega S, Galeiras R, Astola I, Bouza T. Procalcitonin in the burn unit 
and the diagnosis of infection. Burns. 2014;40(2):223-9. 
77. Lavrentieva A, Kontakiotis T, Lazaridis L, Tsotsolis N, Koumis J, Kyriazis G, et al. 
Inflammatory markers in patients with severe burn injury. What is the best indicator of 
sepsis? Burns. 2007;33(2):189-94. 
78. Minami E, Ito S, Sugiura T, Fujita Y, Sasano H, Sobue K. Markedly elevated 
procalcitonin in early postoperative period in pediatric open heart surgery: a prospective 
cohort study. J Intensive Care. 2014;2(1):38. 
79. Pepys MB, Hirschfield GM. C-reactive protein: a critical update. J Clin Invest. 
2003;111(12):1805-12. 
80. Kim H, Hur M, Moon HW, Yun YM, Di Somma S, Network G. Multi-marker 
approach using procalcitonin, presepsin, galectin-3, and soluble suppression of 
tumorigenicity 2 for the prediction of mortality in sepsis. Ann Intensive Care. 2017;7(1):27. 
81. Sapin F, Biston P, Piagnerelli M. Predictive value of C-reactive protein in critically 
ill patients after abdominal surgery. Clinics (Sao Paulo). 2017;72(1):23-9. 
 
242 
 
82. Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of 
procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 
2003;31(6):1737-41. 
83. Lobo SM, Lobo FR, Bota DP, Lopes-Ferreira F, Soliman HM, Melot C, et al. C-
reactive protein levels correlate with mortality and organ failure in critically ill patients. 
Chest. 2003;123(6):2043-9. 
84. Su L, Han B, Liu C, Liang L, Jiang Z, Deng J, et al. Value of soluble TREM-1, 
procalcitonin, and C-reactive protein serum levels as biomarkers for detecting bacteremia 
among sepsis patients with new fever in intensive care units: a prospective cohort study. 
BMC Infect Dis. 2012;12:157. 
85. Pileri D, Accardo Palombo A, D'Amelio L, D'Arpa N, Amato G, Masellis A, et al. 
Concentrations of cytokines IL-6 and IL-10 in plasma of burn patients: their relationship to 
sepsis and outcome. Ann Burns Fire Disasters. 2008;21(4):182-5. 
86. Finnerty CC, Herndon DN, Przkora R, Pereira CT, Oliveira HM, Queiroz DM, et al. 
Cytokine expression profile over time in severely burned pediatric patients. Shock. 
2006;26(1):13-9. 
87. Xia ZF, Coolbaugh MI, He F, Herndon DN, Papaconstantinou J. The effects of 
burn injury on the acute phase response. J Trauma. 1992;32(2):245-50; discussion 50-1. 
88. Jeschke MG, Mlcak RP, Finnerty CC, Norbury WB, Gauglitz GG, Kulp GA, et al. 
Burn size determines the inflammatory and hypermetabolic response. Crit Care. 
2007;11(4):R90. 
89. Gauglitz GG, Finnerty CC, Herndon DN, Mlcak RP, Jeschke MG. Are serum 
cytokines early predictors for the outcome of burn patients with inhalation injuries who do 
not survive? Crit Care. 2008;12(3):R81. 
90. Jeschke MG, Patsouris D, Stanojcic M, Abdullahi A, Rehou S, Pinto R, et al. 
Pathophysiologic Response to Burns in the Elderly. EBioMedicine. 2015;2(10):1536-48. 
91. Kraft R, Herndon DN, Finnerty CC, Cox RA, Song J, Jeschke MG. Predictive 
Value of IL-8 for Sepsis and Severe Infections After Burn Injury: A Clinical Study. Shock. 
2015;43(3):222-7. 
92. Gouel-Cheron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G, 
et al. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful 
association to predict the development of sepsis after major trauma. PLoS One. 
2012;7(3):e33095. 
93. Marck RE, Montagne HL, Tuinebreijer WE, Breederveld RS. Time course of 
thrombocytes in burn patients and its predictive value for outcome. Burns. 
2013;39(4):714-22. 
94. Ha SO, Park SH, Park SH, Park JS, Huh JW, Lim CM, et al. Fraction of immature 
granulocytes reflects severity but not mortality in sepsis. Scand J Clin Lab Invest. 
2015;75(1):36-43. 
95. Simon TL, Curreri PW, Harker LA. Kinetic characterization of hemostasis in 
thermal injury. J Lab Clin Med. 1977;89(4):702-11. 
96. Nierhaus A, Klatte S, Linssen J, Eismann NM, Wichmann D, Hedke J, et al. 
Revisiting the white blood cell count: immature granulocytes count as a diagnostic marker 
to discriminate between SIRS and sepsis--a prospective, observational study. BMC 
Immunol. 2013;14:8. 
97. Nigro KG, O'Riordan M, Molloy EJ, Walsh MC, Sandhaus LM. Performance of an 
automated immature granulocyte count as a predictor of neonatal sepsis. Am J Clin 
Pathol. 2005;123(4):618-24. 
98. Wagner DD, Burger PC. Platelets in inflammation and thrombosis. Arterioscler 
Thromb Vasc Biol. 2003;23(12):2131-7. 
99. Rossaint J, Zarbock A. Platelets in leucocyte recruitment and function. Cardiovasc 
Res. 2015;107(3):386-95. 
100. Clark SR, Ma AC, Tavener SA, McDonald B, Goodarzi Z, Kelly MM, et al. Platelet 
TLR4 activates neutrophil extracellular traps to ensnare bacteria in septic blood. Nat Med. 
2007;13(4):463-9. 
 
243 
 
101. Harrison P, Ault KA, Chapman S, Charie L, Davis B, Fujimoto K, et al. An 
interlaboratory study of a candidate reference method for platelet counting. Am J Clin 
Pathol. 2001;115(3):448-59. 
102. Briggs C, Harrison P, Machin SJ. Continuing developments with the automated 
platelet count. Int J Lab Hematol. 2007;29(2):77-91. 
103. Zini G, d'Onofrio G, Briggs C, Erber W, Jou JM, Lee SH, et al. ICSH 
recommendations for identification, diagnostic value, and quantitation of schistocytes. Int 
J Lab Hematol. 2012;34(2):107-16. 
104. Tanaka Y, Tanaka Y, Gondo K, Maruki Y, Kondo T, Asai S, et al. Performance 
evaluation of platelet counting by novel fluorescent dye staining in the XN-series 
automated hematology analyzers. J Clin Lab Anal. 2014;28(5):341-8. 
105. Lesesve JF, Martin M, Banasiak C, Andre-Kerneis E, Bardet V, Lusina D, et al. 
Schistocytes in disseminated intravascular coagulation. Int J Lab Hematol. 
2014;36(4):439-43. 
106. Lesesve JF, Salignac S, Lecompte T. Laboratory measurement of schistocytes. Int 
J Lab Hematol. 2007;29(2):149-51. 
107. Saukkonen K, Lakkisto P, Pettila V, Varpula M, Karlsson S, Ruokonen E, et al. 
Cell-free plasma DNA as a predictor of outcome in severe sepsis and septic shock. Clin 
Chem. 2008;54(6):1000-7. 
108. Rhodes A, Wort SJ, Thomas H, Collinson P, Bennett ED. Plasma DNA 
concentration as a predictor of mortality and sepsis in critically ill patients. Crit Care. 
2006;10(2):R60. 
109. Dwivedi DJ, Toltl LJ, Swystun LL, Pogue J, Liaw KL, Weitz JI, et al. Prognostic 
utility and characterization of cell-free DNA in patients with severe sepsis. Crit Care. 
2012;16(4):R151. 
110. Lo YM, Rainer TH, Chan LY, Hjelm NM, Cocks RA. Plasma DNA as a prognostic 
marker in trauma patients. Clin Chem. 2000;46(3):319-23. 
111. Shoham Y, Krieger Y, Perry ZH, Shaked G, Bogdanov-Berezovsky A, Silberstein 
E, et al. Admission cell free DNA as a prognostic factor in burns: quantification by use of a 
direct rapid fluorometric technique. Biomed Res Int. 2014;2014:306580. 
112. Yoon KA, Park S, Lee SH, Kim JH, Lee JS. Comparison of circulating plasma 
DNA levels between lung cancer patients and healthy controls. J Mol Diagn. 
2009;11(3):182-5. 
113. Papadopoulou E, Davilas E, Sotiriou V, Georgakopoulos E, Georgakopoulou S, 
Koliopanos A, et al. Cell-free DNA and RNA in plasma as a new molecular marker for 
prostate and breast cancer. Ann N Y Acad Sci. 2006;1075:235-43. 
114. van der Vaart M, Pretorius PJ. Circulating DNA. Its origin and fluctuation. Ann N Y 
Acad Sci. 2008;1137:18-26. 
115. van der Vaart M, Pretorius PJ. The origin of circulating free DNA. Clin Chem. 
2007;53(12):2215. 
116. Summers C, Rankin SM, Condliffe AM, Singh N, Peters AM, Chilvers ER. 
Neutrophil kinetics in health and disease. Trends Immunol. 2010;31(8):318-24. 
117. Segal AW. How neutrophils kill microbes. Annu Rev Immunol. 2005;23:197-223. 
118. Brinkmann V, Reichard U, Goosmann C, Fauler B, Uhlemann Y, Weiss DS, et al. 
Neutrophil extracellular traps kill bacteria. Science. 2004;303(5663):1532-5. 
119. Menegazzi R, Decleva E, Dri P. Killing by neutrophil extracellular traps: fact or 
folklore? Blood. 2012;119(5):1214-6. 
120. Tecchio C, Micheletti A, Cassatella MA. Neutrophil-derived cytokines: facts 
beyond expression. Front Immunol. 2014;5:508. 
121. Scapini P, Lapinet-Vera JA, Gasperini S, Calzetti F, Bazzoni F, Cassatella MA. 
The neutrophil as a cellular source of chemokines. Immunol Rev. 2000;177:195-203. 
122. Tecchio C, Cassatella MA. Neutrophil-derived cytokines involved in physiological 
and pathological angiogenesis. Chem Immunol Allergy. 2014;99:123-37. 
123. Tecchio C, Scapini P, Pizzolo G, Cassatella MA. On the cytokines produced by 
human neutrophils in tumors. Semin Cancer Biol. 2013;23(3):159-70. 
 
244 
 
124. Dinauer MC, Lekstrom-Himes JA, Dale DC. Inherited Neutrophil Disorders: 
Molecular Basis and New Therapies. Hematology Am Soc Hematol Educ Program. 
2000:303-18. 
125. Mocsai A. Diverse novel functions of neutrophils in immunity, inflammation, and 
beyond. J Exp Med. 2013;210(7):1283-99. 
126. Jones DA, Abbassi O, McIntire LV, McEver RP, Smith CW. P-selectin mediates 
neutrophil rolling on histamine-stimulated endothelial cells. Biophys J. 1993;65(4):1560-9. 
127. Ley K, Laudanna C, Cybulsky MI, Nourshargh S. Getting to the site of 
inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol. 2007;7(9):678-
89. 
128. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and 
the inflammatory response. Trends Immunol. 2003;24(6):327-34. 
129. Anderson DC, Springer TA. Leukocyte adhesion deficiency: an inherited defect in 
the Mac-1, LFA-1, and p150,95 glycoproteins. Annu Rev Med. 1987;38:175-94. 
130. Nuzzi PA, Lokuta MA, Huttenlocher A. Analysis of neutrophil chemotaxis. Methods 
Mol Biol. 2007;370:23-36. 
131. Lin F, Nguyen CM, Wang SJ, Saadi W, Gross SP, Jeon NL. Neutrophil migration 
in opposing chemoattractant gradients using microfluidic chemotaxis devices. Ann 
Biomed Eng. 2005;33(4):475-82. 
132. Boner A, Zeligs BJ, Bellanti JA. Chemotactic responses of various differentiational 
stages of neutrophils from human cord and adult blood. Infect Immun. 1982;35(3):921-8. 
133. Hatano Y, Taniuchi S, Masuda M, Tsuji S, Ito T, Hasui M, et al. Phagocytosis of 
heat-killed Staphylococcus aureus by eosinophils: comparison with neutrophils. APMIS. 
2009;117(2):115-23. 
134. Leliefeld PH, Wessels CM, Leenen LP, Koenderman L, Pillay J. The role of 
neutrophils in immune dysfunction during severe inflammation. Crit Care. 2016;20:73. 
135. Babior BM. NADPH oxidase: an update. Blood. 1999;93(5):1464-76. 
136. Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: 
physiology and pathophysiology. Physiol Rev. 2007;87(1):245-313. 
137. Liao Y, Liu P, Guo F, Zhang ZY, Zhang Z. Oxidative burst of circulating neutrophils 
following traumatic brain injury in human. PLoS One. 2013;8(7):e68963. 
138. Dong YL, Abdullah K, Yan TZ, Rutan T, Broemeling L, Robson M, et al. Effect of 
thermal injury and sepsis on neutrophil function. J Trauma. 1993;34(3):417-21. 
139. Spicer SS, Hardin JH. Ultrastructure, cytochemistry, and function of neutrophil 
leukocyte granules. A review. Lab Invest. 1969;20(5):488-97. 
140. Belaaouaj A, Kim KS, Shapiro SD. Degradation of outer membrane protein A in 
Escherichia coli killing by neutrophil elastase. Science. 2000;289(5482):1185-8. 
141. Fox S, Leitch AE, Duffin R, Haslett C, Rossi AG. Neutrophil apoptosis: relevance 
to the innate immune response and inflammatory disease. J Innate Immun. 
2010;2(3):216-27. 
142. Luo HR, Loison F. Constitutive neutrophil apoptosis: mechanisms and regulation. 
Am J Hematol. 2008;83(4):288-95. 
143. Edwards SW, Derouet M, Howse M, Moots RJ. Regulation of neutrophil apoptosis 
by Mcl-1. Biochem Soc Trans. 2004;32(Pt3):489-92. 
144. Akgul C, Moulding DA, White MR, Edwards SW. In vivo localisation and stability of 
human Mcl-1 using green fluorescent protein (GFP) fusion proteins. FEBS Lett. 
2000;478(1-2):72-6. 
145. Lovell JF, Billen LP, Bindner S, Shamas-Din A, Fradin C, Leber B, et al. 
Membrane binding by tBid initiates an ordered series of events culminating in membrane 
permeabilization by Bax. Cell. 2008;135(6):1074-84. 
146. Scatizzi JC, Hutcheson J, Bickel E, Haines GK, 3rd, Perlman H. Pro-apoptotic Bid 
is required for the resolution of the effector phase of inflammatory arthritis. Arthritis Res 
Ther. 2007;9(3):R49. 
 
245 
 
147. Andina N, Conus S, Schneider EM, Fey MF, Simon HU. Induction of Bim limits 
cytokine-mediated prolonged survival of neutrophils. Cell Death Differ. 2009;16(9):1248-
55. 
148. Nolan B, Collette H, Baker S, Duffy A, De M, Miller C, et al. Inhibition of neutrophil 
apoptosis after severe trauma is NFkappabeta dependent. J Trauma. 2000;48(4):599-
604; discussion -5. 
149. Turina M, Hoth JJ, Turpen RM, Scott MJ, Cheadle WG. Alveolar interleukin-10 
regulates neutrophil apoptosis in severely traumatized patients. J Trauma. 
2007;63(4):733-9. 
150. Paunel-Gorgulu A, Kirichevska T, Logters T, Windolf J, Flohe S. Molecular 
mechanisms underlying delayed apoptosis in neutrophils from multiple trauma patients 
with and without sepsis. Mol Med. 2012;18:325-35. 
151. Matsuda T, Saito H, Fukatsu K, Han I, Inoue T, Furukawa S, et al. Cytokine-
modulated inhibition of neutrophil apoptosis at local site augments exudative neutrophil 
functions and reflects inflammatory response after surgery. Surgery. 2001;129(1):76-85. 
152. Scheel-Toellner D, Wang K, Assi LK, Webb PR, Craddock RM, Salmon M, et al. 
Clustering of death receptors in lipid rafts initiates neutrophil spontaneous apoptosis. 
Biochem Soc Trans. 2004;32(Pt 5):679-81. 
153. Dunogue B, Pilmis B, Mahlaoui N, Elie C, Coignard-Biehler H, Amazzough K, et 
al. Chronic Granulomatous Disease in Patients Reaching Adulthood: A Nationwide Study 
in France. Clin Infect Dis. 2017;64(6):767-75. 
154. Introne WJ, Westbroek W, Golas GA, Adams D. Chediak-Higashi Syndrome. In: 
Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. 
GeneReviews(R). Seattle (WA)1993. 
155. Robertson CM, Perrone EE, McConnell KW, Dunne WM, Boody B, Brahmbhatt T, 
et al. Neutrophil depletion causes a fatal defect in murine pulmonary Staphylococcus 
aureus clearance. J Surg Res. 2008;150(2):278-85. 
156. Hazeldine J, Hampson P, Lord JM. The impact of trauma on neutrophil function. 
Injury. 2014;45(12):1824-33. 
157. Cook KM, Sifri ZC, Baranski GM, Mohr AM, Livingston DH. The role of plasma 
granulocyte colony stimulating factor and bone marrow dysfunction after severe trauma. J 
Am Coll Surg. 2013;216(1):57-64. 
158. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, et al. A subset of 
neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J 
Clin Invest. 2012;122(1):327-36. 
159. Warden GD, Mason AD, Jr., Pruitt BA, Jr. Suppression of leukocyte chemotaxis in 
vitro by chemotherapeutic agents used in the management of thermal injuries. Ann Surg. 
1975;181(3):363-9. 
160. Kim Y, Goldstein E, Lippert W, Brofeldt T, Donovan R. Polymorphonuclear 
leucocyte motility in patients with severe burns. Burns. 1989;15(2):93-7. 
161. Warden GD, Mason AD, Jr., Pruitt BA, Jr. Evaluation of leukocyte chemotaxis in 
vitro in thermally injured patients. J Clin Invest. 1974;54(4):1001-4. 
162. Richards MK, Liu F, Iwasaki H, Akashi K, Link DC. Pivotal role of granulocyte 
colony-stimulating factor in the development of progenitors in the common myeloid 
pathway. Blood. 2003;102(10):3562-8. 
163. Lord BI, Bronchud MH, Owens S, Chang J, Howell A, Souza L, et al. The kinetics 
of human granulopoiesis following treatment with granulocyte colony-stimulating factor in 
vivo. Proc Natl Acad Sci U S A. 1989;86(23):9499-503. 
164. Liu F, Poursine-Laurent J, Wu HY, Link DC. Interleukin-6 and the granulocyte 
colony-stimulating factor receptor are major independent regulators of granulopoiesis in 
vivo but are not required for lineage commitment or terminal differentiation. Blood. 
1997;90(7):2583-90. 
165. Sugimoto K, Mori KJ. Cascade regulation of cytokine production in granulopoiesis. 
Leukemia. 1997;11 Suppl 3:464-7. 
 
246 
 
166. Tsuji T, Sugimoto K, Yanai T, Takashita E, Mori KJ. Induction of granulocyte-
macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating 
factor (G-CSF) expression in bone marrow and fractionated marrow cell populations by 
interleukin 3 (IL-3): IL-3-mediated positive feedback mechanisms of granulopoiesis. 
Growth Factors. 1994;11(1):71-9. 
167. Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol. 
2014;14(5):302-14. 
168. Gardner JC, Noel JG, Nikolaidis NM, Karns R, Aronow BJ, Ogle CK, et al. G-CSF 
drives a posttraumatic immune program that protects the host from infection. J Immunol. 
2014;192(5):2405-17. 
169. Drifte G, Dunn-Siegrist I, Tissieres P, Pugin J. Innate immune functions of 
immature neutrophils in patients with sepsis and severe systemic inflammatory response 
syndrome. Crit Care Med. 2013;41(3):820-32. 
170. Tak T, Wijten P, Heeres M, Pickkers P, Scholten A, Heck AJR, et al. Human 
CD62Ldim neutrophils identified as a separate subset by proteome profiling and in vivo 
pulse-chase labeling. Blood. 2017;129(26):3476-85. 
171. Butler KL, Ambravaneswaran V, Agrawal N, Bilodeau M, Toner M, Tompkins RG, 
et al. Burn injury reduces neutrophil directional migration speed in microfluidic devices. 
PLoS One. 2010;5(7):e11921. 
172. Jones CN, Moore M, Dimisko L, Alexander A, Ibrahim A, Hassell BA, et al. 
Spontaneous neutrophil migration patterns during sepsis after major burns. PLoS One. 
2014;9(12):e114509. 
173. Sheng ZY, Tung YL. Neutrophil chemiluminescence in burned patients. J Trauma. 
1987;27(6):587-95. 
174. Alexander JW, Ogle CK, Stinnett JD, Macmillan BG. A sequential, prospective 
analysis of immunologic abnormalities and infection following severe thermal injury. Ann 
Surg. 1978;188(6):809-16. 
175. Arturson G. Neutrophil granulocyte functions in severely burned patients. Burns 
Incl Therm Inj. 1985;11(5):309-19. 
176. Bjerknes R, Vindenes H, Laerum OD. Altered neutrophil functions in patients with 
large burns. Blood Cells. 1990;16(1):127-41; discussion 42-3. 
177. Parment K, Zetterberg A, Ernerudh J, Bakteman K, Steinwall I, Sjoberg F. Long-
term immunosuppression in burned patients assessed by in vitro neutrophil oxidative 
burst (Phagoburst). Burns. 2007;33(7):865-71. 
178. Yipp BG, Kubes P. NETosis: how vital is it? Blood. 2013;122(16):2784-94. 
179. Logters T, Margraf S, Altrichter J, Cinatl J, Mitzner S, Windolf J, et al. The clinical 
value of neutrophil extracellular traps. Med Microbiol Immunol. 2009;198(4):211-9. 
180. Hampson P, Dinsdale RJ, Wearn CM, Bamford AL, Bishop JRB, Hazeldine J, et 
al. Neutrophil Dysfunction, Immature Granulocytes, and Cell-free DNA are Early 
Biomarkers of Sepsis in Burn-injured Patients: A Prospective Observational Cohort Study. 
Ann Surg. 2017;265(6):1241-9. 
181. Hirose T, Hamaguchi S, Matsumoto N, Irisawa T, Seki M, Tasaki O, et al. 
Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream 
of critically ill patients. PLoS One. 2014;9(11):e111755. 
182. Takei H, Araki A, Watanabe H, Ichinose A, Sendo F. Rapid killing of human 
neutrophils by the potent activator phorbol 12-myristate 13-acetate (PMA) accompanied 
by changes different from typical apoptosis or necrosis. J Leukoc Biol. 1996;59(2):229-40. 
183. Steinberg BE, Grinstein S. Unconventional roles of the NADPH oxidase: signaling, 
ion homeostasis, and cell death. Sci STKE. 2007;2007(379):pe11. 
184. Fuchs TA, Abed U, Goosmann C, Hurwitz R, Schulze I, Wahn V, et al. Novel cell 
death program leads to neutrophil extracellular traps. J Cell Biol. 2007;176(2):231-41. 
185. Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and 
myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol. 
2010;191(3):677-91. 
 
247 
 
186. Pilsczek FH, Salina D, Poon KK, Fahey C, Yipp BG, Sibley CD, et al. A novel 
mechanism of rapid nuclear neutrophil extracellular trap formation in response to 
Staphylococcus aureus. J Immunol. 2010;185(12):7413-25. 
187. Rossaint J, Herter JM, Van Aken H, Napirei M, Doring Y, Weber C, et al. 
Synchronized integrin engagement and chemokine activation is crucial in neutrophil 
extracellular trap-mediated sterile inflammation. Blood. 2014;123(16):2573-84. 
188. Branzk N, Lubojemska A, Hardison SE, Wang Q, Gutierrez MG, Brown GD, et al. 
Neutrophils sense microbe size and selectively release neutrophil extracellular traps in 
response to large pathogens. Nat Immunol. 2014;15(11):1017-25. 
189. Wang Y, Li M, Stadler S, Correll S, Li P, Wang D, et al. Histone hypercitrullination 
mediates chromatin decondensation and neutrophil extracellular trap formation. J Cell 
Biol. 2009;184(2):205-13. 
190. Nakashima K, Hagiwara T, Yamada M. Nuclear localization of peptidylarginine 
deiminase V and histone deimination in granulocytes. J Biol Chem. 2002;277(51):49562-
8. 
191. Vossenaar ER, Zendman AJ, van Venrooij WJ, Pruijn GJ. PAD, a growing family 
of citrullinating enzymes: genes, features and involvement in disease. Bioessays. 
2003;25(11):1106-18. 
192. Li Y, Liu B, Fukudome EY, Lu J, Chong W, Jin G, et al. Identification of 
citrullinated histone H3 as a potential serum protein biomarker in a lethal model of 
lipopolysaccharide-induced shock. Surgery. 2011;150(3):442-51. 
193. Marino-Ramirez L, Kann MG, Shoemaker BA, Landsman D. Histone structure and 
nucleosome stability. Expert Rev Proteomics. 2005;2(5):719-29. 
194. Venkatesh S, Workman JL. Histone exchange, chromatin structure and the 
regulation of transcription. Nat Rev Mol Cell Biol. 2015;16(3):178-89. 
195. Abrams ST, Zhang N, Manson J, Liu T, Dart C, Baluwa F, et al. Circulating 
histones are mediators of trauma-associated lung injury. Am J Respir Crit Care Med. 
2013;187(2):160-9. 
196. Gillrie MR, Lee K, Gowda DC, Davis SP, Monestier M, Cui L, et al. Plasmodium 
falciparum histones induce endothelial proinflammatory response and barrier dysfunction. 
Am J Pathol. 2012;180(3):1028-39. 
197. Allam R, Scherbaum CR, Darisipudi MN, Mulay SR, Hagele H, Lichtnekert J, et al. 
Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc 
Nephrol. 2012;23(8):1375-88. 
198. Xu J, Zhang X, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. 
Extracellular histones are major mediators of death in sepsis. Nat Med. 
2009;15(11):1318-21. 
199. Pisetsky DS. The origin and properties of extracellular DNA: from PAMP to DAMP. 
Clin Immunol. 2012;144(1):32-40. 
200. McGinty RK, Tan S. Nucleosome structure and function. Chem Rev. 
2015;115(6):2255-73. 
201. McGhee JD, Felsenfeld G. Nucleosome structure. Annu Rev Biochem. 
1980;49:1115-56. 
202. Marin Oyarzun CP, Carestia A, Lev PR, Glembotsky AC, Castro Rios MA, 
Moiraghi B, et al. Neutrophil extracellular trap formation and circulating nucleosomes in 
patients with chronic myeloproliferative neoplasms. Sci Rep. 2016;6:38738. 
203. van Montfoort ML, Stephan F, Lauw MN, Hutten BA, Van Mierlo GJ, Solati S, et al. 
Circulating nucleosomes and neutrophil activation as risk factors for deep vein 
thrombosis. Arterioscler Thromb Vasc Biol. 2013;33(1):147-51. 
204. Gauthier VJ, Tyler LN, Mannik M. Blood clearance kinetics and liver uptake of 
mononucleosomes in mice. J Immunol. 1996;156(3):1151-6. 
205. Decker P, Wolburg H, Rammensee HG. Nucleosomes induce lymphocyte 
necrosis. Eur J Immunol. 2003;33(7):1978-87. 
 
248 
 
206. Bhagirath VC, Dwivedi DJ, Liaw PC. Comparison of the Proinflammatory and 
Procoagulant Properties of Nuclear, Mitochondrial, and Bacterial DNA. Shock. 
2015;44(3):265-71. 
207. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 
2008;132(1):27-42. 
208. Remijsen Q, Vanden Berghe T, Wirawan E, Asselbergh B, Parthoens E, De Rycke 
R, et al. Neutrophil extracellular trap cell death requires both autophagy and superoxide 
generation. Cell Res. 2011;21(2):290-304. 
209. Nakagawa I, Amano A, Mizushima N, Yamamoto A, Yamaguchi H, Kamimoto T, et 
al. Autophagy defends cells against invading group A Streptococcus. Science. 
2004;306(5698):1037-40. 
210. Gutierrez MG, Master SS, Singh SB, Taylor GA, Colombo MI, Deretic V. 
Autophagy is a defense mechanism inhibiting BCG and Mycobacterium tuberculosis 
survival in infected macrophages. Cell. 2004;119(6):753-66. 
211. Birmingham CL, Brumell JH. Autophagy recognizes intracellular Salmonella 
enterica serovar Typhimurium in damaged vacuoles. Autophagy. 2006;2(3):156-8. 
212. Kenno S, Perito S, Mosci P, Vecchiarelli A, Monari C. Autophagy and Reactive 
Oxygen Species Are Involved in Neutrophil Extracellular Traps Release Induced by C. 
albicans Morphotypes. Front Microbiol. 2016;7:879. 
213. Hashiba M, Huq A, Tomino A, Hirakawa A, Hattori T, Miyabe H, et al. Neutrophil 
extracellular traps in patients with sepsis. J Surg Res. 2015;194(1):248-54. 
214. Czaikoski PG, Mota JM, Nascimento DC, Sonego F, Castanheira FV, Melo PH, et 
al. Neutrophil Extracellular Traps Induce Organ Damage during Experimental and Clinical 
Sepsis. PLoS One. 2016;11(2):e0148142. 
215. Margraf S, Logters T, Reipen J, Altrichter J, Scholz M, Windolf J. Neutrophil-
derived circulating free DNA (cf-DNA/NETs): a potential prognostic marker for 
posttraumatic development of inflammatory second hit and sepsis. Shock. 
2008;30(4):352-8. 
216. Yang J, Selvaganapathy PR, Gould TJ, Dwivedi DJ, Liu D, Fox-Robichaud AE, et 
al. A microfluidic device for rapid quantification of cell-free DNA in patients with severe 
sepsis. Lab Chip. 2015;15(19):3925-33. 
217. Gupta S, Kaplan MJ. The role of neutrophils and NETosis in autoimmune and 
renal diseases. Nat Rev Nephrol. 2016;12(7):402-13. 
218. Demers M, Wagner DD. NETosis: a new factor in tumor progression and cancer-
associated thrombosis. Semin Thromb Hemost. 2014;40(3):277-83. 
219. Jorch SK, Kubes P. An emerging role for neutrophil extracellular traps in 
noninfectious disease. Nat Med. 2017;23(3):279-87. 
220. Altrichter J, Zedler S, Kraft R, Faist E, Mitzner SR, Sauer M, et al. Neutrophil-
derived circulating free DNA (cf-DNA/NETs), a potential prognostic marker for mortality in 
patients with severe burn injury. Eur J Trauma Emerg Surg. 2010;36(6):551-7. 
221. Meng W, Paunel-Gorgulu A, Flohe S, Hoffmann A, Witte I, MacKenzie C, et al. 
Depletion of neutrophil extracellular traps in vivo results in hypersusceptibility to 
polymicrobial sepsis in mice. Crit Care. 2012;16(4):R137. 
222. Tanaka K, Koike Y, Shimura T, Okigami M, Ide S, Toiyama Y, et al. In vivo 
characterization of neutrophil extracellular traps in various organs of a murine sepsis 
model. PLoS One. 2014;9(11):e111888. 
223. Alhamdi Y, Abrams ST, Cheng Z, Jing S, Su D, Liu Z, et al. Circulating Histones 
Are Major Mediators of Cardiac Injury in Patients With Sepsis. Crit Care Med. 
2015;43(10):2094-103. 
224. Caudrillier A, Kessenbrock K, Gilliss BM, Nguyen JX, Marques MB, Monestier M, 
et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. 
J Clin Invest. 2012;122(7):2661-71. 
225. Kolaczkowska E, Jenne CN, Surewaard BG, Thanabalasuriar A, Lee WY, Sanz 
MJ, et al. Molecular mechanisms of NET formation and degradation revealed by intravital 
imaging in the liver vasculature. Nat Commun. 2015;6:6673. 
 
249 
 
226. Kaplan MJ, Radic M. Neutrophil extracellular traps: double-edged swords of innate 
immunity. J Immunol. 2012;189(6):2689-95. 
227. Urban CF, Ermert D, Schmid M, Abu-Abed U, Goosmann C, Nacken W, et al. 
Neutrophil extracellular traps contain calprotectin, a cytosolic protein complex involved in 
host defense against Candida albicans. PLoS Pathog. 2009;5(10):e1000639. 
228. Kawai C, Kotani H, Miyao M, Ishida T, Jemail L, Abiru H, et al. Circulating 
Extracellular Histones Are Clinically Relevant Mediators of Multiple Organ Injury. Am J 
Pathol. 2016;186(4):829-43. 
229. Andrews RK, Arthur JF, Gardiner EE. Neutrophil extracellular traps (NETs) and 
the role of platelets in infection. Thromb Haemost. 2014;112(4):659-65. 
230. Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep 
vein thrombosis. Arterioscler Thromb Vasc Biol. 2012;32(8):1777-83. 
231. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 
2013;39(5):559-66. 
232. Fuchs TA, Brill A, Duerschmied D, Schatzberg D, Monestier M, Myers DD, Jr., et 
al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A. 
2010;107(36):15880-5. 
233. Brill A, Fuchs TA, Savchenko AS, Thomas GM, Martinod K, De Meyer SF, et al. 
Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost. 
2012;10(1):136-44. 
234. Gould TJ, Vu TT, Swystun LL, Dwivedi DJ, Mai SH, Weitz JI, et al. Neutrophil 
extracellular traps promote thrombin generation through platelet-dependent and platelet-
independent mechanisms. Arterioscler Thromb Vasc Biol. 2014;34(9):1977-84. 
235. Gould TJ, Vu TT, Stafford AR, Dwivedi DJ, Kim PY, Fox-Robichaud AE, et al. Cell-
Free DNA Modulates Clot Structure and Impairs Fibrinolysis in Sepsis. Arterioscler 
Thromb Vasc Biol. 2015;35(12):2544-53. 
236. Boneschansker L, Inoue Y, Oklu R, Irimia D. Capillary plexuses are vulnerable to 
neutrophil extracellular traps. Integr Biol (Camb). 2016;8(2):149-55. 
237. Hakkim A, Furnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, et al. 
Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. 
Proc Natl Acad Sci U S A. 2010;107(21):9813-8. 
238. Kotzin BL. Systemic lupus erythematosus. Cell. 1996;85(3):303-6. 
239. Meng W, Paunel-Gorgulu A, Flohe S, Witte I, Schadel-Hopfner M, Windolf J, et al. 
Deoxyribonuclease is a potential counter regulator of aberrant neutrophil extracellular 
traps formation after major trauma. Mediators Inflamm. 2012;2012:149560. 
240. Lee WM, Galbraith RM. The extracellular actin-scavenger system and actin 
toxicity. N Engl J Med. 1992;326(20):1335-41. 
241. Ananthakrishnan R, Ehrlicher A. The forces behind cell movement. Int J Biol Sci. 
2007;3(5):303-17. 
242. Mogilner A, Oster G. Cell motility driven by actin polymerization. Biophys J. 
1996;71(6):3030-45. 
243. Haddad JG, Harper KD, Guoth M, Pietra GG, Sanger JW. Angiopathic 
consequences of saturating the plasma scavenger system for actin. Proc Natl Acad Sci U 
S A. 1990;87(4):1381-5. 
244. Lind SE, Smith CJ. Actin stimulates plasmin generation by tissue and urokinase-
type plasminogen activators. Arch Biochem Biophys. 1993;307(1):138-45. 
245. Lazarides E, Lindberg U. Actin is the naturally occurring inhibitor of 
deoxyribonuclease I. Proc Natl Acad Sci U S A. 1974;71(12):4742-6. 
246. Lee PS, Patel SR, Christiani DC, Bajwa E, Stossel TP, Waxman AB. Plasma 
gelsolin depletion and circulating actin in sepsis: a pilot study. PLoS One. 
2008;3(11):e3712. 
247. Smith DB, Janmey PA, Herbert TJ, Lind SE. Quantitative measurement of plasma 
gelsolin and its incorporation into fibrin clots. J Lab Clin Med. 1987;110(2):189-95. 
248. Yin HL, Kwiatkowski DJ, Mole JE, Cole FS. Structure and biosynthesis of 
cytoplasmic and secreted variants of gelsolin. J Biol Chem. 1984;259(8):5271-6. 
 
250 
 
249. Kwiatkowski DJ, Janmey PA, Yin HL. Identification of critical functional and 
regulatory domains in gelsolin. J Cell Biol. 1989;108(5):1717-26. 
250. Yin HL, Zaner KS, Stossel TP. Ca2+ control of actin gelation. Interaction of 
gelsolin with actin filaments and regulation of actin gelation. J Biol Chem. 
1980;255(19):9494-500. 
251. Yin HL, Iida K, Janmey PA. Identification of a polyphosphoinositide-modulated 
domain in gelsolin which binds to the sides of actin filaments. J Cell Biol. 
1988;106(3):805-12. 
252. Lind SE, Smith DB, Janmey PA, Stossel TP. Depression of gelsolin levels and 
detection of gelsolin-actin complexes in plasma of patients with acute lung injury. Am Rev 
Respir Dis. 1988;138(2):429-34. 
253. Ito H, Kambe H, Kimura Y, Nakamura H, Hayashi E, Kishimoto T, et al. 
Depression of plasma gelsolin level during acute liver injury. Gastroenterology. 
1992;102(5):1686-92. 
254. Huang LF, Yao YM, Li JF, Dong N, Liu C, Yu Y, et al. Reduction of plasma 
gelsolin levels correlates with development of multiple organ dysfunction syndrome and 
fatal outcome in burn patients. PLoS One. 2011;6(11):e25748. 
255. Suhler E, Lin W, Yin HL, Lee WM. Decreased plasma gelsolin concentrations in 
acute liver failure, myocardial infarction, septic shock, and myonecrosis. Crit Care Med. 
1997;25(4):594-8. 
256. Kulakowska A, Ciccarelli NJ, Wen Q, Mroczko B, Drozdowski W, Szmitkowski M, 
et al. Hypogelsolinemia, a disorder of the extracellular actin scavenger system, in patients 
with multiple sclerosis. BMC Neurol. 2010;10:107. 
257. Dahl B, Schiodt FV, Ott P, Gvozdenovic R, Yin HL, Lee WM. Plasma gelsolin is 
reduced in trauma patients. Shock. 1999;12(2):102-4. 
258. Osborn TM, Verdrengh M, Stossel TP, Tarkowski A, Bokarewa M. Decreased 
levels of the gelsolin plasma isoform in patients with rheumatoid arthritis. Arthritis Res 
Ther. 2008;10(5):R117. 
259. Hu Y, Li H, Li WH, Meng HX, Fan YZ, Li WJ, et al. The value of decreased plasma 
gelsolin levels in patients with systemic lupus erythematosus and rheumatoid arthritis in 
diagnosis and disease activity evaluation. Lupus. 2013;22(14):1455-61. 
260. Ordija CM, Chiou TT, Yang Z, Deloid GM, de Oliveira Valdo M, Wang Z, et al. 
Free actin impairs macrophage bacterial defenses via scavenger receptor MARCO 
interaction with reversal by plasma gelsolin. Am J Physiol Lung Cell Mol Physiol. 
2017;312(6):L1018-L28. 
261. Rothenbach PA, Dahl B, Schwartz JJ, O'Keefe GE, Yamamoto M, Lee WM, et al. 
Recombinant plasma gelsolin infusion attenuates burn-induced pulmonary microvascular 
dysfunction. J Appl Physiol (1985). 2004;96(1):25-31. 
262. Bikle DD, Gee E, Halloran B, Kowalski MA, Ryzen E, Haddad JG. Assessment of 
the free fraction of 25-hydroxyvitamin D in serum and its regulation by albumin and the 
vitamin D-binding protein. J Clin Endocrinol Metab. 1986;63(4):954-9. 
263. Cooke NE, Haddad JG. Vitamin D binding protein (Gc-globulin). Endocr Rev. 
1989;10(3):294-307. 
264. Van Baelen H, Bouillon R, De Moor P. Vitamin D-binding protein (Gc-globulin) 
binds actin. J Biol Chem. 1980;255(6):2270-2. 
265. Janmey PA, Lind SE. Capacity of human serum to depolymerize actin filaments. 
Blood. 1987;70(2):524-30. 
266. Dueland S, Nenseter MS, Drevon CA. Uptake and degradation of filamentous 
actin and vitamin D-binding protein in the rat. Biochem J. 1991;274 ( Pt 1):237-41. 
267. Herrmannsdoerfer AJ, Heeb GT, Feustel PJ, Estes JE, Keenan CJ, Minnear FL, et 
al. Vascular clearance and organ uptake of G- and F-actin in the rat. Am J Physiol. 
1993;265(6 Pt 1):G1071-81. 
268. Dahl B, Schiodt FV, Nielsen M, Kiaer T, Williams JG, Ott P. Admission level of Gc-
globulin predicts outcome after multiple trauma. Injury. 1999;30(4):275-81. 
 
251 
 
269. Dahl B, Schiodt FV, Ott P, Wians F, Lee WM, Balko J, et al. Plasma concentration 
of Gc-globulin is associated with organ dysfunction and sepsis after injury. Crit Care Med. 
2003;31(1):152-6. 
270. Dahl B, Schiodt FV, Kiaer T, Ott P, Bondesen S, Tygstrup N. Serum Gc-globulin in 
the early course of multiple trauma. Crit Care Med. 1998;26(2):285-9. 
271. Dahl B, Schiodt FV, Rudolph S, Ott P, Kiaer T, Heslet L. Trauma stimulates the 
synthesis of Gc-globulin. Intensive Care Med. 2001;27(2):394-9. 
272. Wang X, Qin W, Sun B. New strategy for sepsis: Targeting a key role of platelet-
neutrophil interaction. Burns Trauma. 2014;2(3):114-20. 
273. Kimball AS, Obi AT, Diaz JA, Henke PK. The Emerging Role of NETs in Venous 
Thrombosis and Immunothrombosis. Front Immunol. 2016;7:236. 
274. Yang S, Qi H, Kan K, Chen J, Xie H, Guo X, et al. Neutrophil Extracellular Traps 
Promote Hypercoagulability in Patients With Sepsis. Shock. 2017;47(2):132-9. 
275. Martinod K, Fuchs TA, Zitomersky NL, Wong SL, Demers M, Gallant M, et al. 
PAD4-deficiency does not affect bacteremia in polymicrobial sepsis and ameliorates 
endotoxemic shock. Blood. 2015;125(12):1948-56. 
276. Li P, Li M, Lindberg MR, Kennett MJ, Xiong N, Wang Y. PAD4 is essential for 
antibacterial innate immunity mediated by neutrophil extracellular traps. J Exp Med. 
2010;207(9):1853-62. 
277. Kraft R, Herndon DN, Finnerty CC, Shahrokhi S, Jeschke MG. Occurrence of 
multiorgan dysfunction in pediatric burn patients: incidence and clinical outcome. Ann 
Surg. 2014;259(2):381-7. 
278. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of 
disease classification system. Crit Care Med. 1985;13(10):818-29. 
279. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, et al. The 
SOFA (Sepsis-related Organ Failure Assessment) score to describe organ 
dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the 
European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707-10. 
280. Tobiasen J, Hiebert JM, Edlich RF. The abbreviated burn severity index. Ann 
Emerg Med. 1982;11(5):260-2. 
281. Osler T, Glance LG, Hosmer DW. Simplified estimates of the probability of death 
after burn injuries: extending and updating the baux score. J Trauma. 2010;68(3):690-7. 
282. Dinsdale RJ, Devi A, Hampson P, Wearn CM, Bamford AL, Hazeldine J, et al. 
Changes in novel haematological parameters following thermal injury: A prospective 
observational cohort study. Sci Rep. 2017;7(1):3211. 
283. Brinkmann V, Laube B, Abu Abed U, Goosmann C, Zychlinsky A. Neutrophil 
extracellular traps: how to generate and visualize them. J Vis Exp. 2010(36). 
284. Baxter C. Fluid resuscitation, burn percentage, and physiologic age. J Trauma. 
1979;19(11 Suppl):864-5. 
285. Baxter CR, Shires T. Physiological response to crystalloid resuscitation of severe 
burns. Ann N Y Acad Sci. 1968;150(3):874-94. 
286. Goldshtein H, Hausmann MJ, Douvdevani A. A rapid direct fluorescent assay for 
cell-free DNA quantification in biological fluids. Ann Clin Biochem. 2009;46(Pt 6):488-94. 
287. Gogenur M, Burcharth J, Gogenur I. The role of total cell-free DNA in predicting 
outcomes among trauma patients in the intensive care unit: a systematic review. Crit 
Care. 2017;21(1):14. 
288. Hoppenbrouwers T, Autar ASA, Sultan AR, Abraham TE, van Cappellen WA, 
Houtsmuller AB, et al. In vitro induction of NETosis: Comprehensive live imaging 
comparison and systematic review. PLoS One. 2017;12(5):e0176472. 
289. Leshner M, Wang S, Lewis C, Zheng H, Chen XA, Santy L, et al. PAD4 mediated 
histone hypercitrullination induces heterochromatin decondensation and chromatin 
unfolding to form neutrophil extracellular trap-like structures. Front Immunol. 2012;3:307. 
290. Ahmed AI, Soliman RA, Samir S. Cell Free DNA and Procalcitonin as Early 
Markers of Complications in ICU Patients with Multiple Trauma and Major Surgery. Clin 
Lab. 2016;62(12):2395-404. 
 
252 
 
291. Hazeldine J, Naumann DN, Toman E, Davies D, Bishop JRB, Su Z, et al. 
Prehospital immune responses and development of multiple organ dysfunction syndrome 
following traumatic injury: A prospective cohort study. PLoS Med. 2017;14(7):e1002338. 
292. Thalin C, Daleskog M, Goransson SP, Schatzberg D, Lasselin J, Laska AC, et al. 
Validation of an enzyme-linked immunosorbent assay for the quantification of citrullinated 
histone H3 as a marker for neutrophil extracellular traps in human plasma. Immunol Res. 
2017;65(3):706-12. 
293. Liu S, Su X, Pan P, Zhang L, Hu Y, Tan H, et al. Neutrophil extracellular traps are 
indirectly triggered by lipopolysaccharide and contribute to acute lung injury. Sci Rep. 
2016;6:37252. 
294. Nakazawa D, Kumar S, Desai J, Anders HJ. Neutrophil extracellular traps in tissue 
pathology. Histol Histopathol. 2017;32(3):203-13. 
295. Slaba I, Wang J, Kolaczkowska E, McDonald B, Lee WY, Kubes P. Imaging the 
dynamic platelet-neutrophil response in sterile liver injury and repair in mice. Hepatology. 
2015;62(5):1593-605. 
296. Engelmann B, Massberg S. Thrombosis as an intravascular effector of innate 
immunity. Nat Rev Immunol. 2013;13(1):34-45. 
297. de Stoppelaar SF, van 't Veer C, van der Poll T. The role of platelets in sepsis. 
Thromb Haemost. 2014;112(4):666-77. 
298. Chen G, Zhang D, Fuchs TA, Manwani D, Wagner DD, Frenette PS. Heme-
induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease. 
Blood. 2014;123(24):3818-27. 
299. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. 
Surviving Sepsis Campaign: international guidelines for management of severe sepsis 
and septic shock, 2012. Intensive Care Med. 2013;39(2):165-228. 
300. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of 
hypotension before initiation of effective antimicrobial therapy is the critical determinant of 
survival in human septic shock. Crit Care Med. 2006;34(6):1589-96. 
301. Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. 
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and 
Septic Shock: 2016. Intensive Care Med. 2017;43(3):304-77. 
302. Washington JA, 2nd, Ilstrup DM. Blood cultures: issues and controversies. Rev 
Infect Dis. 1986;8(5):792-802. 
303. Weinstein MP. Blood culture contamination: persisting problems and partial 
progress. J Clin Microbiol. 2003;41(6):2275-8. 
304. Avriel A, Paryente Wiessman M, Almog Y, Perl Y, Novack V, Galante O, et al. 
Admission cell free DNA levels predict 28-day mortality in patients with severe sepsis in 
intensive care. PLoS One. 2014;9(6):e100514. 
305. Garnacho-Montero J, Huici-Moreno MJ, Gutierrez-Pizarraya A, Lopez I, Marquez-
Vacaro JA, Macher H, et al. Prognostic and diagnostic value of eosinopenia, C-reactive 
protein, procalcitonin, and circulating cell-free DNA in critically ill patients admitted with 
suspicion of sepsis. Crit Care. 2014;18(3):R116. 
306. Rhodes A, Cecconi M. Cell-free DNA and outcome in sepsis. Crit Care. 
2012;16(6):170. 
307. Lo YM, Zhang J, Leung TN, Lau TK, Chang AM, Hjelm NM. Rapid clearance of 
fetal DNA from maternal plasma. Am J Hum Genet. 1999;64(1):218-24. 
308. Kolialexi A, Tsangaris GT, Antsaklis A, Mavroua A. Rapid clearance of fetal cells 
from maternal circulation after delivery. Ann N Y Acad Sci. 2004;1022:113-8. 
309. Velders M, Treff G, Machus K, Bosnyak E, Steinacker J, Schumann U. Exercise is 
a potent stimulus for enhancing circulating DNase activity. Clin Biochem. 2014;47(6):471-
4. 
310. Sur Chowdhury C, Giaglis S, Walker UA, Buser A, Hahn S, Hasler P. Enhanced 
neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying 
signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 
2014;16(3):R122. 
 
253 
 
311. Hamaguchi S, Akeda Y, Yamamoto N, Seki M, Yamamoto K, Oishi K, et al. Origin 
of Circulating Free DNA in Sepsis: Analysis of the CLP Mouse Model. Mediators Inflamm. 
2015;2015:614518. 
312. Bossola M, Sanguinetti M, Scribano D, Zuppi C, Giungi S, Luciani G, et al. 
Circulating bacterial-derived DNA fragments and markers of inflammation in chronic 
hemodialysis patients. Clin J Am Soc Nephrol. 2009;4(2):379-85. 
313. Szeto CC, Kwan BC, Chow KM, Kwok JS, Lai KB, Cheng PM, et al. Circulating 
bacterial-derived DNA fragment level is a strong predictor of cardiovascular disease in 
peritoneal dialysis patients. PLoS One. 2015;10(5):e0125162. 
314. Simmons JD, Lee YL, Pastukh VM, Capley G, Muscat CA, Muscat DC, et al. 
Potential contribution of mitochondrial DNA damage associated molecular patterns in 
transfusion products to the development of acute respiratory distress syndrome after 
multiple transfusions. J Trauma Acute Care Surg. 2017;82(6):1023-9. 
315. Itagaki K, Kaczmarek E, Lee YT, Tang IT, Isal B, Adibnia Y, et al. Mitochondrial 
DNA released by trauma induces neutrophil extracellular traps. PLoS One. 
2015;10(3):e0120549. 
316. Magna M, Pisetsky DS. The Alarmin Properties of DNA and DNA-associated 
Nuclear Proteins. Clin Ther. 2016;38(5):1029-41. 
317. Timmermans K, Kox M, Vaneker M, van den Berg M, John A, van Laarhoven A, et 
al. Plasma levels of danger-associated molecular patterns are associated with immune 
suppression in trauma patients. Intensive Care Med. 2016;42(4):551-61. 
318. Gu X, Yao Y, Wu G, Lv T, Luo L, Song Y. The plasma mitochondrial DNA is an 
independent predictor for post-traumatic systemic inflammatory response syndrome. 
PLoS One. 2013;8(8):e72834. 
319. Huang H, Tohme S, Al-Khafaji AB, Tai S, Loughran P, Chen L, et al. Damage-
associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile 
inflammatory liver injury. Hepatology. 2015;62(2):600-14. 
320. Boudreau LH, Duchez AC, Cloutier N, Soulet D, Martin N, Bollinger J, et al. 
Platelets release mitochondria serving as substrate for bactericidal group IIA-secreted 
phospholipase A2 to promote inflammation. Blood. 2014;124(14):2173-83. 
321. Demaret J, Venet F, Friggeri A, Cazalis MA, Plassais J, Jallades L, et al. Marked 
alterations of neutrophil functions during sepsis-induced immunosuppression. J Leukoc 
Biol. 2015;98(6):1081-90. 
322. Bhatia R, Dent C, Topley N, Pallister I. Neutrophil priming for elastase release in 
adult blunt trauma patients. J Trauma. 2006;60(3):590-6. 
323. Partrick DA, Moore FA, Moore EE, Barnett CC, Jr., Silliman CC. Neutrophil 
priming and activation in the pathogenesis of postinjury multiple organ failure. New Horiz. 
1996;4(2):194-210. 
324. Raoof M, Zhang Q, Itagaki K, Hauser CJ. Mitochondrial peptides are potent 
immune activators that activate human neutrophils via FPR-1. J Trauma. 
2010;68(6):1328-32; discussion 32-4. 
325. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, et al. ATP 
release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science. 
2006;314(5806):1792-5. 
326. Li H, Itagaki K, Sandler N, Gallo D, Galenkamp A, Kaczmarek E, et al. 
Mitochondrial damage-associated molecular patterns from fractures suppress pulmonary 
immune responses via formyl peptide receptors 1 and 2. J Trauma Acute Care Surg. 
2015;78(2):272-9; discussion 9-81. 
327. Laskay T, van Zandbergen G, Solbach W. Neutrophil granulocytes--Trojan horses 
for Leishmania major and other intracellular microbes? Trends Microbiol. 2003;11(5):210-
4. 
328. Cornet E, Boubaya M, Troussard X. Contribution of the new XN-1000 parameters 
NEUT-RI and NEUT-WY for managing patients with immature granulocytes. Int J Lab 
Hematol. 2015;37(5):e123-6. 
 
254 
 
329. Luo Y, Lin J, Chen H, Zhang J, Peng S, Kuang M. Utility of neut-X, neut-Y and 
neut-Z parameters for rapidly assessing sepsis in tumor patients. Clin Chim Acta. 
2013;422:5-9. 
330. Stiel L, Delabranche X, Galoisy AC, Severac F, Toti F, Mauvieux L, et al. 
Neutrophil Fluorescence: A New Indicator of Cell Activation During Septic Shock-Induced 
Disseminated Intravascular Coagulation. Crit Care Med. 2016;44(11):e1132-e6. 
331. Krysko DV, Agostinis P, Krysko O, Garg AD, Bachert C, Lambrecht BN, et al. 
Emerging role of damage-associated molecular patterns derived from mitochondria in 
inflammation. Trends Immunol. 2011;32(4):157-64. 
332. Hernandez-Jimenez E, Gutierrez-Fernandez M, Cubillos-Zapata C, Otero-Ortega 
L, Rodriguez-Frutos B, Toledano V, et al. Circulating Monocytes Exhibit an Endotoxin 
Tolerance Status after Acute Ischemic Stroke: Mitochondrial DNA as a Putative 
Explanation for Poststroke Infections. J Immunol. 2017;198(5):2038-46. 
333. Zhao C, Itagaki K, Gupta A, Odom S, Sandler N, Hauser CJ. Mitochondrial 
damage-associated molecular patterns released by abdominal trauma suppress 
pulmonary immune responses. J Trauma Acute Care Surg. 2014;76(5):1222-7. 
334. Wang H, Bloom O, Zhang M, Vishnubhakat JM, Ombrellino M, Che J, et al. HMG-
1 as a late mediator of endotoxin lethality in mice. Science. 1999;285(5425):248-51. 
335. Hatada T, Wada H, Nobori T, Okabayashi K, Maruyama K, Abe Y, et al. Plasma 
concentrations and importance of High Mobility Group Box protein in the prognosis of 
organ failure in patients with disseminated intravascular coagulation. Thromb Haemost. 
2005;94(5):975-9. 
336. Schmausser B, Josenhans C, Endrich S, Suerbaum S, Sitaru C, Andrulis M, et al. 
Downregulation of CXCR1 and CXCR2 expression on human neutrophils by Helicobacter 
pylori: a new pathomechanism in H. pylori infection? Infect Immun. 2004;72(12):6773-9. 
337. Nasser MW, Raghuwanshi SK, Malloy KM, Gangavarapu P, Shim JY, 
Rajarathnam K, et al. CXCR1 and CXCR2 activation and regulation. Role of aspartate 
199 of the second extracellular loop of CXCR2 in CXCL8-mediated rapid receptor 
internalization. J Biol Chem. 2007;282(9):6906-15. 
338. Healy LD, Puy C, Fernandez JA, Mitrugno A, Keshari RS, Taku NA, et al. 
Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in 
vivo. J Biol Chem. 2017;292(21):8616-29. 
339. Hosseinzadeh A, Thompson PR, Segal BH, Urban CF. Nicotine induces neutrophil 
extracellular traps. J Leukoc Biol. 2016;100(5):1105-12. 
340. Domingo-Gonzalez R, Martinez-Colon GJ, Smith AJ, Smith CK, Ballinger MN, Xia 
M, et al. Inhibition of Neutrophil Extracellular Trap Formation after Stem Cell Transplant 
by Prostaglandin E2. Am J Respir Crit Care Med. 2016;193(2):186-97. 
341. Okubo K, Kamiya M, Urano Y, Nishi H, Herter JM, Mayadas T, et al. Lactoferrin 
Suppresses Neutrophil Extracellular Traps Release in Inflammation. EBioMedicine. 
2016;10:204-15. 
342. Rohm M, Grimm MJ, D'Auria AC, Almyroudis NG, Segal BH, Urban CF. NADPH 
oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect 
Immun. 2014;82(5):1766-77. 
343. Rohrbach AS, Slade DJ, Thompson PR, Mowen KA. Activation of PAD4 in NET 
formation. Front Immunol. 2012;3:360. 
344. Itakura A, McCarty OJ. Pivotal role for the mTOR pathway in the formation of 
neutrophil extracellular traps via regulation of autophagy. Am J Physiol Cell Physiol. 
2013;305(3):C348-54. 
345. Tarlowe MH, Duffy A, Kannan KB, Itagaki K, Lavery RF, Livingston DH, et al. 
Prospective study of neutrophil chemokine responses in trauma patients at risk for 
pneumonia. Am J Respir Crit Care Med. 2005;171(7):753-9. 
346. Campbell JJ, Foxman EF, Butcher EC. Chemoattractant receptor cross talk as a 
regulatory mechanism in leukocyte adhesion and migration. Eur J Immunol. 
1997;27(10):2571-8. 
347. Sagan L. On the origin of mitosing cells. J Theor Biol. 1967;14(3):255-74. 
 
255 
 
348. Taanman JW. The mitochondrial genome: structure, transcription, translation and 
replication. Biochim Biophys Acta. 1999;1410(2):103-23. 
349. Admyre C, Axelsson LG, von Stein O, Zargari A. Immunomodulatory 
oligonucleotides inhibit neutrophil migration by decreasing the surface expression of 
interleukin-8 and leukotriene B4 receptors. Immunology. 2015;144(2):206-17. 
350. Camicia G, Pozner R, de Larranaga G. Neutrophil extracellular traps in sepsis. 
Shock. 2014;42(4):286-94. 
351. McDonald B, Davis RP, Kim SJ, Tse M, Esmon CT, Kolaczkowska E, et al. 
Platelets and neutrophil extracellular traps collaborate to promote intravascular 
coagulation during sepsis in mice. Blood. 2017;129(10):1357-67. 
352. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. 
Sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15(5):581-614. 
353. Jimenez-Alcazar M, Napirei M, Panda R, Kohler EC, Kremer Hovinga JA, 
Mannherz HG, et al. Impaired DNase1-mediated degradation of neutrophil extracellular 
traps is associated with acute thrombotic microangiopathies. J Thromb Haemost. 
2015;13(5):732-42. 
354. Kung CT, Hsiao SY, Tsai TC, Su CM, Chang WN, Huang CR, et al. Plasma 
nuclear and mitochondrial DNA levels as predictors of outcome in severe sepsis patients 
in the emergency room. J Transl Med. 2012;10:130. 
355. Kawasaki H, Iwamuro S. Potential roles of histones in host defense as 
antimicrobial agents. Infect Disord Drug Targets. 2008;8(3):195-205. 
356. Silk E, Zhao H, Weng H, Ma D. The role of extracellular histone in organ injury. 
Cell Death Dis. 2017;8(5):e2812. 
357. Pavia KE, Spinella SA, Elmore DE. Novel histone-derived antimicrobial peptides 
use different antimicrobial mechanisms. Biochim Biophys Acta. 2012;1818(3):869-76. 
358. Luo D, Szaba FM, Kummer LW, Plow EF, Mackman N, Gailani D, et al. Protective 
roles for fibrin, tissue factor, plasminogen activator inhibitor-1, and thrombin activatable 
fibrinolysis inhibitor, but not factor XI, during defense against the gram-negative bacterium 
Yersinia enterocolitica. J Immunol. 2011;187(4):1866-76. 
359. Loike JD, Sodeik B, Cao L, Leucona S, Weitz JI, Detmers PA, et al. CD11c/CD18 
on neutrophils recognizes a domain at the N terminus of the A alpha chain of fibrinogen. 
Proc Natl Acad Sci U S A. 1991;88(3):1044-8. 
360. Gupta AK, Joshi MB, Philippova M, Erne P, Hasler P, Hahn S, et al. Activated 
endothelial cells induce neutrophil extracellular traps and are susceptible to NETosis-
mediated cell death. FEBS Lett. 2010;584(14):3193-7. 
361. Srinivasan N, Gordon O, Ahrens S, Franz A, Deddouche S, Chakravarty P, et al. 
Actin is an evolutionarily-conserved damage-associated molecular pattern that signals 
tissue injury in Drosophila melanogaster. Elife. 2016;5. 
362. Ahrens S, Zelenay S, Sancho D, Hanc P, Kjaer S, Feest C, et al. F-actin is an 
evolutionarily conserved damage-associated molecular pattern recognized by DNGR-1, a 
receptor for dead cells. Immunity. 2012;36(4):635-45. 
363. Hanc P, Fujii T, Iborra S, Yamada Y, Huotari J, Schulz O, et al. Structure of the 
Complex of F-Actin and DNGR-1, a C-Type Lectin Receptor Involved in Dendritic Cell 
Cross-Presentation of Dead Cell-Associated Antigens. Immunity. 2015;42(5):839-49. 
364. Zhang JG, Czabotar PE, Policheni AN, Caminschi I, Wan SS, Kitsoulis S, et al. 
The dendritic cell receptor Clec9A binds damaged cells via exposed actin filaments. 
Immunity. 2012;36(4):646-57. 
365. Mannherz HG. Crystallization of actin in complex with actin-binding proteins. J Biol 
Chem. 1992;267(17):11661-4. 
366. Bert JL, Bowen BD, Reed RK, Onarheim H. Microvascular exchange during burn 
injury: IV. Fluid resuscitation model. Circ Shock. 1991;34(3):285-97. 
367. Vlachou E, Gosling P, Moiemen NS. Microalbuminuria: a marker of endothelial 
dysfunction in thermal injury. Burns. 2006;32(8):1009-16. 
368. Gould TJ, Lysov Z, Liaw PC. Extracellular DNA and histones: double-edged 
swords in immunothrombosis. J Thromb Haemost. 2015;13 Suppl 1:S82-91. 
 
256 
 
369. Cohen TS, Bucki R, Byfield FJ, Ciccarelli NJ, Rosenberg B, DiNubile MJ, et al. 
Therapeutic potential of plasma gelsolin administration in a rat model of sepsis. Cytokine. 
2011;54(3):235-8. 
370. Mathews ZR, Koyfman A. Blast Injuries. J Emerg Med. 2015;49(4):573-87. 
371. Mitra B, Mori A, Cameron PA, Fitzgerald M, Paul E, Street A. Fresh frozen plasma 
(FFP) use during massive blood transfusion in trauma resuscitation. Injury. 2010;41(1):35-
9. 
372. Chhabra D, Nosworthy NJ, dos Remedios CG. The N-terminal fragment of gelsolin 
inhibits the interaction of DNase I with isolated actin, but not with the cofilin-actin complex. 
Proteomics. 2005;5(12):3131-6. 
373. Zhang LM, Li R, Zhao XC, Zhang Q, Luo XL. Increased Transfusion of Fresh 
Frozen Plasma is Associated with Mortality or Worse Functional Outcomes After Severe 
Traumatic Brain Injury: A Retrospective Study. World Neurosurg. 2017;104:381-9. 
374. Mesar T, Larentzakis A, Dzik W, Chang Y, Velmahos G, Yeh DD. Association 
Between Ratio of Fresh Frozen Plasma to Red Blood Cells During Massive Transfusion 
and Survival Among Patients Without Traumatic Injury. JAMA Surg. 2017;152(6):574-80. 
375. Hagiwara A, Kushimoto S, Kato H, Sasaki J, Ogura H, Matsuoka T, et al. Can 
Early Aggressive Administration of Fresh Frozen Plasma Improve Outcomes in Patients 
with Severe Blunt Trauma?--A Report by the Japanese Association for the Surgery of 
Trauma. Shock. 2016;45(5):495-501. 
376. Chen Q, Ye L, Jin Y, Zhang N, Lou T, Qiu Z, et al. Circulating nucleosomes as a 
predictor of sepsis and organ dysfunction in critically ill patients. Int J Infect Dis. 
2012;16(7):e558-64. 
377. Marsman G, Zeerleder S, Luken BM. Extracellular histones, cell-free DNA, or 
nucleosomes: differences in immunostimulation. Cell Death Dis. 2016;7(12):e2518. 
378. Wildhagen KC, Garcia de Frutos P, Reutelingsperger CP, Schrijver R, Areste C, 
Ortega-Gomez A, et al. Nonanticoagulant heparin prevents histone-mediated cytotoxicity 
in vitro and improves survival in sepsis. Blood. 2014;123(7):1098-101. 
379. Demidenko O, Tsvetkova S. Action of heparin on protein fractions of isolated 
nuclei and on their DNA content. Histochemistry. 1978;57(3):265-71. 
380. Ronnefarth VM, Erbacher AI, Lamkemeyer T, Madlung J, Nordheim A, 
Rammensee HG, et al. TLR2/TLR4-independent neutrophil activation and recruitment 
upon endocytosis of nucleosomes reveals a new pathway of innate immunity in systemic 
lupus erythematosus. J Immunol. 2006;177(11):7740-9. 
381. Abrams ST, Zhang N, Dart C, Wang SS, Thachil J, Guan Y, et al. Human CRP 
defends against the toxicity of circulating histones. J Immunol. 2013;191(5):2495-502. 
382. Du Clos TW, Zlock LT, Rubin RL. Analysis of the binding of C-reactive protein to 
histones and chromatin. J Immunol. 1988;141(12):4266-70. 
383. Du Clos TW, Marnell L, Zlock LR, Burlingame RW. Analysis of the binding of C-
reactive protein to chromatin subunits. J Immunol. 1991;146(4):1220-5. 
384. Lehmann-Werman R, Neiman D, Zemmour H, Moss J, Magenheim J, Vaknin-
Dembinsky A, et al. Identification of tissue-specific cell death using methylation patterns of 
circulating DNA. Proc Natl Acad Sci U S A. 2016;113(13):E1826-34. 
385. Bergman Y, Cedar H. DNA methylation dynamics in health and disease. Nat 
Struct Mol Biol. 2013;20(3):274-81. 
386. Rodriguez AM, Rodin D, Nomura H, Morton CC, Weremowicz S, Schneider MC. 
Identification, localization, and expression of two novel human genes similar to 
deoxyribonuclease I. Genomics. 1997;42(3):507-13. 
387. Napirei M, Wulf S, Eulitz D, Mannherz HG, Kloeckl T. Comparative 
characterization of rat deoxyribonuclease 1 (Dnase1) and murine deoxyribonuclease 1-
like 3 (Dnase1l3). Biochem J. 2005;389(Pt 2):355-64. 
388. Koyama R, Arai T, Kijima M, Sato S, Miura S, Yuasa M, et al. DNase gamma, 
DNase I and caspase-activated DNase cooperate to degrade dead cells. Genes Cells. 
2016;21(11):1150-63. 
 
257 
 
389. Xu XY, Yang WF, Zhang SG, Zhao Q, Linag LJ, Wang X, et al. [Correlation of 
DNase I in serum and synovial fluid with inflammatory activity in patients with rheumatoid 
arthritis]. Nan Fang Yi Ke Da Xue Xue Bao. 2016;36(9):1204-8. 
390. Shiokawa D, Ohyama H, Yamada T, Takahashi K, Tanuma S. Identification of an 
endonuclease responsible for apoptosis in rat thymocytes. Eur J Biochem. 
1994;226(1):23-30. 
391. Shiokawa D, Kobayashi T, Tanuma S. Involvement of DNase gamma in apoptosis 
associated with myogenic differentiation of C2C12 cells. J Biol Chem. 
2002;277(34):31031-7. 
392. Nishimura K, Tanuma S. Presence of DNase gamma-like endonuclease in nuclei 
of neuronal differentiated PC12 cells. Apoptosis. 1998;3(2):97-103. 
393. Baron WF, Pan CQ, Spencer SA, Ryan AM, Lazarus RA, Baker KP. Cloning and 
characterization of an actin-resistant DNase I-like endonuclease secreted by 
macrophages. Gene. 1998;215(2):291-301. 
394. Wilber A, Lu M, Schneider MC. Deoxyribonuclease I-like III is an inducible 
macrophage barrier to liposomal transfection. Mol Ther. 2002;6(1):35-42. 
395. Napirei M, Ludwig S, Mezrhab J, Klockl T, Mannherz HG. Murine serum 
nucleases--contrasting effects of plasmin and heparin on the activities of DNase1 and 
DNase1-like 3 (DNase1l3). FEBS J. 2009;276(4):1059-73. 
396. Carbonella A, Mancano G, Gremese E, Alkuraya FS, Patel N, Gurrieri F, et al. An 
autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical 
presentation mimicking systemic lupus erythematosus. Lupus. 2017;26(7):768-72. 
397. Al-Mayouf SM, Sunker A, Abdwani R, Abrawi SA, Almurshedi F, Alhashmi N, et al. 
Loss-of-function variant in DNASE1L3 causes a familial form of systemic lupus 
erythematosus. Nat Genet. 2011;43(12):1186-8. 
398. Zhao Q, Yang C, Wang J, Li Y, Yang P. Serum level of DNase1l3 in patients with 
dermatomyositis/polymyositis, systemic lupus erythematosus and rheumatoid arthritis, 
and its association with disease activity. Clin Exp Med. 2016. 
399. Sisirak V, Sally B, D'Agati V, Martinez-Ortiz W, Ozcakar ZB, David J, et al. 
Digestion of Chromatin in Apoptotic Cell Microparticles Prevents Autoimmunity. Cell. 
2016;166(1):88-101. 
400. Russell RT, Christiaans SC, Nice T, Banks M, Mortellaro V, Morgan C, et al. 
Histone-Complexed DNA Fragments Levels are Associated with Coagulopathy, 
Endothelial Cell Damage, and Increased Mortality after Severe Pediatric Trauma. Shock. 
2017. 
401. Martinod K, Demers M, Fuchs TA, Wong SL, Brill A, Gallant M, et al. Neutrophil 
histone modification by peptidylarginine deiminase 4 is critical for deep vein thrombosis in 
mice. Proc Natl Acad Sci U S A. 2013;110(21):8674-9. 
402. Mai SH, Khan M, Dwivedi DJ, Ross CA, Zhou J, Gould TJ, et al. Delayed but not 
Early Treatment with DNase Reduces Organ Damage and Improves Outcome in a Murine 
Model of Sepsis. Shock. 2015;44(2):166-72. 
403. Jorgensen CS, Christiansen M, Laursen I, Krogsoe LB, Hojrup P, Blou L, et al. 
Large-scale purification and characterization of non-glycosylated Gc globulin (vitamin D-
binding protein) from plasma fraction IV. Biotechnol Appl Biochem. 2006;44(Pt 1):35-44. 
404. Lee PS, Waxman AB, Cotich KL, Chung SW, Perrella MA, Stossel TP. Plasma 
gelsolin is a marker and therapeutic agent in animal sepsis. Crit Care Med. 
2007;35(3):849-55. 
405. Lee PS, Drager LR, Stossel TP, Moore FD, Rogers SO. Relationship of plasma 
gelsolin levels to outcomes in critically ill surgical patients. Ann Surg. 2006;243(3):399-
403. 
406. Christofidou-Solomidou M, Scherpereel A, Solomides CC, Christie JD, Stossel TP, 
Goelz S, et al. Recombinant plasma gelsolin diminishes the acute inflammatory response 
to hyperoxia in mice. J Investig Med. 2002;50(1):54-60. 
 
258 
 
407. Goldschmidt-Clermont PJ, Van Baelen H, Bouillon R, Shook TE, Williams MH, Nel 
AE, et al. Role of group-specific component (vitamin D binding protein) in clearance of 
actin from the circulation in the rabbit. J Clin Invest. 1988;81(5):1519-27. 
408. Lind SE, Smith DB, Janmey PA, Stossel TP. Role of plasma gelsolin and the 
vitamin D-binding protein in clearing actin from the circulation. J Clin Invest. 
1986;78(3):736-42. 
409. Livingston DH, Anjaria D, Wu J, Hauser CJ, Chang V, Deitch EA, et al. Bone 
marrow failure following severe injury in humans. Ann Surg. 2003;238(5):748-53. 
410. Posluszny JA, Jr., Muthumalaiappan K, Kini AR, Szilagyi A, He LK, Li Y, et al. 
Burn injury dampens erythroid cell production through reprioritizing bone marrow 
hematopoietic response. J Trauma. 2011;71(5):1288-96. 
411. Miranda MB, Xu H, Torchia JA, Johnson DE. Cytokine-induced myeloid 
differentiation is dependent on activation of the MEK/ERK pathway. Leuk Res. 
2005;29(11):1293-306. 
412. Chakraborty A, Tweardy DJ. Stat3 and G-CSF-induced myeloid differentiation. 
Leuk Lymphoma. 1998;30(5-6):433-42. 
413. Ertel W, Keel M, Buergi U, Hartung T, Imhof HG, Trentz O. Granulocyte colony-
stimulating factor inhibits neutrophil apoptosis at the local site after severe head and 
thoracic injury. J Trauma. 1999;46(5):784-92; discussion 92-3. 
414. Sartorelli KH, Silver GM, Gamelli RL. The effect of granulocyte colony-stimulating 
factor (G-CSF) upon burn-induced defective neutrophil chemotaxis. J Trauma. 
1991;31(4):523-9; discussion 9-30. 
415. Nathan C. Points of control in inflammation. Nature. 2002;420(6917):846-52. 
416. Serhan CN, Gotlinger K, Hong S, Arita M. Resolvins, docosatrienes, and 
neuroprotectins, novel omega-3-derived mediators, and their aspirin-triggered 
endogenous epimers: an overview of their protective roles in catabasis. Prostaglandins 
Other Lipid Mediat. 2004;73(3-4):155-72. 
417. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, Gronert K. Novel 
functional sets of lipid-derived mediators with antiinflammatory actions generated from 
omega-3 fatty acids via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and 
transcellular processing. J Exp Med. 2000;192(8):1197-204. 
418. Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class 
switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7):612-9. 
419. Serhan CN, Hong S, Gronert K, Colgan SP, Devchand PR, Mirick G, et al. 
Resolvins: a family of bioactive products of omega-3 fatty acid transformation circuits 
initiated by aspirin treatment that counter proinflammation signals. J Exp Med. 
2002;196(8):1025-37. 
420. Spite M, Norling LV, Summers L, Yang R, Cooper D, Petasis NA, et al. Resolvin 
D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature. 
2009;461(7268):1287-91. 
421. Kurihara T, Jones CN, Yu YM, Fischman AJ, Watada S, Tompkins RG, et al. 
Resolvin D2 restores neutrophil directionality and improves survival after burns. FASEB J. 
2013;27(6):2270-81. 
422. Krishnamoorthy S, Recchiuti A, Chiang N, Fredman G, Serhan CN. Resolvin D1 
receptor stereoselectivity and regulation of inflammation and proresolving microRNAs. Am 
J Pathol. 2012;180(5):2018-27. 
423. Lee J, Jackman JG, Kwun J, Manook M, Moreno A, Elster EA, et al. Nucleic acid 
scavenging microfiber mesh inhibits trauma-induced inflammation and thrombosis. 
Biomaterials. 2017;120:94-102. 
424. Kumagai T, Takeyama N, Yabuki T, Harada M, Miki Y, Kanou H, et al. Apheresis 
of activated leukocytes with an immobilized polymyxin B filter in patients with septic 
shock. Shock. 2010;34(5):461-6. 
425. Ronco C, Klein DJ. Polymyxin B hemoperfusion: a mechanistic perspective. Crit 
Care. 2014;18(3):309. 
